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1. General introduction.
Growth and development of multicellular organisms are complex processes that
are strictly regulated by hormones and growth factors. Growth hormone (GH), which
is synthesized in the pituitary gland, is responsible for the stimulation of postnatal
growth in vertebrates. However, the growth stimulatory effect of GH is indirect, as
evidenced by the initial observation by Salmon and Daughaday that GH in vitro did
not correct a defect in the synthesis of matrix proteins of hypophysectomized rats,
whereas the serum of GH-treated hypophysectomized rats did (Salmon and
Daughaday, 1957). This has led to the so-called ‘somatomedin hypothesis’
(Daughaday et al., 1972) which states that GH acts on skeletal tissues by inducing the
formation of growth factors (=somatomedins) circulating in the blood and acting on
peripheral tissue. Purification and subsequent amino acid sequence determination
revealed the existence of two distinct molecules; the initial name somatomedins was
replaced by insulin-like growth factors I and II (IGF-I and IGF-II) because of their
structural and functional homology with insulin (Rinderknecht and Humbel, 1978a;
Rinderknecht and Humbel, 1978b). It is noteworthy that the synthesis of IGF-II is not
under stringent control of GH, in contrast to IGF-I (Humbel, 1990).
Mature IGF-I and IGF-II are polypeptides of 70 and 67 amino acids,
respectively, with 65% homology to each other and 43 and 41 % homology to pro-
insulin (Rinderknecht and Humbel, 1978a; Rinderknecht and Humbel, 1978b;
Daughaday and Rotwein, 1989). The fully processed and most active form of IGF-II is
7.5 kDa (Kiess et al., 1994), but larger forms of up to 20 kDa have also been isolated
from serum (Zapf et al., 1992; Kotani et al., 1993; Hunter et al., 1994). These large
forms of IGF-II generally constitute less than 10% of the total IGF-II in human serum,
but patients with certain tumors may have up to 75% of their serum IGF-II in the form
of these larger IGF-II variants (Daughaday et al., 1988).
In contrast to insulin, 99% of IGF-I and IGF-II is present in the form of a
complex with specific binding proteins (IGF-BPs). Six different IGF-BPs (IGF-BP1 to
IGF-BP6) have been identified to date (for a recent review, see Baxter (2000)). IGF-
BP3 is the most abundant IGF-BP in serum. After binding to one molecule of IGF-I or
IGF-II, IGF-BP3 also binds to an acid-labile subunit (ALS), thus forming a ternary
complex of 150 kDa (Baxter and Martin, 1989). The human IGF-BPs range in size
from 261 amino acids (IGF-BP6) to 289 amino acids (IGF-BP2) and all contain
cysteine-rich N- and C-terminal domains, each constituting about a third of the mature
peptide. The IGF-BP amino acid sequences are all well conserved between members,
but the IGF-BPs differ among each other in their relative affinity for IGF-I and IGF-II;
IGF-BPs 2, 5, and 6 have a higher affinity for IGF-II than for IGF-I, while IGF-BPs 1,
3, and 4 bind IGF-I and IGF-II with comparable affinity (for a review, see Jones and
Clemmons (1995)). A number of different physiological roles have been postulated for
the IGF-BPs (reviewed by Martin and Baxter (1999)). An important role may be to
prolong the half-lives of the IGFs by preventing their degradation; they also inhibit the
insulin-like effects of the IGFs in serum and they modulate the bioavailability of the
IGFs. In addition, the IGF-BPs may have IGF- independent functions.
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2. Expression and physiological role of the IGFs.
2.1. Receptors.
The actions of the IGFs are mediated through binding to specific membrane
receptors (for recent reviews, see Adams et al. (2000); DaCosta et al. (2000)). The
main receptors to which the IGFs can bind are the IGF type I and type II receptors.
The IGFs can also bind to the insulin receptor, albeit with a much lower affinity
(Ullrich et al., 1986). Nevertheless, the insulin receptor can also mediate the growth
promoting effects of IGF-II (Louvi et al., 1997). As for the insulin receptor and many
other growth factor receptors, the IGF type I receptor is a heterotetrameric receptor of
the tyrosine kinase family. This receptor preferentially binds IGF-I but can also bind
IGF-II with high affinity, implicating that both IGFs can function via the same
receptor (Bondy et al., 1993). Binding of IGF-I or IGF-II leads to autophosphorylation
of the tyrosine residues in the cytoplasmic domains of the receptor (Jacobs et al.,
1983). The phosphotyrosines then serve as binding sites that interact with specific
cytoplasmic signaling molecules, leading to a mitogenic signaling cascade through the
activation of phophatidylinositol 3’-kinase (PI3K) (Dufourny et al., 1997) as well as a
second pathway involving the MAP-kinases (Jhun et al., 1994).
The type II IGF receptor, which is identical to the cation-independent mannose-
6-phosphate (M6P) receptor, binds IGF-II with much higher affinity than IGF-I
(Nissley and Lopaczynski, 1991), although it cannot easily be explained what the
structural basis for this difference in affinity is (Torres et al., 1995). This receptor has
a large extracellular domain consisting of 15 repeated subdomains, and it has been
known to target lysosomal enzymes to the lysosomes. It was suggested that the type II
receptor may also have a role in the clearance of IGF-II from extracellular fluid since
upon IGF-II binding the receptor can be internalized leading to the degradation of
IGF-II (Oka et al., 1985). In addition, binding of IGF-II to this receptor activates a
signaling pathway involving G-proteins (Nishimoto, 1993). Although the lysosomal
enzymes and IGF-II bind to different sites in the type II/M6P receptor, they can
influence each other’s effects (Nissley and Lopaczynski, 1991).
In addition to the above mentioned receptors, another putative receptor that
mediates IGF signaling in mouse placenta and embryos was postulated based on
experiments with combined IGF/type I IGF receptor knockout mice (Baker et al.,
1993). Recently, this receptor was identified as the insulin receptor isoform A
(Morrione et al., 1997); overexpression of the insulin receptor in IGF type I-deficient
cells restored the proliferative response of these cells to IGF-II. Frasca et al. (1999)
established that one of the two isoforms (A and B) of the insulin receptor, isoform A
binds IGF-II with an affinity close to that of insulin. Thus, it appears that there are two
mitogenic receptors for IGF-II, the type I IGF receptor and the insulin receptor isoform
A.
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2.2. Expression and function during development.
Both IGF-I and IGF-II are expressed in a developmental stage-dependent
manner, but their individual expression profiles differ significantly. IGF-I serum
concentrations are low during pre- and neonatal periods and start to rise at the onset of
growth hormone-dependent growth in man at 6-12 months of age. The IGF-I
concentrations are highest during the pubertal stage and then decline with age (Hall et
al., 1980; Hall and Sara, 1984). IGF-II serum levels in humans are high during
embryogenesis, decrease after birth and gradually rise again into adulthood (Bennett et
al., 1983; Gluckman and Ambler, 1993). In adult man, IGF-II serum levels are
fourfold higher than those of IGF-I (Zapf et al., 1981; Enberg and Hall, 1984).
Targeted disruptions of the genes encoding IGF-I and IGF-II in knockout mice have
generated considerable insight into the function of the IGFs during embryonic
development. Mice with a complete disruption of IGF-I expression are viable but show
a significant growth retardation such that birth weights are reduced by about 40% of
that of normal mice (Baker et al., 1993; Liu et al., 1993), indicating that IGF-I plays a
very important role in embryonic development. Due to respiratory insufficiency, a
large number of the IGF-I deficient mice die immediately or shortly after birth
(Powell-Braxton et al., 1993). After birth, IGF-I knockout mice grow very poorly and
adults are about 70% reduced in size compared to the wild type adult animals. Similar
to mice carrying a disruption of IGF-I, mice in which the IGF-II gene was disrupted by
gene targeting are reduced by about 40% in size compared to their wild type
littermates but they are normally proportioned (DeChiara et al., 1990). This indicates
that IGF-II is indispensable for embryonic growth. In contrast with the mice carrying a
disruption of the IGF-I gene, the size difference generated by the retarded fetal growth
rate due to a loss of IGF-II remains the same throughout postnatal life, indicating that
IGF-II in mice plays no significant role in growth after birth.
Clues about the mechanism by which IGF-II exerts its growth promoting
function during development were revealed by double-knockout studies. Knockout of
the IGF type I receptor results in mice with a body weight reduced by about 55% of
the wild type animals and these mice do not survive to adulthood. The IGF-II/IGF type
I receptor double-knockout further decreases the birth weight to 30%, indicating that
not all IGF-II effects are mediated by the type I receptor (Liu et al., 1993).
Knockout mice have also been generated for the IGF type II receptor. One
might expect a growth defect if this receptor would be involved in transducing growth
promoting signals, but such an effect was not observed (Lau et al., 1994; Ludwig et
al., 1996). On the contrary, ablation of its expression results in a moderate fetal and
placental overgrowth of 25 to 40% increase and cardiac hypertrophy, leading to
neonatal lethality. This phenotype could be reversed to normal by combining the IGF
type II receptor null-mutation with a knockout of IGF-II. These results suggest that the
absence of a functional type II receptor leads to increased IGF-II levels, and therefore
regulation of the IGF-II concentration was proposed as a major function of the IGF
type II receptor in the developing mouse (Wang et al., 1994).
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2.3. Biological effects of the IGFs.
The biological effects of IGF-I and IGF-II have been studied extensively using
both in vitro and in vivo experimental systems. Both IGF-I and IGF-II show in vivo
and in vitro insulin-like metabolic effects (such as effects on glucose transport and on
blood glucose levels), but only at relatively high concentrations. The presence of IGF-
binding proteins in plasma prevents hypoglycemia under physiological conditions. The
biologically relevant effects at the usual nanomolar concentrations are the stimulation
of cell proliferation, and at least in certain tissues, cell differentiation.
For IGF-II, a wide range of biological activities in cells in culture have been
observed: in addition to promoting cell proliferation, it can also induce differentiation
in vitro, an effect which has been characterized in detail in myoblasts (Florini et al.,
1991). IGF-II profoundly affects cellular survival and counteracts apoptosis in various
cell systems (Biddle et al., 1988; Granerus et al., 1995; Granerus and Engstrom,
1996), whereas in other cell lines an apoptosis-inducing effect by IGF-II has been
observed (Granerus et al., 1998). IGF-II can also induce a functional modulation in
certain cell types without otherwise altering the differentiated phenotype; it stimulates
hormone synthesis and secretion in ovarian granulosa and theca cells (Giudice, 1992).
Furthermore, IGF-II can also potentiate the release of histamine from basophils in
response to immunoglobulin E (Hirai et al., 1993). Finally, it has been shown that
IGF-II can stimulate motility in cultured rhabdomyosarcoma cells (Minniti et al.,
1992).
3.      IGF-I gene structure and regulation of expression.
In humans, the IGF-I gene is present as a single copy which has been mapped to
chromosome 12 (Brissenden et al., 1984). The gene consists of six exons and 5
introns, and spans more than 80 kb of chromosomal DNA (Fig. 1). Alternative
splicing, polyadenylation at three different sites, the usage of two different promoters
and variable transcription initiation sites generates a diverse population of transcripts,
which range in size from 1.1 to 7.6 kb.
       
5’ 3’
1 2 3 4 5 6
P1 P2
* * * *
Figure 1. Structure of the human IGF-I gene. The intron sequences are indicated by a line, the exons
are indicated by boxes and are numbered. The coding exons are indicated in black and the
untranslated regions are indicated in white. Promoters P1 and P2 are indicated by bent arrows.
Polyadenylation sites are indicated by asterisks. The large central intron between exons 3 and 4 has
been truncated, as indicated.
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Exons 1 and 2 contain different 5’-UTR sequences, accompanied with different
N-terminal parts of the signal peptide of the precursor IGF-I. The mature IGF-I protein
is encoded by exons 3 and 4. Exons 5 and 6 encode different C-terminal parts of the E-
domain of the precursor IGF-I protein as well as different 3’-UTR sequences
(Rotwein, 1986; Steenbergh et al., 1991). Thus, four different precursor IGF-I proteins
can be formed by the alternative usage of two different N-terminal- and two different
C-terminal peptide sequences, whereas the mature IGF-I sequence is invariant.
The IGF-I gene contains two promoters, P1 and P2, of which P1 is the major
promoter. While P1 is active in all tissues in which IGF-I is expressed, P2 is active
primarily in the liver, where it is responsible for transcription of approximately 20% of
all IGF-I mRNAs (for a review, see Holthuizen et al. (1999)).
IGF-I gene expression can be regulated by a host of external stimuli; a very
strong activator of IGF-I expression is growth hormone (GH) that has been found to
have a strongly stimulating effect on IGF-I gene transcription in liver tissue and in
primary hepatocytes (Norstedt and Moller, 1987; Bichell et al., 1992). This is in
agreement with the somatomedin hypothesis that GH exerts its growth promoting
effect indirectly via increasing the serum concentrations of IGF-I.
4. IGF-II gene structure and regulation of expression.
4.1. Gene structure.
The human IGF-II gene has been mapped to chromosomal locus 11p15, directly
downstream of the insulin gene and spans 30 kb of chromosomal DNA. The gene
consists of 9 exons of which exons 7, 8, and the most 5’ part of exon 9 encode the
IGF-II precursor protein (De Pagter-Holthuizen et al., 1988; Holthuizen et al., 1990)
(Fig. 2). Transcription of the gene is driven by four different promoters, P1 to P4,
which precede exons 1, 4, 5, and 6, respectively. Transcription from these different
promoters generates a family of mRNAs, which all share the IGF-II coding region, but
differ in their 5’-UTR sequences. The transcripts from promoters P1 to P4 differ in
size: 5.3 kb (P1), 5.0 kb (P2), 6.0 kb (P3), and 4.8 kb  (P4). Further heterogeneity of
the family of transcripts is accomplished by the differential usage of two alternative
polyadenylation sites located in the 3’ part of the gene. In most cases, a poly(A) site
located approximately 4 kb downstream of the stopcodon is used, but a minor P3
derived mRNA species of 2.2 kb has been identified that is polyadenylated at an
upstream poly(A) site leading to a shorter 3’-UTR (Sussenbach et al., 1992). In
addition to this population of mRNAs, a 1.8 kb RNA species has been identified that
results from endonucleolytic cleavage, rather than from transcription from an
additional promoter (De Pagter-Holthuizen et al., 1988; Meinsma et al., 1991) (see
below).
As shown above, IGF-II is involved in many physiological processes, and
interference with its expression causes a severe growth defect. Thus, a tight regulation
of IGF-II gene expression is of crucial importance, which is reflected by the presence
of a complex set of regulatory mechanisms operating to control IGF-II protein
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production. A schematic overview of the different levels of control varying from
genomic imprinting to translational regulation will be discussed below.
                 
Figure 2. Structure of the human IGF-II gene with the different mRNAs generated by transcription
from promoters P1 to P4, which are indicated by bent arrows. The sizes of the transcripts are
indicated on the left. The exons are indicated by boxes and are numbered 1 to 9. Open boxes
represent untranslated sequences; black boxes indicate the prepro-IGF-II encoding exons. The
asterisks indicate the two alternative poly(A) sites in the 3’-UTR.
4.2. Effects of exogenous stimuli on IGF-II gene expression.
Regulation of IGF-II gene expression shows remarkable differences with
regulation of the IGF-I gene. Whereas the IGF-I gene is stringently regulated by
growth hormone (GH) (for a review, see Humbel (1990)), the expression of IGF-II is
mainly regulated by other hormones and local environmental factors play an important
role. For example, human ovarian cells in culture produce increased IGF-II mRNA
levels in response to follicle stimulating hormone, chorionic gonadotropin, or prolactin
(Voutilainen and Miller, 1987; Ramasharma and Li, 1987). One of the exogenous
factors that influence IGF-II expression in a number of cell systems is glucose; in a rat
pancreatic b-cell line, elevated glucose concentrations caused a threefold increase in
IGF-II expression (Asfari et al., 1995) and also in primary cultures of fetal rat
hepatocytes, a glucose-dependent increase in IGF-II mRNA levels was observed
(Goya et al., 1999). Another local stimulus that can lead to increased IGF-II
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expression is oxygen deprivation (hypoxia); exposure of the human hepatoma cell line
HepG2 to hypoxia results in IGF-II overexpression which appears to be mediated via
increased transcription from the fetal promoter P3 (Kim et al., 1998; Bae et al., 1999).
These findings, and the fact that hepatocellular carcinoma is a typical hypervascular
tumor (Mise et al., 1996), raised the hypothesis that IGF-II may play an important role
in the development of neovascularization of hepatocellular carcinoma.
IGF-II gene expression can also be controlled by glucocorticoids as evidenced
by a number of studies. In some systems, IGF-II expression is downregulated by
glucocorticoids (Beck et al., 1988; Levinovitz and Norstedt, 1989; Backlin et al.,
1998), whereas in others an upregulation of IGF-II expression has been observed
(Price et al., 1992; Mouhieddine et al., 1996). Dell et al. (1997) have reported that
glucocorticoid treatment of mouse embryonic fibroblasts activates the murine fetal
promoter P3, which is analogous to the human promoter P4.
4.3. Imprinting.
Genomic imprinting is a genetic mechanism by which genes are exclusively
expressed from the maternal or paternal chromosome. It has been shown in human, rat
and mouse that the IGF-II gene is subject to genomic imprinting as well as the H19
gene located at the same locus (chromosome 11p15). In most human tissues, the IGF-
II gene is actively transcribed from the paternal allele, in contrast to the maternal
allele, which is transcriptionally silent (DeChiara et al., 1990; DeChiara et al., 1991).
Only in the adult human liver (in contrast to the fetal liver) and in the choroid plexus
and the leptomeninges of the central nervous system, biallelic expression of IGF-II is
observed (Weksberg et al., 1993).
Clues of the mechanism by which imprinting of the IGF-II gene is controlled
were obtained from studies on the H19 gene, which is located about 90 kb downstream
of the IGF-II gene. The H19 and the IGF-II genes are reciprocally imprinted, and H19
RNA, which does not exhibit any conserved open reading frames, is expressed
exclusively from the maternal allele (Bartolomei et al., 1991). It was shown that
deletion of the H19 gene and some flanking sequences results in loss of imprinting of
the IGF-II gene (Leighton et al., 1995). Based on these results, the ‘enhancer-
competition’ model was proposed which states that the promoters of the IGF-II and
H19 genes compete for two enhancers located downstream of H19; these enhancers
normally stimulate H19 gene transcription, but upon deletion of the H19 region, the
enhancers become available for activation of IGF-II transcription. In agreement with
this model, the introduction of an extra set of enhancers between the IGF-II and the
H19 gene resulted in a loss of transcription repression of the IGF-II gene on the
maternal chromosome in fetal liver (Webber et al., 1998). Contrary to the prediction of
the enhancer competition model however, a smaller deletion encompassing only the
H19 promoter has no effect on the IGF-II gene in liver and only a small effect in
skeletal muscle (Schmidt et al., 1999). Instead, deletion of an 1.6 kb sequence in the
region between the IGF-II and H19 genes results in a complete loss of imprinting in
mice with both genes co-expressed at reduced levels on both parental chromosomes
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(Thorvaldsen et al., 1998). Thus, these recent results suggest that a chromatin
boundary between the IGF-II and the H19 genes may be responsible for the reciprocal
imprinting rather than enhancer competition.
The physiological importance of imprinting of the IGF-II gene is evident, since
loss of imprinting is associated with a variety of diseases and tumors. A major
example is the Beckwith-Wiedemann syndrome (BWS), where in 80% of the cases
IGF-II imprinting is lost and IGF-II is also expressed from the maternal allele
(Weksberg et al., 1993). Relaxation of IGF-II imprinting has also been implicated in
the onset of several cancers including Wilms’ tumor (Ogawa et al., 1993), embryonic
rhabdomyosarcoma (Zhan et al., 1994), and non-small cell myosarcoma (Suzuki et al.,
1994).
4.4. Transcription regulation.
Transcription of the human IGF-II gene is driven by four promoters (P1 to P4),
that are active in a tissue-specific and developmental stage-dependent fashion. During
fetal development, P3 is the most active promoter in many fetal tissues including fetal
liver, and is the main promoter in many tumor tissues as well. P4 is also active in
many fetal tissues, while P2 activity has only been detected in certain tumor cell lines
(Ikejiri et al., 1991). Promoter P1 is inactive during fetal stages, but is switched on
after birth whereas P3 and P4 are downregulated in the adult liver. Thus, P1 is the
main activator of IGF-II gene expression in the adult liver, which is the source for
circulating endocrine IGF-II. Although the molecular mechanism for this promoter
switch is still unknown, extensive studies have revealed a number of important factors
involved in the regulation of the different promoters (reviewed by Holthuizen et al.
(1999)). Promoter P1 comprises a region of approximately 1 kb. A single binding site
for the general transcription factor Sp1 is present in the proximal part of the promoter
and is essential for basal P1 activity (Rodenburg et al., 1997). In addition, a number of
liver-enriched transcription factors, including C/EBP, HNF4, and HNF3b were found
to play a role in the regulation of P1 (Rodenburg, 1996). Major contributors to the
postnatal liver-specific activation of P1 are the postnatally expressed C/EBP
transcription factors. Two of the C/EBP family members are able to activate P1;
C/EBPa activates the promoter six-fold and C/EBPb leads to an even stronger
activation of the promoter of fifteen-fold. HNF-3b stimulates P1 activity ten-fold,
whereas HNF-4 strongly suppresses P1. Interestingly however, this suppressing effect
is abolished by the presence of the C/EBP transcription factors. This provides a clue to
the mechanism of P1 activation after birth: during the prenatal stage, HNF-4
suppresses P1, while around birth, the C/EBP transcription factors appear and
counteract the suppressive effect of HNF-4, causing the full induction of P1 activity.
Little information is available about the regulation of promoter P2, which
precedes exon 4. P2 is generally very weak, although some human tumors have been
described that show elevated P2 activity (Ikejiri et al., 1991). In contrast to promoters
P1, P3, and P4, no Sp1 recognition sequences were found in P2 (Holthuizen et al.,
1990), and no other enhancer elements have been identified to date. However, an
alternatively spliced P2 transcript, which contains an additional exon downstream of
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exon 4 has been described by Mineo et al. (2000). This exon is named exon 4b, and is
proposed as a tenth exon in the IGF-II gene by Mineo et al. (2000).
The major fetal promoter, P3, spans 1300 bp upstream of exon 5 and is very
GC-rich with 70-80% GC base pairs (van Dijk et al., 1991; van Dijk et al., 1992). The
promoter can be subdivided into two separate regions; a proximal region up to position
-289 relative to the transcription start site and an upstream region from positions -1231
to -1063. The proximal region supports basal activity in several cell types, while the
upstream region is important for cell-type specific expression of P3 (van Dijk et al.,
1992; Raizis et al., 1993; Rietveld et al., 1997). Cell-specific factors that may be
involved in the cell-type specific regulation of P3 activity have been found to bind to
the upstream region -1231/-1063 (Schneid et al., 1993).
Several elements can be distinguished in the proximal P3 region that bind
specific transcription factors, including promoter elements PE3-1 to PE3-4 (van Dijk
et al., 1992; Raizis et al., 1993). The ubiquitous transcription factor Sp1 activates P3
through binding to several different sites in the promoter. The Egr transcription factor
is also able to recognize and bind to multiple sites in P3 (Rauscher, 1993).
Interestingly, these sites can also be bound by WT1 (Drummond et al., 1992),
and it has been postulated that the Egr proteins may play a role in stimulating
expression of the IGF-II gene resulting in autocrine growth stimulation of specific
tumors, whereas WT1 may act as a suppressor of P3 activity (Madden and Rauscher,
1993). An element near position -180 is subdivided into two protein binding sites,
named box A and box B. Box A is bound by a still unidentified protein, and box B is
bound by the transcription factor AP2 and another protein that awaits identification
(van Dijk et al., 1992; Rietveld et al., 1997; Rietveld et al., 1999).
Promoter P4 precedes exon 6 and exhibits a moderate activity in most fetal and
nonhepatic tissues adult human tissues examined. The Sp1 transcription factor is the
major regulator of P4 and can bind to four sites within the first 125 nucleotides
upstream of the transcription start site (van Dijk et al., 1991; Hyun et al., 1993). In
addition, two binding sites for the retinoblastoma (Rb) protein have been identified
and Rb can act as a positive regulator on Sp1 mediated transcription of P4 (Kim et al.,
1992).
4.5. Translation regulation.
As indicated above, transcription from the four different promoters generates a
population of mRNAs that differ in their 5’-UTRs (leaders) (Fig. 2). These leaders
vary significantly in length and composition. Leader 1 consists of exons 1-3 and is 586
nt long and is GC rich; leader 2 consists of exon 4 sequence and is 408 nt long and
moderately rich in G and C residues; leader 3 consists of exon 5 sequence, is rich in C-
residues and is the longest 5’-UTR with 1171 nt; leader 4 consist of exon 6 sequence
and is the shortest 5’-UTR with only 109 nt. Two interesting additional features of
leader 1 are the presence of an upstream open reading frame and an internal ribosome
entry site (IRES), allowing cap-independent translation initiation (Teerink et al.,
1995). On the basis of its minor length, leader 4 can be expected to allow efficient
translation, and that is in fact what has been observed; mRNAs with leader 4
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sequences are associated with the membrane-bound polysomes and are actively
translated. Also leader 2-containing mRNAs were found to be completely in the
polysomal fraction in proliferating tissue culture cells and in fetal liver, indicating that
leader 2 does not inhibit translation (de Moor et al., 1994). The high GC content of
leader 1 (32%G, 35% C) and the presence of an upstream open reading frame make it
likely that mRNAs starting with leader 1 will be poorly translated. However, since this
mRNA species is the only IGF-II mRNA detectable in adult liver, it is supposed to
direct the synthesis of most or all of the IGF-II protein in the circulation. Thus,
surprisingly, mRNAs with leader 1 can be expected to be translated efficiently, and
this is what actually has been observed (de Moor, 1994). In contrast to mRNAs with
leaders 1, 2, and 4, the mRNAs carrying leader 3 are hardly found in the polyribosome
fraction, indicating that this mRNA species is not efficiently translated (Nielsen et al.,
1990; de Moor et al., 1994). However, also the leader 3-containing IGF-II transcripts
can be efficiently translated depending on the growth conditions; in
rhabdomyosarcoma cells, the transcripts are translationally silent when the cells are
quiescent but become selectively mobilized and actively translated in exponentially
growing cells (Nielsen et al., 1995). Activation of translation is inhibited by rapamycin
and mimicked by anisomycin, suggesting that the translation of leader 3 mRNAs is
regulated by the p70S6k signaling pathway. In contrast, the translation of P4-derived
4.8  kb mRNA does not appear to be dependent on the growth status of the cell. Thus,
mRNAs containing leader 4 are constitutively translated, whereas translation of leader
3 mRNA is related to cell growth and is regulated by the p70S6k signaling pathway.
4.6. Endonucleolytic cleavage: scope of this thesis.
The subject of this thesis is site-specific endonucleolytic cleavage of the IGF-II
mRNAs. In addition to the population of mRNAs transcribed from promoters P1 to P4,
which differ in size from 6.0 to 2.2 kb, a shorter RNA species of 1.8 kb has been
detected on Northern blots when a 3’-UTR-specific probe was used (Fig. 3A) (De
Pagter-Holthuizen et al., 1988). Further characterization of this 1.8 kb RNA revealed
that it is produced by endonucleolytic cleavage of the full length IGF-II mRNAs and
not by transcription from an additional promoter (Fig. 3B). Cleavage was found to
occur at a unique site in the 3’-UTR, and the cleavage site was mapped to the single
nucleotide resolution (De Pagter-Holthuizen et al., 1988; Meinsma et al., 1991).
Northern analysis using a coding region-specific probe also detected a 5’ cleavage
product that contains the IGF-II coding region. This RNA, however, is much less
abundant than the 1.8 kb 3’ cleavage product, indicating that the 5’ cleavage product is
less stable than the 3’ cleavage product (Fig. 3A). This observation raised the
hypothesis that cleavage may act to destabilize the coding part of the IGF-II mRNAs
and thus downregulate IGF-II protein synthesis.
Subsequent deletion analyses using an in vivo IGF-II minigene system mapped
the sequences required for IGF-II mRNA cleavage to a region encompassing the
cleavage site from position -173 to + 150 relative to the cleavage site (element II;
positions 3723 to 4046 in the 6.0 kb transcript) (Fig. 4). Two stable stem-loops are
predicted in the upstream part of element II and the downstream part is very G-rich.
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Surprisingly, a distantly located upstream region from positions -2116 to -2013
relative to the cleavage site also appeared to be necessary (element I; positions 1780 to
1883 in the 6.0 kb transcript). RNA folding algorithms and biochemical assays
indicated that the C-rich element I can interact with the G-rich region in element II
downstream of the cleavage site, forming a 83 nt long base paired duplex (Scheper et
al., 1995). In the absence of the duplex, the G-rich downstream region may fold into a
compact G-quadruplex structure, thus accounting for the observed stability of the 1.8
kb RNA (Christiansen et al., 1994).
(A)
                                                      
(B)
  
Figure 3. (A) Northern blot analysis of total RNA isolated from SHSY-5Y cells (adapted from De
Pagter-Holthuizen et al. (1988)), that endogenously express IGF-II. When an IGF-II coding region
(CR)-specific probe is used, the full-length IGF-II mRNAs of 6.0 kb and 4.8 kb are detected, and in
addition the 5’ cleavage product of 4.2 kb that contains the coding region. With an IGF-II 3’-UTR-
specific probe, the full-length IGF-II mRNAs are detected as well as the 1.8 kb 3’ cleavage product.
The sizes of the different RNA species are indicated on the left. The probes used are indicated above
the lanes. (B) Schematic representation of the endonucleolytic cleavage at a specific site in the 3’-
UTR of the IGF-II mRNAs that generates an unstable 5’ cleavage product containing the coding region
and a stable 3’ cleavage product that consists of 3’-UTR sequence. Shown is the 6.0 kb IGF-II mRNA
as a target for cleavage, but the other IGF-II mRNAs are also cleaved. The cleavage site (CS) is
indicated by an arrow, and the IGF-II coding region is indicated by an open box. The untranslated
sequences are represented by lines, and the positions of the coding region and the cleavage site are
indicated.
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Figure 4. Schematic representation of the 6.0 kb IGF-II mRNA. Elements I and II can be brought into
proximity by formation of a duplex of 83 nucleotides. Elements I and II (bars), the cleavage site
(arrow), and the IGF-II coding region (open box), are indicated.
The work described in this thesis provides a follow-up study of the above-
described studies. Chapter 3 describes the identification of a protein that specifically
binds to a stem-loop in the proximity of the cleavage site and that may have a
modulating effect on cleavage. In addition, an extensive mutational analysis is
described that reveals the importance of the identity of specific nucleotides around the
cleavage site for cleavage. In Chapter 4, RNA structural studies are described that
provide insight into the importance of the various RNA folding domains in cleavage of
the IGF-II mRNAs. In Chapter 5, clues about the physiological role of cleavage are
presented.
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1. Introduction.
Many important events in the cell such as RNA processing, translation, RNA
transport, and RNA degradation involve RNA-protein interactions. All post-
transcriptional events in mRNA biogenesis require the formation of specific RNA-
protein complexes. For example, in pre-mRNA splicing, a complex machinery built of
RNA-protein particles (snRNPs) is required to correctly excise the introns and join the
adjacent exons. Capping and polyadenylation require specific proteins that interact
with the 5’ end of the nascent transcript and the poly(A) signal, respectively. The
coordinate actions of these complexes yield a mature mRNA that typically contains an
N7-methylated G-residue (the cap structure) at the 5’ end, and a poly(A) tail at the 3’
end (Fig. 1).
m7Gppp
CR5’-UTR 3’-UTR
(A)nAUG UAG
UGA
UAA
Figure 1. Structure of a typical mRNA. The cap structure at the 5’ end, and the poly(A) tail at the 3’
terminus of the messenger are shown. The 5’-UTR and the 3’-UTR are indicated by a line, the coding
region (CR) is boxed. The AUG translation startcodon and the three possible translation stopcodons
are indicated.
The sequence between the cap and the AUG translation start codon is
designated the 5’-untranslated region (5’-UTR); the coding region of the transcript is
flanked at its 3’ end by a 3’-untranslated region (3’-UTR), which constitutes the
sequence between the translation stopcodon and the poly(A) tail. The poly(A) tail
generally consists of about 200 A-residues in mammalian cells. All these features of an
mRNA can serve as specific binding sites for RNA-binding proteins. The cap and the
poly(A) tail can be recognized by the translation initiation machinery and poly(A)
binding proteins, respectively, which play an important role in translation and stability
of the messenger. The 5’-UTR, the coding region, and especially the 3’-UTR
commonly harbor cis-acting recognition sequences for specific proteins involved in
regulation of translation, mRNA degradation, and mRNA localization.
Clearly, it is of vital importance that the RNA-protein interactions involved in
the above mentioned processes occur in a highly specific manner. In order to form a
specific RNA-protein complex, a specialized peptide motif must correctly recognize a
specific target site in an RNA molecule. In this chapter, a brief summary of domains
commonly found in RNA-binding proteins and several RNA motifs serving as specific
binding sites for proteins will be described first. Secondly, proteins involved in
endonucleolytic cleavage of RNA and their target sites in RNA will be discussed.
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2. RNA binding proteins.
A wide range of RNA binding motifs has been found to date, and new RNA
binding folds keep appearing. Since the topic has been extensively reviewed (Burd and
Dreyfuss, 1994; Siomi and Dreyfuss, 1997; Cusack, 1999), only a few examples of the
most common RNA binding motifs will be presented here.
The most widely found and best-characterized RNA-binding motif is the
ribonucleoprotein (RNP) motif, also known as RNA-binding domain (RBD) or RNA-
recognition motif (RRM), and it is present in many proteins involved in RNA
processing and transport. Each RNP motif contains two conserved sequence motifs
designated RNP1 and RNP2 that are part of the RNA-binding surface of this domain.
The general pattern found in RNP motif structures is babbab, which forms a large
four-stranded antiparallel b-sheet packed against the two a-helices, which are
perpendicularly oriented (Fig. 2). The conserved RNP1 and RNP2 sequences are
located in the two central b-strands with the side chains of the conserved aromatic
amino acids displayed on the surface. The crystal structure of a complex between the
RNP domain of the U1A protein and a stem-loop structure from U1 snRNA was
determined at a resolution of 1.92 Angstrom and provides a detailed view of the mode
of specific RNA recognition by this motif (Oubridge et al., 1994). The loop between
the second and the third b strand is rich in basic residues and plays a critical role in
specific binding by protruding into the RNA loop, while the b-sheet forms a non-
sequence specific RNA binding platform. The nucleotides in the U1 snRNA loop,
which can normally adopt multiple conformations through the formation of non-
Watson-Crick base pairings, become ordered upon complex formation and are made
available for specific interactions with amino acids from the b strands of the RNP
domain. Thus, the observed structural adaptation of these nucleotides upon binding to
the protein can be seen as an example of an induced-fit mechanism.
Figure 2. The typical fold of the ribonucleoprotein (RNP) motif. The two perpendicularly oriented a-
helices A and B are indicated in white. The four b-strands are numbered and colored black; the
conserved RNP1 and RNP2 sequences are indicated. Adapted with permission from Jessen et al.
(1991).
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Apparently, the RNP motif employs a b-sheet as a surface for RNA binding and
stacking interactions between nucleotide bases and aromatic side chains on the b-sheet
play an important role in stabilizing the complex. The use of b-sheets in RNA-protein
complexes is a common theme seen in many RNA binding proteins. This is probably
due to the fact that both the major and the minor grooves of helical RNA are too
narrow to form a suitable surface for specific interactions with a-helices (a situation
which is dramatically different from the smooth contact between a-helices and the
major groove of DNA). Clearly, however, this is not a universal theme since in several
RNA binding motifs a-helices also appear to have a major role in RNA binding.
One of these is the double-stranded RNA binding domain (dsRBD), a 65 amino
acid motif that is formed in a variety of proteins that interact specifically with double-
stranded RNA, but in a sequence-independent manner. Examples of dsRNA-binding
proteins are the Drosophila Staufen protein (Bycroft et al., 1995) and Escherichia coli
RNase III (Kharrat et al., 1995). How does this motif discriminate between dsRNA
and DNA? Double-stranded RNA is distinguished from DNA by the presence of the
ribose 2’ hydroxyl group and by the fact that the extended RNA double helix is
predominantly A-form, whereas DNA is generally B-form with significantly different
helical parameters and groove dimensions. These general features permit nonspecific
dsRNA binding proteins to recognize their correct nucleic acid substrate. The basic
fold of the dsRBD is abbba, in which the three antiparallel b-strands pack to form
two a-helices on one face (Fig. 3). Thus, the dsRBD shows some resemblance to the
RNP domain. Its mode of binding to RNA is significantly different, however, since
mutational analyses have indicated that the highly conserved basic residues at the
amino terminus of the second a helix may directly interact with RNA and that dsRNA
binds to one face of the domain, a cleft between the amino terminus of the second
helix and one face of the second b strand.
                                      
Figure 3. The typical structure of the double-stranded RNA-binding domain (dsRBD). The three
antiparallel b-strands and the two a-helices are indicated. Adapted from the Protein Data Bank
(www.rcsb.org/pdb/) (Berman et al., 2000).
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Another motif in which a-helices play an important role in RNA binding is the
KH domain (for hnRNP K homology domain) that was first identified in the human
hnRNP K protein (Siomi et al., 1993). The KH domain is found in a wide variety of
RNA-binding proteins, including ribosomal S3 proteins from divergent organisms
such as archaebacteria, the yeast alternative splicing factor Mer1p, and numerous
human RNA-binding proteins, suggesting that it is an ancient protein structure with
important cellular functions (Siomi et al., 1993; Gibson et al., 1993). The KH domain
is comprised of about 60 amino acids and its typical pattern is baabba. Insight into
the three-dimensional structure has come from NMR spectroscopy analysis of one of
the KH domains of human vigilin (Musco et al., 1996). The b-strands form a three-
stranded antiparallel b-sheet which is packed against the three a-helices on one face of
the b-sheet (Fig. 4). Sequence conservation and UV crosslinking experiments suggest
that the helical side of the KH domain interacts with RNA. The loop between the first
two a-helices contains the strongly conserved tetrapeptide Gly-X-X-Gly (in which X
varies for different KH domains, but is often a positively charged amino acid) and
plays an important role in RNA binding. This loop may penetrate the widened groove
or a single-stranded loop of a target site in RNA and, because of steric hindrance, the
glycines could therefore not be substituted by residues that contain large side chains.
              
The arginine-rich motif  (ARM) is a short module of 10 to 20 amino acids
which is common in viral, bacteriophage and ribosomal proteins. The ARM is
sufficient for specific binding to RNA target sites, but amino acids located outside the
motif also contribute to binding (Tan et al., 1993). Other than the abundance of
arginine, there is little resemblance between different ARM sequences. Detailed
structural information is available for the ARM regions of two HIV-encoded RNA-
binding proteins, Rev and Tat. The structures of these regions appear to differ
significantly, suggesting that most ARM proteins do not share a common structure
(Fig. 5A and B). Rev is a regulatory RNA-binding protein that facilitates the export of
unspliced HIV pre-mRNAs from the nucleus and mediates its function by binding to
an internal loop designated the Rev responsive element (RRE) (Zapp et al., 1991).
Peptides encompassing the Rev ARM of 17 amino acids specifically bind the RRE as
Figure 4. The solution structure of one of the
human vigilin KH domains. The strongly
conserved Gly-X-X-Gly loop between helices
a1 and a2 is indicated by an arrow, and the
conserved positively charged residues which
are likely to interact with RNA are drawn as
ball-and stick models. The three a-helices and
the three b-sheets are indicated. Adapted with
permission from Musco et al. (1996).
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an a-helix and at least six amino acids, including four arginines, are essential for
specificity (Tan et al., 1993). Battiste et al. (1996) solved the solution structure of the
Rev-RRE complex by NMR spectroscopy (Fig. 5A). Several arginine side chains were
found to make base-specific contacts, and an asparagine residue contacts an unusual
G-A base-pair in the loop. Interestingly, a non-Watson-Crick G-G base-pair in the
loop, which is not in direct contact with the peptide through hydrogen bonds, plays a
critical role in the interaction. This base-pair, which can be replaced by an isosteric
A-A pair (Bartel et al., 1991), creates an important structural feature for specific
binding. Thus, RNA structure plays an important role in the Rev-RRE interaction.
          (A)       (B)
                             
Figure 5. (A) A peptide derived from the HIV-1 Rev protein in complex with the HIV-1 Rev-responsive
element (RRE) RNA. (B) A peptide derived from the BIV Tat protein in complex with the BIV TAR
RNA. Adapted with permission from Ramos et al. (1997).
In contrast to the Rev ARM, the Tat ARM peptides are unstructured but adopt a
stable conformation upon binding to TAR (transacting region) (Calnan et al., 1991).
This conformation appears to be a two-stranded antiparallel b-sheet, in contrast to the
a-helical structure of the Rev ARM (Fig. 5B) (Puglisi et al., 1995). The RNA target
site of Tat contains a three nucleotide 5’-UCU-3’ bulge that is part of the binding site
for the Tat protein. Upon binding of Tat, a conformational change in the bulge region
of TAR occurs, which allows the formation of a specific binding pocket. This indicates
that also in the case of the Tat-TAR interaction, the structure of the RNA binding site
rather than its particular sequence may be the major binding determinant.
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The above examples, of the Rev-RRE and the Tat-TAR interaction, illustrate
the importance of RNA structure to provide specific recognition surfaces for RNA-
binding motifs. In the next paragraph, a brief overview of how RNA molecules create
specific recognition sites through folding will be presented.
3. RNA structure: the formation of specific recognition sites.
Unlike DNA, all RNAs (except in double-stranded RNA viruses) are
synthesized as single strands without a complementary second strand. However, RNAs
do not exist as unstructured single-stranded molecules, but fold into secondary
structures in which regions of Watson-Crick base-pairing are interrupted by single-
stranded regions forming loops, mismatches, bulges, and helix junctions (Fig. 6). It is
common for an RNA sequence to be presented in the form of a possible secondary
structure, usually predicted by computer algorithms that are based on the assumption
that RNA molecules adopt their thermodynamically most stable structure out of a
number of alternatives that are energetically less favorable. However, since the
structure adopted by an RNA molecule in vivo may be altered by the binding of
proteins or other ligands, more recent algorithms also take the suboptimal structures
into account (Zuker, 1989).
                    
                 
     Figure 6. The various secondary structural elements of RNA.
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How do RNA molecules form specific binding sites for proteins? As mentioned
above, dsRNA differs from DNA in its helical parameters and groove dimensions.
Undistorted A-form dsRNA is characterized by a deep and narrow major groove and a
shallower minor groove, in contrast with B-form DNA, which has an easily accessible
major groove (Fig. 7).
   (A)                                              (B)
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Figure 7. (A) Structure of a B-form DNA helix. The narrow minor groove and the easily accessible
major groove are indicated by lines on the left. (B) Structure of an A-form RNA double helical
fragment. The deep, narrow major groove and the wide, shallow minor groove are indicated. (adapted
with permission from Dr. Kahn;  http://www.chem. umd.edu/biochem/kahn/teach_res/dna_tutorial/)
As a consequence, the bases in the major groove of dsRNA are not well accessible for
specific recognition by hydrogen bonding, and the readily accessible minor groove
contains less information for base discrimination (varying only by the presence or
absence of the exocyclic N2 of guanine). Thus, although the helix structure of dsRNA
is the determinant that is used by non-sequence-specific dsRNA-binding proteins to
distinguish it from DNA, it is not suitable for recognition by sequence-specific RNA-
binding proteins. As a consequence, these proteins must use the single-stranded
regions for specific binding. In fact, these ‘single-stranded’ regions are often
structured through the formation of ‘non-Watson-Crick’ base-pairing interactions. In
addition to the classical A-U and G-C Watson-Crick base-pairs, an extensive list of
non-Watson-Crick base-pairs has been identified in NMR and crystallographic studies,
and new types of base-pairs are still being discovered (reviewed by Schuster et al.
(1997); Westhof and Fritsch (2000)). In fact, almost any type of base-pair can occur,
including A-A, G-A, and U-U pairs. Such non-Watson-Crick base-pairs are commonly
formed in RNA loops, creating a helical geometry. In contrast to a continuous Watson-
Crick helix, however, in which the consecutive base-pairs are isosteric and form
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independently of their neighboring base-pairs, these non-Watson-Crick helices have
irregular shapes that depend on the combination of base-pairs. The specific irregular
structures formed by these non-Watson-Crick base-pairs play an important role in the
formation of specific recognition sites for proteins, as illustrated by the examples of
the Rev-RRE and the Tat-TAR interaction (see above). Another classical example of
how non-Watson-Crick base-pairs can produce a unique RNA shape suitable for
recognition by proteins is the loop E of 5S ribosomal RNA, which is present both in
prokaryotes as well as in eukaryotes. The loop E is a purine-rich internal loop that
serves as a binding site for the ribosomal L25 protein (Douthwaite et al., 1979). It was
originally shown that the loop adopts a structured geometry in the presence of
magnesium ions (Leontis et al., 1986; Romby et al., 1988). Later, NMR evidence
indicated the presence of a non-Watson-Crick A-U and a G-A pair in the loop E of
eukaryotic 5S rRNA (Wimberly et al., 1993). Correll et al. (1997) determined the
crystal structure of the E. coli  loop E at 1.5 Angstrom resolution, and also observed
the non-Watson-Crick A-U followed by G-A, and called this motif a ‘cross-strand A
stack’ because the A residues, which come from opposite strands, stack on each other.
This motif was found to occur three times in the loop E region, significantly altering
the shape of both the major and minor groove; the minor groove obtains a unique
hydrogen-bonding surface and the adjacent major groove is made wide enough to
allow recognition by the ribosomal protein L25.
                           
Figure 8. Folding of the classic RNA pseudoknot. Top: stems 1 and 2 are indicated by solid and
hatched regions, respectively; loop 1 and 2 are indicated in white. Bottom: The three-dimensional
structure of a pseudoknot with a continuous stacked structure for the two stems. Loop 1 crosses the
major groove of stem 2, and loop 2 crosses the minor groove of stem 1.
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Another important structural motif in RNA that can serve as a specific binding
site for proteins is the pseudoknot (for a review, see Pleij (1995)). An RNA
pseudoknot forms upon Watson-Crick base-pairing of a loop region with a
complementary sequence outside the loop. That complementary sequence can be
located in an unconstrained single-stranded region or in another loop. Pleij et al.
(1985) proposed a model of the ‘classic’ pseudoknot which is characterized by two
stem regions S1 and S2 and two loop regions L1 and L2 (Fig. 8). The two stem regions
coaxially stack to form a continuous helical region, and the two loops L1 and L2 cross
the deep major groove and the shallow minor groove in the helix, respectively. Several
recent studies describe specific interactions between RNA pseudoknots and proteins.
Detailed information is available of the interaction of the ribosomal protein S15 from
E. coli and a pseudoknot in its own mRNA, an essential step in the translational
autoregulation of S15 (Benard et al., 1994). Two adjacent base-pairs, U-G/C-G, in the
center of stem S1 of the pseudoknot are essential for S15 autoregulation and are
presumably directly recognized by the protein (Benard et al., 1998). A pseudoknot
RNA aptamer was found to bind with high affinity to HIV-1 reverse transcriptase
(Kensch et al., 2000). The interaction was highly specific, since the closely related
HIV-2 reverse transcriptase showed an almost four times lower binding affinity. Gilley
and Blackburn (1999) identified an important biological role of a pseudoknot in the
RNA component of telomerase in Tetrahymena thermophila. The pseudoknot was
found to be critical for the stable association of the RNA with the catalytic reverse
transcriptase component of telomerase.
In summary, it appears that RNA molecules can form specific three-
dimensional interfaces for interaction with peptide motifs. The specific nucleotide
composition of RNA loops determines their three dimensional configuration due to the
interdependence of the individual nucleotide interactions. Thus, it is not so
straightforward to distinguish between sequence- or structure recognition since there is
a very close coupling between the presence of specific nucleotides in the RNA loop
and the formation of a distinctive geometry that can be recognized by an RNA binding
protein.
4. Endonucleolytic cleavage of RNA.
Endonucleolytic cleavage of RNA is a widespread phenomenon and plays a
major role in RNA biogenesis and metabolism. Processes in which endonucleolytic
cleavage occurs include pre-mRNA splicing and 3’ end formation, maturation of small
nucleolar (sno)RNAs, tRNAs and ribosomal RNAs, and mRNA turnover. A variety of
endoribonucleases that are involved in these processes have been described.  These
enzymes differ among each other in their specificities and modes of substrate
recognition.
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4.1. Endoribonucleases.
A host of enzymes that hydrolyze phosphodiester bonds in RNA have been
described to date. These enzymes can be classified into two large groups: (1) the
exoribonucleases, which progressively cleave the bonds between consecutive
nucleotides, starting at either the 5’- or the 3’ end of an RNA chain, and (2) the
endoribonucleases, which can cleave internal bonds in an RNA strand. In contrast to
the exonucleases, which generally do not recognize specific RNA targets but degrade
any RNA that is single-stranded, the endonucleases differ greatly among each other in
their individual substrate specificities. Also the features recognized by these enzymes
are different. The simplest modes of recognition are employed by the RNases T2 and
V1, which cleave without any sequence specificity the bonds between nucleotides in a
single- or double-stranded configuration, respectively. Examples of RNases that show
a limited degree of sequence specificity are RNase A and RNase T1, which cleave 3’
to single-stranded pyrimidines and G-residues, respectively. More complex
recognition determinants are required for cleavage by the bacterial RNase E, which
plays an important role in rRNA processing, mRNA degradation and regulation of
plasmid replication. The consensus recognition site for this endoribonuclease is
5’-A/GAUUA/U-3’ in a single-stranded environment usually flanked by a stem-loop
structure (Ehretsmann et al., 1992). Cleavage can occur at multiple different sites
within this sequence, depending on the RNA molecule in which the sequence is
located. A human homolog of RNase E was found that appeared to have a similar
substrate specificity (Wennborg et al., 1995). Later, Claverie-Martin et al. (1997)
identified a similar activity and designated it ARD-1. These enzymes have the ability
to cleave mRNAs in the well-described AU-rich instability elements, characterized by
the occurrence of the 5’-AUUUA-3’ motif.
An interesting and extensively studied group of endoribonucleases, exhibiting a
very high degree of substrate specificity, is the group of endonucleases involved in
eukaryotic tRNA maturation (a similar set of pre-tRNA processing endonucleases is
present in prokaryotes). This group comprises three enzymes: (1) RNase P, which is
responsible for the removal of the 5’ leader of pre-tRNAs, (2) the 3’ processing
endonuclease which removes the 3’ trailer of pre-tRNAs, and (3) the tRNA splicing
endonuclease, which carries out the excision of an intron present in some (but not all)
tRNA precursors. These three endonucleases, which differ significantly among each
other (RNase P is a ribozyme in contrast to the other two enzymes), use a common
tripartite set of substrate features for recognition. First, all three enzymes recognize
determinants in the L-shaped mature tRNA domain, which is highly conserved and
common for all tRNAs. This enables these enzymes to recognize all different tRNAs
irrespective of their individual differences. Second, the enzymes ‘measure’ the
distance from the binding site in the mature tRNA domain to their respective cleavage
sites, determined by the length of the acceptor stem for RNase P, the anticodon stem
for the intron endonuclease, and both the acceptor stem and the T stem for the 3’
processing endonuclease (Altman, 2000; Kurz and Fierke, 2000; Phizicky and Greer,
1993; Nashimoto et al., 1999a). Third, specific interactions with nucleotides in the
proximity of the cleavage site provide an additional level of specificity for all three
enzymes. The intron endonuclease requires a pyrimidine to be located 5’ to the 5’
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splice site and the 3’ splice site to be located in a three nucleotide bulge loop (Di
Nicola et al., 1997). The 3’ processing endonuclease interacts with the 3’ trailer in
which the identity of the nucleotide 3’ to the cleavage site affects cleavage efficiency
in the order (G~A>U>C) (Nashimoto et al., 1999a; Nashimoto et al., 1999b). A recent
study by Ziehler et al. (2000) shows that the single-stranded 3’ terminus also plays a
substantial role in substrate binding by RNase P.
The above-described endoribonucleases are only a few examples of the
extensive list of known endonucleases generally involved in RNA metabolism. As
mentioned, the bacterial RNase E and its human homologs play a role in both RNA
processing and mRNA turnover by cleaving AU-rich elements in mRNA molecules.
The next paragraph will focus on specific endoribonucleases and their target sites in
mRNAs involved in mRNA degradation.
4.2. Endonucleolytic cleavage of mRNA-regulation of mRNA stability
To date, a number of mRNAs have been described to be subject to
endonucleolytic cleavage. In general, cleavage is thought to be the rate-limiting step in
the degradation of a target message, although not necessarily the first step. A summary
of the various systems described to date, and the differences and similarities among
these different systems will be discussed in the next paragraph. First, two systems in
which a group of mRNAs appears to be coordinately regulated by a common
endoribonuclease activity will be described; second, a number of individual
messengers that have been found to be targets for specific cleavage will be discussed.
4.2.1. Estrogen-regulated mRNAs.
An interesting example of selective stabilization or destabilization of mRNAs
by environmental stimuli is the regulated turnover of specific mRNAs in response to
estrogen stimulation. One system in which this occurs is the avian liver in which
apolipoprotein (apo)II mRNA and vitellogenin II mRNA are relatively stable with a
half-life of 13 hours in the presence of estrogen. After estrogen withdrawal, the half-
life of these mRNAs is reduced to 1.5 hours. This suggests that estrogen either directly
or indirectly represses an activity that selectively destabilizes apoII and vitellogenin II
mRNAs upon hormone withdrawal (Gordon et al., 1988). Subsequently, specific
degradation intermediates were found for the apoII message that appeared to result
from endonucleolytic cleavages at a number of sites flanked by 5’-AAU-3’ or
5’-UAA-3’ sequences in the 3’-UTR (Binder et al., 1989). A correlation between
destabilization of the apoII mRNA and an increase in the abundance of the cleavage
products, but no difference in the poly(A) tail length was observed, indicating that
endonucleolytic cleavage may be the first and rate-limiting step in the degradation of
this message.
Also in the Xenopus liver, estrogen causes the stabilization of vitellogenin
(Nielsen and Shapiro, 1990). In contrast, the mRNAs encoding the major serum
proteins including albumin, transferrin and the fibrinogens are coordinately
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destabilized by estrogen (Schoenberg et al., 1989; Pastori et al., 1990; Pastori et al.,
1991a). Pastori et al. (1991b) describe an estrogen-inducible endoribonuclease activity
that may be responsible for this selective destabilization, since it degrades albumin
mRNA 4 times faster in vitro than ferritin mRNA. Although the activity is present in a
polysome extract, destabilization of albumin mRNA appears to be independent of
translation (Moskaitis et al., 1991). An RNase consisting of two isoforms of molecular
mass 62 and 64 kDa was purified (Dompenciel et al., 1995) which shares many of the
features with the activity present in crude polysome extract, including selectivity for
albumin versus ferritin mRNA, resistance to inhibition by EDTA or placental RNase
inhibitor and an independence of divalent cations for activity. Subsequent cloning of
the gene identified the protein as a novel member of the peroxidase family termed
polysomal RNase 1, or PMR-1 (Chernokalskaya et al., 1998).
Preferential cleavage sites for PMR-1 are located in the 5’ half of the albumin
mRNA in the sequence 5’-AU¯UGAC¯UGA-3’. This sequence can be seen as two
overlapping copies of the pentamer ApyrUGA, which is present in multiple copies in
mRNAs that are destabilized in response to estrogen stimulation; 14 copies are found
in albumin mRNA, 9 in transferrin- and 7 in g-fibrinogen mRNA. However, this
element is absent from ferritin mRNA, which is not a target for PMR-1. Structural
studies have indicated that cleavage requires the pentamer to be in a single-stranded
configuration (Chernokalskaya et al., 1997). Interestingly, the element is also present
in the vitellogenin mRNA and is the specific binding site for an estrogen-inducible
protein (Dodson and Shapiro, 1994). As a consequence, binding of this protein may
protect the RNA from cleavage by PMR-1, resulting in the specific stabilization of this
RNA in the presence of estrogen.
4.2.2. Interferon/ RNase L-regulated mRNAs.
In response to interferon stimulation, an RNA degradation pathway can be
activated, which is responsible for many of the antiviral and antiproliferative/pro-
apoptotic effects of interferons (Sen and Lengyel, 1992). This pathway is known as the
2-5A system, which is comprised of two major enzymatic components: (1) 2-5A
synthetase which polymerizes ATP into 5’-phosphorylated, 2’,5’-linked
oligoadenylates in the presence of double-stranded RNA, and (2) RNase L which is
activated upon binding to 2-5A (Dong and Silverman, 1995). Upon activation, RNase
L cleaves RNA 3’ of UpNp sequences (Floyd-Smith et al., 1981). In addition to viral
RNAs, which are targeted for degradation by RNase L in virus-infected cells, also
cellular RNA substrates in the absence of virus infection have recently been identified.
An mRNA encoding a 43 kDa ubiquitin-specific protease, designated ISG43 and a
transcript encoding ISG15 were found to be selectively destabilized by RNase L in
fibroblasts (Li et al., 2000) and RNase L dependent degradation of MyoD mRNA has
been observed in mouse myoblasts (Bisbal et al., 2000).
Thus, both estrogen and interferon activate signaling pathways that lead to the
selective destabilization or stabilization of a subset of mRNAs by regulating a specific
endoribonuclease activity. These two systems represent examples of regulatory
networks where groups of genes can be coordinately regulated at the post-
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transcriptional level by a common endoribonuclease. In addition to the above-
described systems, a number of individual mRNAs have been described to be targets
for specific cleavage.
4.2.3. c-myc mRNA.
The human c-myc mRNA is a very labile messenger with a half-life of about 30
minutes and is an intriguing and a very complex example of modulation of  mRNA
turnover in response to physiological agents. It has been shown that two separated
decay pathways exist for c-myc mRNA. In one pathway, 3’-UTR sequences containing
two copies of the AUUUA motif stimulate poly(A) shortening followed by 3’ to 5’
exonucleolytic degradation of the message (Jones and Cole, 1987). In addition to the
AUUUA motifs, other segments in the 3’-UTR may also contribute to the rapid decay
(Bonnieu et al., 1990). The second pathway involves destabilization through a region
in the C-terminal part of the coding region from positions 1705 to 1886 encoding
c-myc amino acids 335-439, referred to as the Coding Region mRNA stability
Determinant or CRD (Swartwout and Kinniburgh, 1989; Wisdom and Lee, 1991). This
region can confer instability on a heterologous mRNA independently of the 3’-UTR
elements, indicating that it contains independently destabilizing sequences. The
destabilizing effect of the CRD is coupled to translation, since cycloheximide or the
introduction of an upstream stopcodon stabilizes mRNA that contains the CRD
(Wisdom and Lee, 1991; Herrick and Ross, 1994). Ioannidis et al. (1996) provided
direct evidence that the CRD is a target for endonucleolytic cleavage by the
observation of truncated c-myc RNA species. The CRD is also a binding site for a
protein that inhibits degradation, presumably by shielding the RNA from endonuclease
attack (Bernstein et al., 1992; Herrick and Ross, 1994; Prokipcak et al., 1994). This
binding protein is implicated in the developmental regulation of c-myc expression
(Leeds et al., 1997).
Recently, an endoribonuclease with the properties of the c-myc mRNase has
been partially purified (Lee et al., 1998). The enzyme is associated with polysomes,
consistent with the requirement of ongoing translation for cleavage. The estimated size
of the protein is 39 kDa and the major cleavage sites reside within a 10 nt segment
between nucleotides 1727 and 1736 with the sequence 5’-C¯AAUG¯AAAAG-3’.
This sequence slightly resembles the ApyrUGA recognition motif for the albumin
endonuclease PMR-1, which is also polysome-associated (see above). However, the
endoribonuclease activity responsible for cleavage of c-myc mRNA is probably
distinct from the albumin nuclease, since this enzyme is considerably larger (62-64
kDa) and is independent of divalent cations in contrast to the c-myc endonuclease,
which is inactive in the absence of magnesium (Lee et al., 1998). In addition, cleavage
of the c-myc mRNA is dependent on translation, which is not the case for the albumin
mRNA, a target of PMR-1 (Moskaitis et al., 1991).
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4.2.4. Xlhbox2 mRNA.
Xlhbox2 is a homeobox gene of the Antennapedia class whose transcripts are
found in Xenopus oocytes, eggs and embryos (Muller et al., 1984). In contrast to most
mRNAs, which are very stable in Xenopus oocytes,  the transcripts from the homeobox
gene Xlhbox2 are specifically destabilized during development, suggesting that these
mRNAs are targets for a specific nuclease (Wright et al., 1987). Brown and Harland
(1990) demonstrated that the Xlhbox2 mRNA is endonucleolytically cleaved at 4 sites
in a 90 nucleotides region in the 3’-UTR close to the translation stopcodon; the
cleavage sites are flanked by 5’-ACCU-3’ repeats and must be in a single-stranded
configuration to allow cleavage. Subsequently, it was shown that a single copy of the
sequence 5’-CCUACCUACCCACCUA-3’ is sufficient for cleavage of a heterologous
b-globin mRNA and reduces its half-life from 57 to 15 minutes (Brown et al., 1993).
Furthermore, it was established that cleavage is independent of translation since global
inhibition of translation using cycloheximide or message-specific translation inhibition
by injecting uncapped RNAs in the oocytes did not affect cleavage.
Brown et al. (1993) also showed that Xenopus oocytes contain a specific RNA-
binding protein that protects the Xlhbox2 mRNA from cleavage by binding to the
cleavage site. The protein is regulated in a development-specific manner and may thus
account for the developmental regulation of Xlhbox2 mRNA stability. This provides a
striking similarity with the c-myc system, where a protective binding protein is also
implicated in the development-specific expression of c-myc by modulating cleavage of
its mRNA (Leeds et al., 1997). Brown et al. (1993) also identified another Xenopus
gene named Xoo1 of which the transcript can be cleaved in a similar target sequence as
Xlhbox2 mRNA in oocytes, suggesting that at least these two (and potentially more)
different transcripts can be controlled by the same endoribonuclease in this system.
Partial purification of the endonuclease activity revealed that the protein is about 123
kDa in size and is resistant to pancreatic RNase inhibitors (Brown et al., 1993).
4.2.5. Interleukin-2 (IL-2) mRNA.
The cytokine interleukin-2 (IL-2) is expressed in human T lymphocytes, and its
mRNA normally has a relatively short half-life of about 30 minutes. Stimulation of the
CD28 surface antigen, however, leads to the stabilization of IL-2 mRNA (Lindstein et
al., 1989). Hua et al. (1993) have identified an endonuclease activity in cytosolic
extract from the T cell line Jurkat that selectively cleaves IL-2 RNA at several sites in
the C-terminal part of the coding region. Initial characterization revealed that the
enzyme is 60 to 70 kDa in size, requires magnesium for optimal activity, and is
insensitive to placental RNase inhibitor. More recently, a specific binding protein of
50 –60 kDa was identified that protects IL-2 mRNA against degradation (Hua and
Paetkau, 1996). Thus, also the IL-2 mRNA is degraded through endonucleolytic
cleavage, which may be regulated by a protective binding protein.
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4.2.6. 9E3 mRNA.
The 9E3 (or CEF-4) gene is expressed in chicken embryo fibroblasts (CEF) and
encodes a secreted 6 kDa protein that is related to platelet growth factor 4 and to a
number of other inducible proteins that are thought to be inflammatory mediators
(Kawahara and Deuel, 1989). In CEF infected with a temperature-sensitive strain of
Rous sarcoma virus (RSV), 6E3 mRNA is more stable at a permissive temperature
than at a nonpermissive temperature, suggesting that the 9E3 mRNA is stabilized in
RSV-transformed CEF (Bedard et al., 1987). Evidence that 9E3 mRNA stability may
be regulated by endonucleolytic cleavage in the 3’-UTR was provided by Stoeckle and
Hanafusa (1989) who observed small RNA species that appeared to be degradation
intermediates of 9E3 mRNA. The relative amount of the small RNAs was increased
under conditions in which 9E3 mRNA was less stable, suggesting that increased
cleavage activity may account for the destabilization of the 9E3 messenger. The
cleavage site was roughly mapped to a region in the 3’-UTR 360 nt downstream of the
stopcodon from positions 760 to 781within the sequence 5’-GUAAUUCCUCC
UGCUCCCUGG-3’. The determined half-life of the 9E3 transcript was 8 hours in
RSV-transformed CEF and 1 to 2 hours in untransformed cells.
For some mRNAs that are related to 9E3, degradation intermediates have been
described, suggesting that these RNAs may also be subject to endonucleolytic
cleavage. It was reported that several minor species of MONAP mRNA, another
member of the platelet growth factor 4 family, exist; most of these small RNAs lack a
poly(A) tail and were proposed to be degradation intermediates (Kowalski and
Denhardt, 1989). However, for MONAP mRNA, cleavage was suggested to occur at
AUUUA sites, which is not the case for 9E3 mRNA. Also for the gro gene, a
mammalian homolog of 9E3, minor RNA species lacking 3’ terminal sequences have
been detected (Anisowicz et al., 1987; Anisowicz et al., 1988).
4.2.7. Groa mRNA.
Groa is an inflammatory cytokine gene that is also known as melanoma growth
stimulatory activity (MGSA). It is a member of a large superfamily of inducible
cytokine genes which encode secreted peptides structurally related to platelet factor 4
and b-thromboglobulin (Arraiano et al., 1997).
It has been shown that interleukin-1 (IL-1) regulates groa and related genes
(grob, grog, and IL-8) at the level of mRNA stability (Arnold et al., 1998). The gro
mRNAs were stable in the presence of IL-1, with a half-life of 8 hours, and were
destabilized to a half-life of 1 hour in the absence of IL-1. Withdrawal of interleukin-1
was found to be associated with the increased abundance of a smaller RNA species of
0.9 kb derived from the full-length 1.3 kb groa mRNA that lacks a poly(A) tail
(Stoeckle, 1992). It was shown that this shorter RNA species is formed by removal of
a 130 nt sequence from the 3’-UTR. The 3’ end of the 0.9 kb groa RNA  maps to a
region around position 970 in the 3’-UTR, 130 nt upstream of the poly(A) site with the
sequence 5’-AAUAU-3’. This sequence is presumably a target site for an
endonuclease, although exonuclease trimming cannot be excluded since no 3’ cleavage
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product has been detected. Furthermore, it was shown that degradation of groa RNA
is associated with poly(A) tail shortening and requires ongoing translation. A coupling
between endonucleolytic cleavage and deadenylation has been observed for two other
mRNAs: the yeast PGK1 mRNA, and the human a-globin mRNA.
4.2.8. PGK1 mRNA.
The half-life of the yeast phosphoglycerate kinase (PGK1) mRNA can be
increased about twofold by insertion of an 18 nucleotides long poly(G) stretch in the
3’-UTR (Vreken et al., 1991). This insertion also caused the accumulation of a
degradation intermediate extending from the poly(G) stretch to the transcription
termination site. In a later report, Vreken and Raue (1992) showed that the poly(G)
stretch stabilizes the RNA by interfering with endonucleolytic cleavage of the PGK1
mRNA at two upstream sites between positions 1100 and 1200 near the 3’ end
(position 1251) of the coding region. Presumably, the poly(G) stretch inhibits cleavage
by altering the RNA structure around the cleavage site and causes the accumulation of
the 3’ cleavage product by protecting it against 5’ to 3’ exonucleolytic degradation.
Cleavage was found to occur in the sequence 5’-GGU¯G-3’, and is the rate-limiting
step in the degradation of PGK1 mRNA, although not the first step; cleavage occurs
after removal of the poly(A) tail.
4.2.9. a-globin mRNA.
The a-globin mRNA is very stable, which is conferred by a cytosine-rich
element (CRE) in the 3’-UTR that forms an mRNP complex including the poly(C)
binding proteins aCP1 and aCP2 (a-complex) (Wang et al., 1995; Weiss and
Liebhaber, 1995). The a-complex was found to stabilize the mRNA by an interaction
with the poly(A) binding protein to slow the rate of deadenylation (Wang et al., 1999).
In addition to impeding deadenylation, the a-complex also protects the a-globin
mRNA from cleavage by a specific endoribonuclease activity (Wang and Kiledjian,
2000a) that is enriched in erythroid cells. In agreement with the observation that the a-
complex inhibits cleavage, the cleavage site was mapped to a position 63 nucleotides
downstream of the translation stopcodon and 47 nucleotides upstream of the poly(A)
site in a region protected by the complex. Endonucleolytic cleavage occurs in the
sequence 5’-UCC¯UUG-3’, and these specific nucleotides around the cleavage site are
important for recognition, since cleavage is abolished when this sequence is mutated to
5’-GAGAGA-3’. A fragment of 45 nucleotides containing the cleavage site is
sufficient for cleavage of a heterologous mRNA, indicating that all information
required for cleavage is contained within this region. Thus, the a-complex stabilizes
the mRNA by at least two mechanisms: one is to lower the rate of deadenylation by a
stabilizing interaction with PABP, and the other is to protect the RNA from
endonucleolytic cleavage. In a subsequent study, Wang and Kiledjian (2000b)
demonstrated that both mechanisms are linked to each other, since the interaction
between the a-complex and PABP also appears to stabilize the binding of the a-
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complex to the CRE, and as a consequence inhibits cleavage. Thus, the a-globin
mRNA becomes a more efficient substrate for cleavage upon removal of the poly(A)
tail. This provides a mechanistic explanation of the link between deadenylation and
endonucleolytic cleavage in the a-globin mRNA, and it is tempting to speculate that
similar mechanisms might be operating in the groa and the yeast PGK1 mRNAs
described above.
4.2.10. Transferrin receptor mRNA.
The transferrin receptor (TfR) plays an important role in cellular iron uptake
and its expression is tightly regulated by iron. Regulation of expression occurs
primarily at the post-transcriptional level through modulation of the stability of the
TfR mRNA, which displays a relatively short half-life of about 45 minutes when iron
is abundant and a relatively long half-life of more than three hours when iron is scarce
(Koeller et al., 1991). The modulation of TfR mRNA stability is mediated via a region
in the 3’-UTR. This region contains a rapid turnover determinant (Mullner and Kuhn,
1988; Casey et al., 1989) and 5 RNA motifs named iron responsive elements (IREs)
which are binding sites for a cytoplasmic IRE binding protein (IRE-BP). A region of
250 nucleotides is sufficient for iron regulation (Casey et al., 1989). Binding of the
IRE-BP to the IREs inhibits degradation of the transcript, suggesting that the function
of the rapid turnover determinant is masked (Casey et al., 1989). Evidence that the
rapid turnover determinant is a target site for endonucleolytic cleavage was presented
by Binder et al. (1994), who observed the appearance of shorter TfR RNA species
upon treatment of cells with an iron source. The cleavage site was mapped to a single-
stranded region near one of the iron-responsive elements in the 3’-UTR with the
sequence 5’-AUAAAG¯AACAAG-3’. Nucleotide substitutions around the cleavage
site render the RNA refractory to cleavage, indicating that the identity of specific
nucleotides adjacent to the cleavage site is important for recognition by an
endoribonuclease. Furthermore, cleavage was found to be independent of poly(A) tail
shortening since the 3’ cleavage product appears to be polyadenylated to the same
extent as the full-length RNA. Interestingly, cleavage of the TfR mRNA requires
rather large regions of RNA structure, including a segment located about 300
nucleotides upstream of the cleavage site. This suggests that the endonuclease
recognition site in the TfR mRNA is relatively complex in comparison with various
other systems where short sequences are sufficient for recognition. Degradation of the
TfR transcript was found to require ongoing translation since the translation inhibitors
cycloheximide and puromycin led to a stabilization of the RNA. However, this does
not reflect a requirement for translation of the TfR mRNA per se because the
introduction of stable secondary structures in the 5’-UTR did not affect the stability of
the message (Koeller et al., 1991). Thus, the ongoing synthesis of a labile
endoribonuclease may be required rather than translation of the TfR mRNA itself.
 In summary, a growing number of mRNAs are found to be targets for specific
endoribonucleases. The various systems differ among each other in their dependence
on translation, either because a labile component is involved in degradation or the
target message itself must be translated, and poly(A) tail removal. Differences with
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respect to the cleavage site requirements are also evident. Populations of mRNAs exist
that can be coordinately regulated by a common endoribonuclease, in which cleavage
of individual messengers can be modulated by ‘protective factors’ that mask the
endonuclease cleavage site. In fact, regulation of cleavage through protective binding
proteins appears to be a common mechanism for most of the systems described. This
allows the specific regulation of a large number of mRNAs by a limited set of
endoribonucleolytic enzymes.
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Table 1
Overview of endonucleolytic cleavage sites in eukaryotic mRNAs
mRNA number of
cleavage
sites
positions of
cleavage
sites
target
sequence(s)
regulation
by (a)
protective
factor(s)
references
apoII
(human)
~14 sites region from
472 to 638 in
3’-UTR
(stopcodon
at position
401)
5’-AAU-3’,
and 5’-UAA-
3’
not
determined
(Binder et al., 1989)
albumin
(Xenopus
oocytes)
3 major sites,
and 2 minor
sites
5’ region of
the mRNA
5’-ApyrUGA-
3’
not
determined
(circumstanti
al evidence
suggests
yes)
(Pastori et al., 1991a;
Pastori et al., 1991b;
Chernokalskaya et
al., 1997)
c-myc
(human)
2 major sites 3’ part of the
coding region
between nt
1727 and
1736
5’-
C¯AAUG¯A
AAAG-3’
Yes, CDR-
BP
(Herrick and Ross,
1994; Ioannidis et al.,
1996; Lee et al.,
1998; Doyle et al.,
1998)
Xlhbox2
(Xenopus
oocytes)
4 sites 90 nt long
region in 3’-
UTR close to
stopcodon
5’-
CACCUACC
UACCCAAC/
AUACU-3’
yes,
unknown
protein
(Brown and Harland,
1990; Brown et al.,
1993)
IL-2 (human) 3-4 major
sites
Region from
positions
400-430
(position
stopcodon is
536)
not
determined
yes,
unknown
protein
(Hua et al., 1993; Hua
and Paetkau, 1996)
9E3 (chicken
embryo)
1 site 3’-UTR, 360
nt
downstream
of stopcodon
5’-
GUAAUUCC
UCCUGCUC
CCUGG-3’
not
determined
(Stoeckle and
Hanafusa, 1989)
PGK-1
(yeast)
2 sites 3’ part of the
coding region
between
1100 and
1200
(stopcodon:
1251)
5’-GGU¯G-3’ not
determined
(Vreken and Raue,
1992)
groa
(human)
1 site 3’-UTR, 130
nt upstream
of poly(A)
site
5’-AAUAU-3’ not
determined
(Stoeckle, 1991;
Stoeckle, 1992)
a-globin
(human)
1 site 3’-UTR, 63 nt
downstream
of  stopcodon
5’-
UCC¯UUG-
3’
yes, aCP1+
aCP2
(Wang and Kiledjian,
2000a)
transferrin
receptor
(TfR)
(human)
1 site 3’-UTR, 184
nt
downstream
of stopcodon
5’-
AAG¯AAC-3’
Yes, IRE-BP (Casey et al., 1989;
Binder et al., 1994)
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CHAPTER 3
Identification of RNA sequences and structures involved in
site-specific cleavage of IGF-II mRNAs
Erwin L. van Dijk, John S. Sussenbach, and P. Elly Holthuizen. University
Medical Center Utrecht, Department Physiological Chemistry, Utrecht, The
Netherlands.
RNA (1998) 4, 1623-1635
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SUMMARY
Insulin-like growth factor-II (IGF-II) mRNAs are subject to site-specific
endonucleolytic cleavage in the 3' untranslated region (UTR) rendering an unstable 5'
cleavage product containing the coding region and a very stable 3' cleavage product of
1.8 kb consisting of the 3'-UTR sequence and the poly(A) tail. Previously, it was
established that two widely separated elements in the 3'-UTR (elements I and II), that
can form a duplex structure, are necessary and sufficient for cleavage. To further
investigate the sequence and secondary structure requirements for cleavage, we have
introduced a number of mutations around the cleavage site and assayed their effects on
cleavage. Several recognition determinants involved in the endonucleolytic cleavage
of IGF-II mRNAs were identified. Mutational analysis around the cleavage site
revealed that cleavage is sequence-specific and that the cleavage site must be in a
single-stranded conformation to allow efficient cleavage. In addition, we have
identified an accessory protein that specifically interacts with a stem-loop structure
located 133 to 73 nucleotides upstream of the cleavage site.
INTRODUCTION
The regulation of mRNA stability plays a very important role in the control of gene
expression, and an increasing number of genes appears to be regulated at the post-
transcriptional level (for reviews, see Beelman and Parker (1995); Ross (1995);
Jacobson and Peltz (1996); Wickens et al. (1997)). The elements required for
regulation of stability are often located in the 3' untranslated region (UTR) of mRNAs.
These elements can be recognized by trans-acting factors serving as mediators of RNA
degradation. In addition to poly(A) shortening or arrest of translation at a premature
stopcodon, the initial and rate-limiting step in RNA degradation often appears to be an
endonucleolytic attack on the mRNA resulting in efficient exonucleolytic processing
of the mRNA. Due to the instability of the cleavage products, intermediate RNA
fragments are usually difficult to detect. To date, a number of mRNAs has been found
to be degraded through endonucleolytic cleavage, including the mRNAs encoding the
transferrin receptor (Binder et al., 1994), the cytokine groá (Stoeckle, 1992), avian
apo-very low density lipoprotein II (Binder et al., 1989), maternal homeodomain-
proteins (Brown and Harland, 1990; Brown et al., 1993), and albumin (Dompenciel et
al., 1995; Chernokalskaya et al., 1997). The c-myc mRNA can be cleaved
endonucleolytically in its coding region, but can also be destabilized through AU-rich
elements in the 3'-UTR (Swartwout and Kinniburgh, 1989; Ioannidis et al., 1996).
Human insulin-like growth factor II (IGF-II) is a mitogenic polypeptide
consisting of 67 amino acids showing strong structural and functional homology to
insulin (Daughaday and Rotwein, 1989). It is essential for embryonic growth and
development (DeChiara et al., 1990). The human IGF-II gene comprises nine exons, of
which exons 7, 8, and the first 237 nucleotides of exon 9 provide the coding region for
pre-pro-IGF-II. The remaining part of exon 9 consists of a 4 kb long 3'-UTR. Human
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IGF-II is expressed in a developmental stage dependent and tissue-specific manner by
differential activation of four promoters (P1- P4) yielding multiple mature transcripts
with different 5'-UTRs derived from exons 1-6. In addition, IGF-II expression is
regulated at the post-transcriptional, translational, and the post-translational levels (for
a recent review, see Holthuizen et al. (1999)).
In previous studies, we have shown that human IGF-II mRNAs are subject to
site-specific endonucleolytic cleavage in the 3'-UTR, rendering an unstable 5' cleavage
product and an exceptionally stable 3' cleavage product of 1.8 kb (De Pagter-
Holthuizen et al., 1988; Meinsma et al., 1991; Meinsma et al., 1992). It was
established that for in vivo cleavage of IGF-II mRNAs two widely separated sequence
elements in the 3'-UTR (elements I and II) are necessary and sufficient (Meinsma et
al., 1992). Element II spans a region of 323 nucleotides long running from positions
-173 to +150 relative to the cleavage site. It comprises two domains that are highly
conserved among human, rat, and mouse: a domain from positions -133 to -7
containing two stable stem-loop structures and a G-rich domain from positions -5 to
+59 (Fig. 2A). In fact, the region from -14 to +60 exhibits the highest sequence
homology within the entire IGF-II mRNA between human, rat and mouse (Nielsen and
Christiansen, 1992). Element I (103 nucleotides long) is located approximately 2 kb
upstream of the cleavage site at positions -2116 to -2013 (Fig. 1, 2A) and forms an
RNA: RNA duplex structure with the downstream region in element II from positions
+18 to +101 (Scheper et al., 1995).
To investigate the structural requirements for cleavage of IGF-II mRNAs in
more detail, we have altered the nucleotide sequence and/or secondary structures in the
proximity of the cleavage site and assessed the consequences of the changes on
cleavage efficiency and cleavage specificity. In addition, we have identified a protein
that specifically binds to a stem-loop structure in element II upstream of the cleavage
site and that may have a modulating effect on cleavage.
RESULTS
Experimental strategy
In order to study in vivo cleavage of IGF-II mRNAs, we previously constructed
a human IGF-II minigene construct. In this construct, designated EP7-9, the
immediate-early cytomegalovirus (CMV) enhancer-promoter region (Boshart et al.,
1985) is fused to the IGF-II protein-encoding exons 7, 8, and 9 (Fig. 1), giving rise to
an IGF-II transcript of 4.8 kb (Meinsma et al., 1992). Transient transfection assays of
this construct into human 293 cells that do not express IGF-II endogenously, and
subsequent Northern blotting analysis of the IGF-II mRNAs showed that in addition to
the 4.8 kb transcript also a specific 1.8 kb cleavage product of IGF-II is formed as a
consequence of site-specific endonucleolytic cleavage in the 3'-UTR of IGF-II
mRNAs (Meinsma et al., 1991). A NotI site was introduced in EP7-9 at position +83
for several cloning purposes (Fig. 1B), and it was shown that the cleavage efficiency
Chapter 3
48
of this construct (EP7-9/Not) is comparable to that of EP7-9 (Meinsma et al., 1992). In
our studies we have used EP7-9/Not for the introduction of mutations disrupting a
specific RNA-protein complex (see below). Analysis of deletion derivatives from
EP7-9 revealed that a region in the 3'-UTR between elements I and II from positions
-1955 to -174 relative to the cleavage site could be deleted without affecting cleavage
efficiency (Fig. 1B). In this study, construct EP7-9Ä-1955/-174 (in short ÄWT) giving
rise to a 3.0 kb IGF-II transcript was used for the introduction of several point
mutations in the proximity of the cleavage site. The cleavage efficiencies of ÄWT and
EP7-9/Not were set at 100% in the separate experiments. All mutants are named after
the positions of the altered residues relative to the cleavage site.
Figure 1. Schematic representation of the CMV-IGF-II minigenes. (A) Construct EP7-9 contains the
enhancer/promoter region and exon 1 of cytomegalovirus (CMV) fused to a 10.9 kb genomic fragment
of the human IGF-II gene containing exons 7, 8, and 9 cloned in pUC8 (bold line). The CMV regions
and the IGF-II and pUC regions are drawn at different scales. The arrow indicates the transcription
start site. Translated and untranslated IGF-II regions are depicted by filled and open boxes,
respectively. The stippled area in exon 9 represents the 1.8 kb RNA region. (B) Enlarged
representation of human IGF-II exon 9. Positions (bp) in exon 9 are relative to the cleavage site (+1).
The two elements required for cleavage, Element I (-2116 to -2013) and Element II (-174 to +150) are
indicated by bars (I, II). The EP7-9 derivatives, EP7-9/Not that contains an additional NotI site at
position +83, and ÄWT in which the region between elements I and II (-1955 to -174) is deleted, are
indicated. The transcripts of EP7-9/Not (4.8 kb) and ÄWT (3.0 kb) are endonucleolytically cleaved with
wild type cleavage efficiency (Meinsma et al., 1992).
     E-P
 CMV     IGF-II                                                                 pUC8
         7          8                      9
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0.1 kb                   1.0 kb
    I                                                     II
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Nucleotide sequence requirements around the cleavage site
Previous experiments have shown that cleavage of IGF-II mRNAs occurs at a
unique site in the cleavage unit consisting of elements I and II (De Pagter-Holthuizen
et al., 1988). The secondary structure of the region around the cleavage site was
predicted by computer folding using the MFOLD computer program from the GCG
package based on the algorithm of Zuker and Stiegler (Zuker and Stiegler, 1981) (Fig.
2A). The position of the cleavage site is indicated in the figure. To investigate whether
specific nucleotides around the cleavage site are important for cleavage, several point
mutations were introduced in the IGF-II minigene construct ÄWT in the highly
conserved region surrounding the cleavage site. Mutations were introduced at
positions -6,-5; -2,-1; +1,+13, and +5,+6, relative to the cleavage site. The effects of
the mutations on the secondary structure of the corresponding RNA were predicted by
computer folding using MFOLD (Fig. 2B).
Human 293 cells, which do not express IGF-II endogenously, but are able to
perform cleavage of the various IGF-II minigene RNAs (Meinsma et al., 1991), were
transiently transfected with the minigene constructs. Subsequently, RNA was isolated
from the transfected cells and subjected to Northern blot analysis using a probe that
detects the 3' cleavage product as well as the full-length IGF-II RNA (Fig. 2C). As
previously shown (Meinsma et al., 1992), transcripts from ÄWT are efficiently
cleaved (Fig. 2C, lane 1). Mutations at positions -2,-1 and +5,+6 relative to the
cleavage site, that affect both the primary nucleotide sequence and the secondary
structure around the cleavage site, completely abolish cleavage (lanes 3 and 7,
respectively). Mutations at positions -6,-5 and +1,+13, only slightly affecting the
secondary structure, have a less severe effect, reducing the cleavage efficiency to
25-30 % of the wild type (Fig. 2B and C, lanes 2 and 5). In order to discriminate
between effects at the level of the primary nucleotide sequence and the secondary
structure, we introduced compensatory mutations in the opposite strand for mutants
[-2,-1], [+1,+13], and [+5,+6] (Fig. 2B). Compensatory mutations in the opposite
strand restoring the wild type structure, but not the sequence (mut[-145,-143,-140,
-137,-2,-1] and mut[-149,-148,+5,+6]) cannot restore cleavage (lanes 4 and 8). This
indicates that the wild type structure alone is not sufficient for recognition and that the
identity of the nucleotides at these positions around the cleavage site is important as
well. Introduction of a compensatory mutation at position -144 in mut[+1,+13],
restoring the predicted wild type structure, does not yield the wild type cleavage
efficiency, but even further reduces cleavage to about 5% (lane 6). This indicates that
the reduced cleavage efficiency observed with mut[+1,+13] is not solely due to the
effect of mutation +1 on the secondary structure, but that the identity of the nucleotide
at position +1 as well as the opposing nucleotide in the complementary strand are
important.
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Figure 2. (A) Schematic representation of the 3'-UTR of IGF-II mRNAs. Elements I and II are indicated
by bars, the secondary structure of the RNA region around the cleavage site (arrow) is shown. The
positions of the conserved stem-loop region and the G-rich domain in element II are indicated. (B)
Predicted local secondary structures around the cleavage site in ÄWT and the various mutant
minigene constructs. In each structure, the cleavage site (arrow), the altered nucleotides (bold italics),
and their positions are indicated. (C) Northern blot analysis of total RNA isolated from human 293 cells
transiently transfected with the constructs indicated in (B). The blot was probed with a radiolabeled
DNA fragment (+84 to +1096) that detects both full-length IGF-II mRNA as well as the 3' cleavage
product of 1.8 kb. Sizes of the RNA species are indicated in kb. The numbers of the lanes correspond
to the numbers of the constructs shown in (B). Mean cleavage efficiencies (determined as described in
Materials and Methods) of 2-3 separate experiments are given as a percentage relative to the
efficiency of cleavage of ÄWT, which was set at 100%. Variation between the calculated cleavage
efficiencies in independent experiments was less than 10%.
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Structural requirements around the cleavage site
The results described above suggest that the identity of specific nucleotides
around the cleavage site is important for cleavage. To gain more insight into the role of
secondary structures in this region, we introduced mutations in ÄWT in the strand
opposite to the strand in which the cleavage site is located (positions -160 to -136).
These mutations were predicted to affect local secondary structure formation, but the
nucleotide sequence surrounding the cleavage site was left intact (Fig 3A).
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Figure 3. (A) Predicted local secondary structures around the cleavage site in ÄWT and the various
mutant minigene constructs. In each structure, the cleavage site (arrow), the altered nucleotides (bold
italics), and their positions are indicated. (B) Northern blot analysis of total RNA from 293 cells
transfected with the CMV-IGF-II minigene constructs. The lanes are numbered according to the
numbers of the constructs shown in (A). The blot was hybridized to the 3'-end specific probe that
detects both the full-length IGF-II RNA as well as the 3' cleavage product. The calculated mean
cleavage efficiencies of 2-3 separate experiments are indicated (see Materials and Methods for
calculation method). Variation between the calculated cleavage efficiencies in independent
experiments was less than 10%.
Chapter 3
52
The effects of these mutations were studied in transient transfection assays followed
by Northern blot analysis of the RNAs isolated from the transfected cells (Fig. 3B).
Mutations at positions -149,-148 in mut[-149,-148] cause a mismatch in the stem
below the cleavage site and decrease the size of the single-stranded bubble from 3 to 2
nucleotides (Fig 3A). This mutant is cleaved with wild type efficiency (Fig. 3B, lane
2), in contrast to mut[-144], which is cleaved with a reduced efficiency of 30% (Fig.
3B, lane 3). In mut[-144], the size of the bubble is reduced from 3 to 2 nucleotides due
to base-pairing of the G-residue downstream of the cleavage site, as in mut[-149,-148]
(Fig. 3A). The difference with mut[-149,-148] is, however, that the stem below the
cleavage site is uninterrupted. Thus, in mut[-149,-148] the structure shown in Fig. 3A
may be in a dynamic equilibrium with a more open conformation, whereas in mut[-
144] the cleavage site is less exposed. Cleavage is abolished when the bubble is
completely distorted as in mut [Ä-144, Ä-143,-142,-141,-140], leaving the cleavage
site in a perfect duplex (Fig. 3A,B, lane 5). This suggests that for cleavage, the
cleavage site must be sufficiently exposed in a single-stranded conformation. To study
the effect of a more open conformation around the cleavage site, we introduced
mutations creating a bubble of increased size (mut[-149,-147,-146,-145], Fig. 3A).
This mutant was cleaved with wild type efficiency, indicating that changing the
structure towards a larger bubble is tolerated (Fig. 3B, lane 6). Surprisingly, no
cleavage product was detected with mut[-145,-143,-140,-137], though the sequence
surrounding the cleavage site is left intact and the predicted secondary structure is only
slightly changed (Fig. 3A and B, lane 4) . This indicates that the identity of certain
nucleotides in the opposite strand may also be important for efficient cleavage. In
summary, these results suggest that secondary structure requirements are limited to a
single-stranded conformation around the cleavage site of at least three nucleotides. In
addition, the identity of certain nucleotides in the cleaved strand as well as in the
opposite strand are important for efficient cleavage.
Primer extension analysis
The cleavage site has been determined previously to the nucleotide resolution
(De Pagter-Holthuizen et al., 1988). In order to investigate whether the mutations that
still allowed cleavage, although with a reduced efficiency, affect the specificity of the
site of cleavage, we performed primer extension analysis of poly(A) + RNA isolated
from 293 cells transiently transfected with the IGF-II minigene constructs bearing
mutations which affect cleavage efficiency to a different extent. For mut[+1,+13] and
mut[-6,-5], having a reduced cleavage efficiency of 30% and 25%, respectively (Figs.
2B, 2C, lanes 5 and 2), a single extension product of the expected length is observed
(Fig. 4, lanes 2 and 3, respectively), as is the case with the wild type control (lane 1).
This indicates that cleavage specificity was not affected in these mutants. No extension
product was observed for mut[-2,-1], where cleavage is completely abolished (lane 4).
Thus, although the cleavage efficiency may be decreased for some constructs,
specificity of cleavage remains unaltered.
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Figure 4. Primer extension analysis of IGF-II transcripts. A 5' end-labeled primer complementary to
positions +99 to +120 was annealed to poly(A)+ RNA from 293 cells transiently transfected with CMV-
IGF-II minigene construct ÄWT (lane 1), mut[+1,+13] (lane 2), mut[-6,-5] (lane 3), or mut[-2,-1] (lane
4). A sequencing reaction carried out with the same primer was used as a marker. The cleavage site
(CS) as determined previously (De Pagter-Holthuizen et al., 1988) is indicated by an arrow on the left.
Specific RNA-protein interaction in element II
In a search for trans-acting factors that specifically bind to the elements
required for cleavage, we performed electrophoretic mobility shift assays (EMSAs)
using in vitro synthesized RNAs containing element I and/or element II in forward or
reverse orientation (Fig. 5A) and incubated these with cytoplasmic extracts from
human Hep3B cells, that endogenously express and cleave IGF-II mRNAs. Due to the
length of the RNA probes, it was necessary to digest the unbound RNA and the RNA-
protein complexes with RNase T1 and RNase A prior to gel electrophoresis. Two
RNA-protein complexes appeared with all probes tested, even with a control probe
containing only pBluescript polylinker sequences (Fig. 5B, lane 11). Thus, these two
complexes were nonspecific. A distinct complex, specific for IGF-II mRNA was
observed when the synthesized RNAs contained element II in the forward orientation
(lanes 1 and 5).
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Figure 5. A specific RNA-protein complex is formed with element II. (A) Schematic representation of in
vitro synthesized RNAs used for protein binding experiments. Elements I and II were cloned in forward
(fw) or reverse (rev) orientation in plasmid pBluescript (BS). (B) Electrophoretic mobility shift assay of
RNA-protein complexes separated by native polyacrylamide gel electrophoresis. Indicated 32P-labeled
RNAs were incubated in the presence (+) or absence (-) of cytoplasmic extract (10 ìg of protein) from
human Hep3B cells. RNA containing only pBluescript (BS) polylinker sequences was used as a
control. IGF-II specific (S) and nonspecific (NS) RNA-protein complexes are indicated by arrows as
well as the degraded probe (DP).
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To determine the binding site of the protein more precisely, we used RNAs
truncated in element II at positions +83 (SmaI), -23 (AvaI), -76 (AvrII), and -106
(BglII) (Fig. 6A). Truncations up to position -76 had no effect on complex formation
(Fig. 6B, lanes 2, 3, and 4), but further truncation to position -106 abolished binding of
the protein (lane 5). In addition, a mutant construct lacking the 5' part of element II
from position -174 to -109 was tested for protein binding, but no specific complex
formation was observed (lane 6). Based on these data, we anticipated that the protein
binds to a region overlapping position -106, for which the formation of a stem-
structure with a side-loop (from positions -133 to -73) is predicted (Fig. 7A). To test
this, we introduced mutations in this stem structure as well as in the side-loop and
investigated these mutants for binding of the protein (Fig. 7A and B). In contrast to
deletion of the side-loop (positions -103 to -92), which has no effect on protein
binding (Fig. 7B, lane 2), mutation of a part of the stem from positions -89 to -85
disrupts complex formation (lane 3). Even more subtle mutations of only 2 nucleotides
in the region from -88 to -81 completely abolish binding of the protein (lanes 4-7).
This confirms that the protein specifically binds to the stem, and not to the loop.
Specificity of binding was further assessed in a competition experiment (Fig. 8).
Several unlabeled competitor RNAs were added to the radiolabeled probe containing
element II in forward orientation in a 100- and 250-fold molar excess, respectively.
Effective competition was only observed with unlabeled wild type element II RNA
and mutant IIfw Ä-103/-92 (which efficiently binds to the protein when used as a
probe; Fig. 7B, lane 2, Fig. 8, lanes 3-6); the other mutated RNAs poorly competed for
protein binding, confirming the results obtained with these RNAs as radiolabeled
probes (Fig. 8, lanes 7 to 10; and data not shown).
In summary, we have identified a protein that specifically interacts with an
RNA region from positions -89 to -81 pairing with nucleotides -126 to -117 in a stem-
structure 133 to 73 nucleotides upstream of the cleavage site.
To examine whether this RNA-protein complex actually plays a role in
cleavage, the mutations shown in Fig. 7 were introduced in the IGF-II minigene
EP7-9/Not (Fig 1B) and the in vivo cleavage efficiency of the different mutants was
studied. Mutants that lacked RNA-protein complex formation in vitro showed a 15 to
30% reduction in cleavage efficiency. Mutant Ä-103/-92, that still allowed efficient
binding of the protein, could be cleaved in vivo with wild type efficiency (data not
shown). This indicates that although the RNA-protein complex is not essential for
cleavage, it may have a modulating effect on cleavage efficiency.
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Figure 6. Determination of the binding
site of the specific RNA-protein complex.
(A) Schematic representation of a series
of 3'-end truncations of element II in
forward orientation (fw), at positions +83,
-23, -76, and -106, respectively.
Ifw/IIfwÄ-174/-109 is a deletion mutant
containing element I, but lacking the 5'
end of element II. (B) Electrophoretic
mobility shift assay of 32P-labeled RNAs
with 10 ìg of Hep3B cytoplasmic extract.
IGF-II specific (S) and nonspecific (NS)
RNA-protein complexes are indicated by
arrows as well as the degraded probe
(DP).
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Figure 7. Fine-mapping of the protein
binding site. (A) Various mutations
were introduced in the stem-loop
structure from positions -133 to -73 to
determine the binding site of the
protein in detail. WT: construct BS-
Ifw/IIfw that contains the wild type
configuration. The side-loop from
positions -103 to -92 was deleted
(Ä-103/-92), and nucleotides -89 to -85
in the stem-structure were mutated
(5'-CGGAG-3' changed into 5'-AUA
UA-3') (mut -89/-85). In addition, a set
of four subtle mutations of two
nucleotides each were introduced in
the stem-structure: (-88G;-87G) were
changed into (-88A;-87A) (M1),
(-86A;-85G) were changed into (-86U;-
85A) (M2), (-84C;-83A) were changed
into (-84G;-83U) (M3), and (-82C;-81A)
were changed into (-82G;-81U) (M4).
The cleavage site (CS) is indicated by
an arrow. (B) Electrophoretic mobility
shift assay of 32P-labeled RNAs with
10 ìg of Hep3B cytoplasmic extract.
IGF-II specific (S) and nonspecific (NS)
RNA-protein complexes are indicated
by arrows as well as the degraded
probe (DP).
Chapter 3
58
DISCUSSION
A key to understanding the mechanism by which IGF-II mRNAs are cleaved lies in the
determination how a specific site in the mRNAs is recognized by a putative
endoribonuclease, and in the identification of factors involved in this process. Here we
describe experiments addressing both issues. Mutational analyses indicate that for
proper cleavage, both the primary nucleotide sequence as well as the local secondary
structure of the IGF-II mRNAs are of relevance; recognition may occur mainly at the
level of the primary nucleotide sequence, but the cleavage site must also be in an open
conformation to allow cleavage. The effects of the mutations on secondary structure
formation were predicted by computer folding using the MFOLD computer program
from the GCG package based on the algorithm of Zuker and Stiegler (Zuker and
Stiegler, 1981). Although it is not certain whether the structures shown here will
exactly represent the RNA structures present in the cell, the effects of the mutations on
the predicted structures are all in good agreement with the observed effects on
cleavage efficiency. In addition to the RNA sequences and structures involved in
cleavage, we have identified a protein that specifically interacts with a stem-loop
structure in the 3'-UTR of the mRNA located 133 to 73 nucleotides upstream of the
cleavage site.
To gain more insight in the sequence requirements for cleavage, a series of
mutants was generated with alterations at positions -6,-5; -2,-1; +1,+13; and +5,+6
relative to the cleavage site (Fig. 2B). Mutations at positions -6,-5 and at positions
+1,+13 reduce the cleavage efficiency to 25-30% of the wild type, and mutations at
positions -2,-1 and at positions +5,+6 abolish cleavage completely. As each mutation
Figure 8. Electrophoretic
mobility competition shift assay.
Radiolabeled in vitro synthesized
RNA containing element II in
forward orientation (IIfw) was
incubated without (-) or with (0)
cytoplasmic extract from Hep3B
cells. IIfw RNA as well as several
of the mutated RNAs (indicated
in Figure 7) were added in 100-
or 250-fold molar excess as
unlabeled competitor RNAs. As
a control for nonspecific
competition, yeast tRNA was
added.
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is predicted to affect the local secondary structure, it is difficult to determine whether
the effect should be ascribed to the change in primary nucleotide sequence, the altered
secondary structure, or both. To solve this problem, we introduced compensatory
mutations in the complementary sequence upstream of the cleavage site from positions
-160 to -136, restoring the predicted wild type secondary structure of mut[-2,-1],
mut[+1,+13], and mut[+5,+6] (see Fig. 2B). Cleavage was not restored in any of these
mutants, indicating that a predicted wild type structure is not sufficient for proper
cleavage. Surprisingly, in the case of mut[-144,+1,+13] cleavage efficiency was even
further reduced. This might indicate that certain nucleotides in the complementary
strand are also important for recognition. Alternatively, this mutation may cause
structural alterations at the tertiary structure level, thus hampering cleavage. An
additional set of mutations was introduced to assess the secondary structure
requirements. Mutations at positions -149 and -148, which were used to restore the
wild type secondary structure in mut[+5,+6], cause a mismatch in the stem below the
cleavage site in the wild type context (Fig. 3A). This mutant is cleaved with wild type
efficiency, indicating that the full integrity of this stem is not necessary for cleavage.
Also, when the single-stranded bubble in which the cleavage site is located is enlarged
and the lower stem is shortened by one base-pair, as in mut[-149,-147,-146,-145], no
major effects are observed. This shows that a small increase in the size of the bubble is
allowed, but leaves open the question whether decreasing the size of the bubble affects
cleavage efficiency. Therefore, we introduced nucleotides able to base-pair with
nucleotides adjacent to the cleavage site. In mut[Ä-144,Ä-143,-142,-141,-140], the
cleavage site is in a perfect duplex, in mut[-144] the nucleotide 3' to the cleavage site
is base-paired (as in the case of mut[+1,+13], Fig. 2B), and in mut[-145,-143,-140,
-137], the second nucleotide 5' to the cleavage site is base-paired (Fig. 3A), as in the
case of mut[-6,-5] (Fig. 2B). Mut[-144] is cleaved with a moderately reduced
efficiency of about 40%, and surprisingly, mut[-145,-143,-140,-137] is not cleaved,
though its predicted secondary structure is similar to that of mut[-6,-5], which is
cleaved with 40% efficiency. Mut[Ä-144,Ä-143,-142,-141,-140] is not cleaved,
indicating that the cleavage site must be in a single-stranded conformation to allow
cleavage. This result is not unexpected, since in several other systems endonucleolytic
cleavage appears to occur in single-stranded regions of the target RNA (Binder et al.,
1989; Binder et al., 1994; Kim et al., 1996).
The results obtained with mut[-144,+1,+13] and mut[-145,-143,-140,-137]
indicate that nucleotides in the complementary strand are also important for
recognition, either because they are specifically contacted by the endonuclease, or
because they are involved in non-Watson-Crick base-pairings in the bubble which are
not revealed by computer folding algorithms. The ability of RNA molecules to adopt
unusual structures is now commonly recognized, as structural models have revealed
the existence of a number of different non-Watson-Crick arrangements occurring as
single, tandem, or consecutive base-pairs, among which A-A, U-U, G-G, G-A, and
G-U are often found (Schuster et al., 1997). Our finding that in contrast to mutations in
the opposite strand, all mutations around the cleavage site affect cleavage shows that
the sequence surrounding the cleavage site is less tolerant to mutations than the
complementary sequence. This observation is in agreement with the fact that the
nucleotide sequence surrounding the cleavage site is more conserved among human,
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rat and mouse IGF-II mRNAs than the upstream sequence (Meinsma et al., 1991;
Nielsen and Christiansen, 1992). The reduced conservation of the upstream sequences
results in differences at the secondary structure level, though in all three species the
cleavage site is located in a single-stranded bubble. Interestingly, the mutated
nucleotides in the upstream sequence affecting cleavage efficiency are conserved,
whereas most of the residues which can be mutated without effect on cleavage
efficiency are not conserved. These data strengthen the hypothesis that the identity of
specific nucleotides, especially around the cleavage site, and to a lesser extent also in
the opposite strand is important. In addition, the severe effects of mutations affecting
the secondary structure formation around the cleavage site reveal a requirement for an
open structure around the cleavage site.
In summary, we have identified three major determinants involved in
recognition of the cleavage site; (a) the sequence surrounding the cleavage site, (b) the
sequence in the opposite strand, and (c) secondary (and perhaps tertiary) structure
formation of the cleavage site region.
Addition of these new data to our previous findings that for cleavage of IGF-II
mRNAs two elements (I and II; 103 and 323 nucleotides long, respectively) which can
form a stable duplex structure, are necessary and sufficient (Meinsma et al., 1992;
Scheper et al., 1995), reveals that we are dealing with an unusually complex system.
For comparison, short sequence elements resembling the AUUUA-motif, present in a
number of short-lived human oncogene and growth factor mRNAs, appear to be
sufficient for recognition by human RNase E-like endoribonucleases (Wennborg et al.,
1995; Claverie-Martin et al., 1997). For sequence-specific cleavage of Drosophila and
Xenopus maternal homeobox mRNAs, a 17 nt element is sufficient, and secondary
structure formation does not seem to play a role (Brown and Harland, 1990; Brown et
al., 1993). Albumin mRNA is preferentially cleaved at the pentamer A(C/U)UGA, but
can also be cleaved at other sites (Chernokalskaya et al., 1997). To our knowledge, the
only other described system where endonucleolytic cleavage of an mRNA involves
recognition of specific sequences at the cleavage site as well as complex structures, is
the transferrin receptor mRNA (Casey et al., 1989; Binder et al., 1994).
The highly structured nature of the cleavage unit formed by elements I and II
raises the question whether cleavage could occur through a self-cleavage mechanism
catalyzed by the RNA itself. However, incubation of IGF-II transcripts in the absence
of cellular extract did not result in cleavage, whereas addition of extract led to the
formation of the 1.8 kb 3’ cleavage product (Nielsen and Christiansen, 1992); our
unpublished results). Thus, it is clear that trans-acting factors are required for
cleavage.
In addition to studying RNA features involved in recognition of the cleavage
site, we have also searched for proteins binding specifically to RNA sequences/
structures necessary for cleavage. To this end, we performed electrophoretic mobility
shift assays and identified a protein exhibiting specific binding to the first stem-loop
structure located 133 to 73 nucleotides upstream of the cleavage site (Figs. 5 and 6).
We determined the binding site of the protein in more detail by introducing subtle
point mutations and assessing the consequences on RNA-protein complex formation.
Mutations in a region of the stem from positions -88 to -81 disrupted protein binding
completely, but deletion of a side-loop (positions -103 to -92) had no effect (Fig. 7).
sequences and structures involved in cleavage
61
We conclude from these results that the protein interacts specifically with the stem-
structure, and not with the loop. Computer prediction of secondary structure formation
indicated that the 2 nt mutations in the stem-structure only cause local mismatches in
the stem, but that the overall structure is unaffected. Thus, it cannot be determined
from these data whether the altered bases or the mismatches in the stem are
responsible for the effect on binding of the protein. To examine a possible role in
cleavage for the identified protein, the mutations described in Fig. 7 were introduced
in the EP7-9 minigene and the effect on cleavage efficiency in vivo was studied. We
observed a reduction in cleavage efficiency for the mutations that abolish protein
binding in vitro, but the effects were modest and varied among each other (data not
shown). Thus, it is clear that additional experiments will be required to elucidate the
function of the protein; our results suggest that the identified protein is not an essential
factor in cleavage, but may have a modulating effect on the process.
Our results, obtained studying RNA features involved in site-specific
endonucleolytic cleavage of IGF-II mRNAs and obtained with the search for protein
factors involved in the process, shed new light on the mechanism of cleavage. It
appears to be a highly specific process where multiple RNA features coordinately
serve as a recognition site for an endoribonuclease. A proximally binding protein may
have a modulating effect on cleavage.
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MATERIALS AND METHODS
Materials. Plasmid pBluescript II (KS+) was obtained from Stratagene (La Jolla, CA, USA).
Restriction enzymes, T4 DNA ligase, and T7 RNA polymerase were purchased from
Boehringer, Mannheim, Germany. Pfu DNA polymerase was purchased from Stratagene,
RNase-free DNase was from Kabi-Pharmacia (Uppsala, Sweden). RNase A and RNase T1
were purchased from Calbiochem (La Jolla CA, USA). Enzymes were used as specified by
the manufacturers. Nucleoside triphosphates (NTPs) and dNTPs were obtained from Kabi-
Pharmacia, BES [N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid] was purchased from
Sigma (St. Louis, MO, USA). A random primer labeling kit was purchased from Amersham,
United Kingdom, and a DNA sequencing kit was purchased from Kabi-Pharmacia. RNAzol
reagent was purchased from Biotecx Laboratories, Inc. (Houston, Texas, USA), and
Genescreen membranes were purchased from Du Pont de Nemours (Dreieich, Germany).
[á-32P]dCTP (3,000 Ci/mmol) and [á-32P]CTP (760 Ci/mmol) were purchased from
Amersham.
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Construction of plasmids. Molecular cloning was performed according to established
protocols (Sambrook et al., 1989). Where necessary, 3' recessed ends were filled in with
Klenow polymerase and 3' protruding ends were removed with T4 DNA polymerase. All
positions within exon 9 of the IGF-II gene are indicated relative to the cleavage site; the
nucleotide upstream of the cleavage site is -1, the nucleotide downstream is +1 (Fig. 1). When
exon 9 sequences are deleted or additional restriction sites are introduced, the numbers
indicated still refer to their original position in exon 9 relative to the cleavage site. IGF-II
minigene constructs were based on the construct EP7-9 and its deletion derivative
EP7-9Ä-1957/-174 (ÄWT), both described previously in (Meinsma et al ., 1992). EP7-9
contains a human genomic IGF-II fragment that starts 373 bp upstream of exon 7 and extends
to 4.7 kb downstream of the gene. ÄWT lacks the sequence between elements I and II, which
is dispensable for cleavage (Meinsma et al., 1992). Expression of EP7-9 in transfected cells
was driven by the immediate-early cytomegalovirus enhancer/promoter. Introduction of point
mutations in the proximity of the cleavage site (the region from positions -6 to +14) was done
in ÄWT, and was performed via site-directed mutagenesis using the pAlter system according
to the manufacturer’s instructions (Promega). The mutants are named after the positions of the
mutated nucleotides. Oligonucleotides used are shown below; WS9502 was used to construct
mut[-6,-5], WS9504 was used for mut[-2,-1], WS9505 was used for mut[+1,+13], and
WS9507 was used for mut[+5,+6]. Mutations in the upstream region (from positions -160 to
-136) complementary to the region surrounding the cleavage site were introduced via the
substitution of a ClaI/BglII fragment (positions -174/-109) in ÄWT by double-stranded
oligonucleotides carrying the desired mutations. Again, the names of the mutants are after the
positions of the altered residues. Oligonucleotides used are described below. Oligonucleotides
ED9726 and ED9727 were introduced into ÄWT to construct mut[Ä-144,Ä-143,-142,-141,
-140]; ED9728 and ED9729 to construct mut[-149,-148], ED9830 and ED9831 were inserted
to generate mut[-144], ED9832 and ED9833 to generate mut[-149,-147,-146,-145] and
ED9834 and ED9835 to generate mut[-145,-143,-140,-137]. To construct mut[-149,
-148,+5,+6], oligonucleotides ED9828 and ED9829 were inserted in the above described
mut[+5,+6]. To create mut[-144,+1,+13], oligonucleotides ED9830 and ED9831 were
inserted in mut[+1,+13], and oligonucleotides ED9834 and ED9835 were inserted in
mut[-2,-1] to generate mut[-145,-143,-140,-137,-2,-1].
To generate constructs for in vitro transcription, elements I and II were cloned in
pBluescript II KS+ in the forward (fw) and reverse (rev) orientation behind the T7 promoter as
follows. First, elements I and II were PCR amplified using oligonucleotides ED9601 (5' XbaI
-2119/-2100 3') and ED9602 (5' XbaI-1964/-1983 3') for element I, and oligonucleotides
ED9603 (5' BamHI -204/-185 3') and ED9604 (5' BamHI +181/+202 3') for element II. The
PCR products containing element I and element II were digested with XbaI and BamHI,
respectively, and subsequently cloned in the corresponding sites in pBluescript II KS+. This
resulted in 5 plasmids: BS-Ifw, BS-Irev, BS-IIfw, BS-IIrev, BS-Ifw/IIfw.
Introduction of mutations into the region 130-80 nucleotides upstream of the cleavage
site in element II was performed as follows. Plasmid BS-IIfw was digested with BglII and
AvrII (positions -110 and -80, respectively) and religated to create BS-IIfwÄ-110/-80.
Double-stranded oligonucleotides containing the desired mutations were inserted in the
BglII/Avr II sites to generate the other mutants (for sequences of the oligonucleotides, see list
below). A deletion mutant lacking the 5' part of element II from positions -174 to -110 was
constructed by digesting plasmid BS-Ifw/IIfw with BglII (position -110) and SpeI (in the 10
nt long polylinker fragment of pBluescript between the 3' XbaI site of element I and the 5'
BamHI site of element II) and religation of the plasmid.
Several of the mutations originally introduced into BS-IIfw were transferred to the
expression plasmid EP7-9/NotI (plasmid EP7-9 with a unique NotI site constructed at position
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+83, Meinsma et al., 1992) via PCR amplification of the region in element II containing the
mutations using the upstream primer ED9723 hybridizing to nucleotides -154/-128 (upstream
of the BglII site at position -110) and the downstream primer ED9722 hybridizing to
nucleotides +60/+93 (introducing a NotI site at position +80). Subsequent digestion of the
PCR products with BglII and NotI resulted in BglII/NotI fragments that were cloned in the
corresponding sites in EP7-9/NotI. Sequences of the oligonucleotides used for the
introduction of (point) mutations or PCR amplification are listed below. Altered nucleotides
that were introduced in order to construct restriction sites or point mutations are underlined.
Oligonucleotide          Sequence
WS9502         5'-CACACTCCCATCATCAGTGCAC-3'
WS9504         5'-TTCCCACACGACCCGCATCAGT-3'
WS9505         5'-CGACTTCCCACCATCCCCGCAT-3'
WS9507         5'-GCCAGACTTCAAACACTCCCCG-3'
DM6              5'-CTGTCAATCCTCCTGACTTTTC-3'
ED9601         5'-GGCTGGTCTAGA GTTTCCATCAGGTTCCATCC-3'
ED9602         5'-GAGGCCTCTAGA TTGTACATGTTTGAAGATGC-3'
ED9603         5'-TGCCGC GGATCCTGAGGAAGGAGTTTGGCCAC-3'
ED9604         5'-GTCCGCGGATCCAAGAAACAAAGAGGGGGAAT-3'
ED9706         5'-GATCTTACCGGAGCACAC-3'
ED9707                   3'-AATGGCCTCGTGTGGATC-5'
ED9708         5'-GATCTTGGGGACCCCCCCACCGGC-3'
ED9709                   3'-AACCCCTGGGGGGGTGGCCGGATC-5'
ED9710         5'-GATCTTGGGGACCCCCCCACATATACACAC-3'
ED9711                   3'-AACCCCTGGGGGGGTGTATATGTGTGGATC-5'
ED9714         5'-GATCTTGGGGACCCCCCCAAAGCACAC-3'
ED9715                   3'-AACCCCTGGGGGGGTTTCGTGTGGATC-5'
ED9716         5'-GATCTTGGGGACCCCCCCACCGGTACACAC-3'
ED9717                   3'-AACCCCTGGGGGGGTGGCCATGCGTGGATC-5'
ED9718         5'-GATCTTGGGGACCCCCCCACCGGAGGTCAC-3'
ED9719                   3'-AACCCCTGGGGGGGTGGCCTCCAGTGGATC-3'
ED9720         5'-GATCTTGGGGACCCCCCCACCGGAGCAGTC-3'
ED9721                   3'-AACCCCTGGGGGGGTGGCCTCGTCAGGATC-3'
ED9722         5'-AAAATCTCCCGCGGCCGCTTCCTACCCCAGAAC-3'
ED9723         5'-TGCCCCCACGAGTAGCCTGACTCCCTG-3'
ED9726         5'-CGATGCCGGTAGCTGAGCAGACATGCCCCCACGCTCCC-
                           TGACTCCCTGGTGTGCTCCTGGAAGGAA-3'
ED9727         3'-TACGGCCATCGACTCGTCTGTACGGGGGTGCGAGGGAC-
                           TGAGGGACCACACGAGGACCTTCCTTCTAG-5'
ED9728         5'-CGATGCCGGTAGCTGAGCAGACATGCCCAAACGAGT-
                          AGCCTGACTCCCTGGTGTGCTCCTGGAAGGAA-3'
ED9729         3'-TACGGCCATCGACTCGTCTGTACGGGTTTGCTCATCG-
                          GACTGAGGGACCACACGAGGACCTTCCTTCTAG-5'
ED9830         5'-CGATGCCGGTAGCTGAGCAGACATGCCCCCACGCGTAGC-
                          CTGACTCCCTGGTGTGCTCCTGGAAGGAA-3'
ED9831         3'-ACGGCCATCGACTCGTCTGTACGGGGGTGCGCATCGGA-
                          CTGAGGGACCACACGAGGACCTTCCTTCTAG-5'
ED9832         5'-CGATGCCGGTAGCTGAGCAGACATGCCCACTATAGTA-
                          GCCTGACTCCCTGGTGTGCTCCTGGAAGGAA-3'
ED9833         3'-TACGGCCATCGACTCGTCTGTACGGGTGATATCATCGGA-
                          CTGAGGGACCACACGAGGACCTTCCTTCTAG-5'
ED9834         5'-CGATGCCGGTAGCTGAGCAGACATGCCCCCACAAATACC-
                          CCGACTCCCTGGTGTGCTCCTGGAAGGAA-3'
ED9835         3'-TACGGCCATCGACTCGTCTGTACGGGGGTGTTTATGGG-
                          GCTGAGGGACCACACGAGGACCTTCCTTCTAG-5'
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Cell culture and transfection. Human 293 cells were grown in Dulbecco’s modified Eagle’s
medium, and human Hep3B cells were grown in á-modified minimum essential medium.
Both media were supplemented with 10% fetal calf serum, 100 IU of penicillin per ml, 100 ìg
of streptomycin per ml, and 300 ìg of glutamine per ml. Human 293 cells were transfected in
75 cm2 flasks at a confluence of about 50% by the calcium phosphate coprecipitation method
(Sambrook et al ., 1989; Graham and van der Eb, 1973). Precipitates were prepared with BES-
buffered saline (BBS) (Sambrook et al., 1989) and contained 10 ìg of CMV/IGF-II constructs
and 1.0 ìg of RSV-Luciferase (de Wet et al ., 1987), and were added to the cells. After 4 h, the
medium was aspirated and the cells were treated for 1 min with medium containing 10%
dimethylsulfoxide. Subsequently, the cells were refed with serum-containing medium. After
30 to 48 h, the cells were washed with PBS and harvested in PBS with 0.025 % trypsin-0.02
% EDTA. To compare transfection efficiencies of the various IGF-II expression constructs,
10% of the cells were used for a luciferase assay (de Wet et al., 1987). RNA was isolated
from the remaining 90% of the cells.
RNA isolation and analysis. Total RNA was isolated using the RNAzol reagent according to
the manufacturer’s instructions. Cells isolated from a 75 cm2 flask were lysed in 1.5 ml of
RNAzol reagent and RNA was isolated from the water phase by isopropanol precipitation and
resuspended in water. RNA was glyoxalated, size-separated on a 1% agarose-10 mM sodium
phosphate gel, and transferred to a Genescreen membrane. The RNA was fixed on the
membrane by irradiation with long-wavelength UV light for 2.5 min. Northern blots were
hybridized in the presence of 50% formamide in glass cylinders with continuous rotation at 42
oC according to the Genescreen protocols. As a probe, a 1.0 kb SmaI fragment from the
human IGF-II exon 9 (positions +84 to +1096), hybridizing to both the full-length IGF-II
RNAs and the 3' cleavage product, was used. The DNA fragments were labeled by random
priming with [á-32P]dCTP following the Amersham protocols. After a 2-h prehybridization,
probe was added at a final concentration of 106 cpm/ml. Blots were washed after overnight
hybridization, to a final stringency of 0.5 x SSC- 1% SDS at 65 oC (1xSSC is 0.15 M NaCl
plus 0.015 M sodium citrate) and exposed to Fuji RX X-ray film. The amounts of cleavage
products were determined by densitometric scanning of the autoradiographs of at least 2
independent experiments. Cleavage efficiencies were determined by calculating the amount of
3' cleavage product divided by the total amount of IGF-II RNA. Variation between the
calculated cleavage efficiencies in separate experiments was less than 10%.
In vitro transcription. Radiolabeled RNA probes were synthesized using T7 RNA
polymerase on linearized DNA templates according to instructions of the manufacturer in the
presence of 1 mM ATP, GTP, and UTP each and 20 ìCi [á-32P]-CTP and 0.1 mM CTP.
pBluescript plasmids containing IGF-II inserts (described above) were linearized with EcoRV
to generate full-length RNA. To obtain RNAs harboring progressive truncations in element II,
pBluescript-IGF-II plasmids were linearized with SmaI, AvaI, AvrII or BglII, resulting in
RNAs truncated at positions +83, -23, -76, and -106, respectively. After RNA synthesis (30
min.), the template was removed by DNase I treatment (1 U in 20ìl reaction mixture for 10
min. at 37 oC) and the RNA was phenol/chloroform extracted, ethanol precipitated, washed in
70% ethanol and dissolved in DEPC-treated water. Specific activity of the RNA was
determined by scintillation counting.
Electrophoretic mobility shift assays. For electrophoretic mobility shift assays (EMSAs),
32P-labeled RNA probes (105 cpm, 2-3 ng RNA) were incubated in cytoplasmic extracts from
Hep3B cells, with a protein content of 10 ìg in a 10 ìl reaction mixture containing 20 mM
Hepes-KOH pH 7.5, 100 mM KCl, 1 mM MgCl2 1 mM DTT, and 0.01 % NP40 for 45 min on
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ice. After the binding reaction, the samples were incubated at room temperature for 20 min
with a mixture of 12.5 ìg/ml RNase A and 2 U/ml RNase T1. Samples were subsequently
electrophoresed on non-denaturing 6% polyacrylamide gels. Gels were dried and exposed to
Fuji RX X-ray film. In competition assays, a 100- to 500-fold molar excess of unlabeled
competitor RNA was added to the reaction mixture 10 min prior to addition of the probe.
Primer extension analysis. Primer extension was carried out as described by (McKnight and
Kingsbury, 1982). A 5' [ã32 P]ATP end-labeled oligonucleotide (DM 6), complementary to
nucleotides +99/+120 downstream of the cleavage site, was annealed to 1 ìg of poly(A)+
RNA (from cells expressing the EP7-9 Ä-1957/-110 construct, 8 ìg of poly(A)+ RNA was
used instead of 1 ìg, because of the low abundance of the 3' cleavage product) in 1 M NaCl,
0.17 M Hepes-KOH pH 7.5, and 0.33 mM EDTA pH 8.0. Subsequently, the primer was
extended towards the cleavage site in 0.55 mM dATP/dCTP/dGTP/dTTP, 50 mM \Tris-HCl
pH 8.2, 5 mM MgCl2, 50 mM KCl, 0.05 mg/ml BSA, and 5 mM DTT. The extension
products were electrophoresed on sequencing gels along with a sequencing reaction carried
out with the same primer as a marker. The gels were exposed to Fuji RX X-ray films or to
phosphoimager screens (Molecular Dynamics, USA).
Preparation of extracts. Cells were washed in PBS and harvested in 0.025 % trypsin/0.02%
EDTA, followed by washing in PBS twice. Then the cells were spun down quickly and the
pellet was dissolved in 20 mM Hepes-KOH pH 7.5, 5 mM KCl, 0.1% NP40, 10 mM sodium
metabisulfite and left on ice for 20 min. Subsequently, the cells were Dounce homogenized
and centrifuged for 5 min at 4  oC 3500rpm. After additional centrifugation for 40 min at 4  oC,
30,000 rpm in a Beckman SW 50.1 rotor, the supernatant was supplemented with 20%
glycerol and 1 mM DTT and stored at -80 oC.
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CHAPTER 4
Distinct RNA structural domains cooperate to maintain a
specific cleavage site in the 3’-UTR of IGF-II mRNAs
Erwin L. van Dijk, John S. Sussenbach, and P. Elly Holthuizen. University
Medical Center Utrecht, Department Physiological Chemistry, Utrecht, The
Netherlands.
J. Mol. Biol (2000) 300, 449-467
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SUMMARY
The insulin-like growth factor II (IGF-II) mRNAs are targets for site-specific
endonucleolytic cleavage in the 3’-UTR, which results in a very stable 3’ cleavage
product of 1.8 kb that consists of 3’-UTR sequences and a poly(A) tail. The 5’
cleavage product contains the coding region and is rapidly degraded. Thus, cleavage is
thought to provide an additional way to control IGF-II protein synthesis. We have
established previously that cleavage requires two widely separated sequence elements
(I and II) in the 3’-UTR that form a stable duplex of 83 nucleotides. The cleavage site
itself is located in an internal loop preceded by two stable stem-loop structures.
Furthermore, in a study that was based on RNA folding algorithms, we have shown
that there are specific sequence- and structural requirements for the cleavage reaction.
In this study, the functions of the different structural domains in cleavage were
assessed by deletion/mutational analyses, and biochemical structure probing assays
were performed to better characterize the RNA structures formed and to verify the
computer folding predictions. The data suggest that the stem-loop domain contributes
to maintain a highly specific cleavage site by preventing the formation of alternative
structures in the cleavage site domain. Involvement of the nucleotides in the cleavage
site loop itself in non-Watson-Crick interactions may be important to provide a
specific recognition surface for an endoribonuclease activity.
INTRODUCTION
Human insulin-like growth factor II (IGF-II) is a mitogenic polypeptide
consisting of 67 amino acids showing strong structural and functional homology to
insulin (Daughaday and Rotwein, 1989). IGF-II is essential for embryonic growth and
development as was demonstrated by targeted gene disruption (DeChiara et al., 1990).
IGF-II also exerts a wide range of biological activities in cultured cells: it can promote
either cell proliferation or differentiation, depending on the cell type in which it is
expressed. IGF-II profoundly affects cellular survival and counteracts apoptosis in
some cell systems, whereas in other cell lines an apoptosis-inducing effect by IGF-II is
observed (Engstrom et al., 1998, and references therein). Thus, as IGF-II is involved in
many physiological processes, a proper regulation of IGF-II gene expression is of
crucial importance. Therefore, an elaborate set of regulatory mechanisms is available
for this gene, ranging from developmental stage-dependent and tissue-specific
expression of four different promoters to post-translational processing of the IGF-II
precursor protein (for a review, see Holthuizen et al. (1999)).
Previously, we established that the human IGF-II gene can also be regulated at
the level of mRNA stability. It was shown that the protein-coding part of the IGF-II
mRNAs is targeted for rapid degradation through site-specific endonucleolytic
cleavage in the 3’-UTR. In contrast to the unstable 5’ cleavage product, a very stable
3’ cleavage product of 1.8 kb is formed (De Pagter-Holthuizen et al., 1988; Meinsma
et al., 1991; Meinsma et al., 1992). Similar observations were made for the rat IGF-II
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gene (Nielsen and Christiansen, 1992), and also for the mouse IGF-II gene (Holthuizen
et al., 1993).
Regulation of gene expression at the level of mRNA stability is now becoming
a common theme, as a rapidly increasing number of genes appears to be regulated at
this post-transcriptional level (for reviews, see Beelman and Parker (1995); Ross
(1995); Jacobson and Peltz (1996); Wickens et al. (1997)). Initiation of mRNA
degradation can occur through poly(A) shortening, arrest of translation at a premature
stopcodon (nonsense-mediated decay, or NMD), or through endonucleolytic cleavage.
To date, for a number of mRNAs endonucleolytic cleavage has been found to be the
first step of degradation. Examples are the mRNAs encoding albumin (Dompenciel et
al., 1995; Chernokalskaya et al., 1997), the cytokine groa  (Stoeckle, 1992), avian
apo-very-low density lipoprotein II (Binder et al., 1989), the transferrin receptor
(Binder et al., 1994), and maternal homeodomain proteins (Brown and Harland, 1990;
Brown et al., 1993). The c-myc mRNA can be cleaved in the coding region, but can
also be destabilized through AU-rich elements in the 3’-UTR (Swartwout and
Kinniburgh, 1989; Ioannidis et al., 1996).
We have established that for in vivo cleavage of IGF-II mRNAs, two widely
separated sequence elements in the 3’-UTR are necessary and sufficient (Fig. 1A)
(Meinsma et al., 1992). Element II encompasses the cleavage site, and is located from
positions -173 to +150 relative to the cleavage site. It contains two domains that are
highly conserved among human, rat and mouse: an upstream domain from positions
-133 to -7 containing two stable stem-loop structures, and a downstream G-rich
domain from positions -5 to +59. Element I is a very C-rich element of 103
nucleotides long and it is located approximately 2 kb upstream of the cleavage site
from positions -2116 to -2013 (Fig. 1A).
Previous RNA folding studies have shown that element I can form a stable
RNA:RNA duplex with the downstream region of element II from positions +18 to
+101 (Scheper et al., 1995). Thus, the RNA regions found to be required for cleavage
can be subdivided into three separate folding domains: (1) the upstream stem-loop
domain consisting of a 5’- and a 3’ stem-loop; (2) the duplex domain consisting of the
downstream region of element II that folds into an extended duplex of 83 nt with
element I, and (3) the cleavage site itself, located in an internal loop flanked by two
helical regions and a second internal loop (Fig. 1B). We will refer to this latter region
as the ‘cleavage site domain’. In a previous study, we have found that there are both
sequence- and structural requirements for efficient cleavage (van Dijk et al., 1998).
Here, we assess the roles of the various RNA folding domains in cleavage. Structure
probing experiments were performed to obtain biochemical information on the RNA
structures formed and to evaluate the computer predictions. Our data indicate that the
stem-loop domain serves to stabilize a proper conformation in the cleavage site
domain. Non-Watson-Crick interactions in the cleavage site loop may be important for
recognition by an endoribonuclease.
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(A)
                
(B)
Figure 1. (A) Schematic representation of the 3'-UTR of the human IGF-II mRNAs. Elements I and II
are indicated by bars, the secondary structure of the RNA region around the cleavage site (arrow) is
shown. The 5’ and the 3’ stem-loop are indicated. (B) MFOLD secondary structure prediction of the
RNA structural domains formed by elements I and II. Shown is a folding where the spacing between
the elements is identical to construct DWT, which lacks the region from -1955 to -174. Thus, a 59 nt
long 3’ flanking sequence of element I still separates the two elements. The site of the deletion is
indicated by a bent arrow; the cleavage site (CS) is indicated by a straight arrow.
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RESULTS
Experimental strategy
In order to study in vivo cleavage of IGF-II mRNAs, we previously constructed
a human IGF-II minigene construct. In this construct, designated EP7-9, the
immediate-early cytomegalovirus (CMV) enhancer-promoter region (Boshart et al.,
1985) is fused to the IGF-II protein-encoding exons 7, 8, and 9 (Fig. 2A), giving rise to
an IGF-II transcript of 4.8 kb (Meinsma et al., 1992). Transient transfection assays of
this construct into human 293 cells that do not express IGF-II endogenously, and
subsequent Northern blotting analysis of the IGF-II mRNAs showed that in addition to
the 4.8 kb transcript also a specific 1.8 kb cleavage product is formed as a
consequence of site-specific endonucleolytic cleavage in the 3'-UTR of IGF-II
mRNAs (Meinsma et al., 1991). Analysis of deletion derivatives of EP7-9 revealed
that a region in the 3'-UTR between elements I and II from positions -1955 to -174
relative to the cleavage site could be deleted without affecting cleavage efficiency
(Meinsma et al., 1992). This construct, named DWT in (van Dijk et al., 1998) (Fig.
2B), gives rise to a full-length 3.0 kb IGF-II transcript and a 1.8 kb 3’ cleavage
product (Fig. 3B, lane 1).
In the present study, we have generated a number of constructs that are similar
to DWT, but contain in addition deletions in the stem-loop region upstream of the
cleavage site (-133/-7). Since DWT RNA is cleaved as efficiently as the full-length
wild type RNA, the cleavage efficiency of DWT was set at 100%. All mutants are
named after the positions of the deletions relative to the cleavage site. The minimal
free energy foldings of the various RNAs were predicted using the MFOLD version
2.3 Internet server (http://mfold2.wustl.edu/~mfold/ rna/form1-2.3.cgi) based on the
computer algorithm by (Zuker, 1989). For each mutant, the energetically most
favorable structure out of a maximum of five alternative foldings is shown.
Major deletions in the stem-loop domain.
To gain insight into the importance of the RNA region from positions -133 to
-7, which is predicted to fold into two stem-loop structures, a set of several major
deletions was introduced using the Bal31 exonuclease system (see Materials and
Methods). All four resulting deletion mutants lacked a major part of the stem-loop
domain, and in two mutants ([D-145/-22] and [D-170/-6]) also the residues opposite of
the cleavage site were deleted (Fig. 3A). In all four mutants, the nucleotides directly
adjacent to the cleavage site are still present, and in [D-116/-31] and [D-116/-24], all
sequences constituting the cleavage site domain (Fig. 1B) are still intact. Computer
folding however, predicted that formation of the internal loop around the cleavage site
is distorted in all mutants, causing the cleavage site to be in a structurally different
environment than in the wild type situation (Fig. 3A). The minimal free energy
foldings of mutants [D-116/-31] and [D-116/-24], which bear similar deletions, might
be expected to be similar, but are in fact significantly different.
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Figure 2. Schematic representation of the CMV-IGF-II minigenes. (A) Construct EP7-9 contains the
enhancer/promoter region and exon 1 of cytomegalovirus (CMV) fused to a 10.9 kb genomic fragment
of the human IGF-II gene containing exons 7, 8, and 9 cloned in pUC8 (bold line). The CMV regions
and the IGF-II and pUC regions are drawn at different scales. The arrow indicates the transcription
start site. Translated and untranslated IGF-II regions are depicted by filled and open boxes,
respectively. The stippled area in exon 9 represents the 1.8 kb RNA region. (B) Enlarged
representation of human IGF-II exon 9. Positions (bp) in exon 9 are relative to the cleavage site (+1).
The two elements required for cleavage, element I (-2116 to -2013) and element II (-174 to +150) are
indicated by bars (I, II). The EP7-9 derivative DWT, in which the region between elements I and II
(-1955 to -174) is deleted, is shown. The transcript of DWT (3.0 kb) is endonucleolytically cleaved with
wild type cleavage efficiency (Meinsma et al., 1992).
A suboptimal folding of mutant [D-116/-24] with only a slight increase in DG (from
-185.7 to -184.1), however, appeared similar to the folding shown for [D-116/-31],
indicating that both mutants can fold into the same structure.
The effects of the deletions on cleavage efficiency were tested in transient
transfection experiments of human 293 cells, which do not express IGF-II
endogenously. After transfection, RNAs were isolated from the cells and subjected to
Northern blot analysis using a probe that detects the 1.8 kb 3’ cleavage product and the
full-length IGF-II RNA (Fig. 3B). Cleavage of the wild type RNA (DWT) was very
efficient as shown by the amount of 1.8 kb RNA relative to full-length IGF-II mRNAs
(lane 1). This cleavage efficiency was set to 100%. Compared to the wild type RNA,
all mutants showed a severe reduction in cleavage activity, or were not cleaved at all
(lanes 2-5). These results indicate that large deletions of the stem-loop region upstream
of the cleavage site strongly interfere with cleavage. Although the nucleotide sequence
around the cleavage site itself is intact, the folding of the RNA is severely affected.
Absence of IGF-II mRNA cleavage could be caused either because one or both of the
stem-loops has/have a specific function in cleavage or because this RNA region is
involved in maintaining a proper fold around the cleavage site.
     E-P
 CMV     IGF-II                                                                 pUC8
         7          8                       9+1
0.1 kb                   1.0 kb
    I                                                     II
-2400      -2000       -1600       -1200        -800         -400           +1          +400        +800       +1200      +1600 
-1955/-174 (   WT)            D            D
(B) 
(A)
3.0 kb
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Subdomain deletions in the stem-loop domain.
To distinguish between these two possibilities, several specific deletions were
introduced in the stem-loop region while maintaining the predicted wild type
secondary structure around the cleavage site (Fig 4A).
It should be noted that in all these constructs, the duplex domain (positions
-2108 to -2029 and +18 to +101) was left intact, since this region is absolutely
required for cleavage; absence of the duplex domain was shown to abolish cleavage
completely (Scheper et al., 1995). Computer folding and structure probing studies
indicate that absence of the duplex interaction results in structural changes in the
cleavage site domain (see Discussion). The cleavage efficiency of the various mutants
was tested in transient transfection assays of human 293 cells followed by Northern
blot analysis of the isolated RNAs. A region from positions -104 to -78 was deleted in
mutant [D-104/-78], leading to a truncated 5’ stem-loop (Fig 4A, structure 2). This
mutant shows a moderate reduction in cleavage efficiency to 57% of the wild type, as
shown in Fig. 4B, lane 2. In mutant [D-135/-72], the entire 5’ stem-loop is deleted
while the 3’ stem-loop is intact (Fig. 4A, structure 3). This mutant structure can also
still be cleaved with a reasonable efficiency (51%), indicating that the 5’ stem-loop is
not absolutely required for cleavage. In mutant [D-135/-72, D-60/-18], the 5’ stem-loop
is deleted and the 3’ stem-loop is truncated, leading to the predicted structure shown in
Fig. 4A, structure 4. Although the cleavage site loop is still predicted to be in the wild
type configuration in this mutant, cleavage is almost absent (Fig. 4B, lane 4).
Surprisingly, however, when the deletion is extended with another 11 nucleotides, as
in mutant [D-135/-18] (Fig. 4A, structure 5), thus practically removing both the 5’ and
the 3’ stem-loops, the cleavage efficiency is restored again to 47% of the wild type
level (Fig. 4B, lane 5). These data indicate that although the deletions in the stem-loop
region reduce the cleavage efficiency about twofold, cleavage is not completely
abolished. The result with mutant [D-135/-18] shows that cleavage can occur even in
the complete absence of both stem-loops. Thus, it appears that the stem-loop domain
per se is not required for cleavage, but rather that the maintenance of a native
conformation around the cleavage site is important. The observation that mutant
[D-135/-72, D-60/-18] is cleaved with a markedly reduced efficiency while the
predicted cleavage site domain is intact might be explained by conformational changes
around the cleavage site, which are not predicted by the computer program. To
identify such conformational changes, we have performed RNA structure probing
experiments (see below), and primer extension analysis was performed to check the
integrity of the cleavage site position in the various mutants.
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Figure 3. (A) MFOLD predicted secondary structures of the RNA regions encompassing the cleavage
site in DWT and the various deletion mutants generated with the Bal31 exonuclease system (see
Materials and Methods). Shown are the energetically most favorable structures. In all constructs,
nucleotides are numbered according to their original position relative to the cleavage site (straight
arrow) in the wild type RNA, irrespective of position changes due to the introduced deletions. The
deletions are indicated by bent arrows. (B) Northern blot analysis of total RNA isolated from human
293 cells transiently transfected with the CMV-IGF-II minigene constructs. The lanes are numbered
according to the numbers of the constructs shown in (A). The blot was hybridized to a radiolabeled
DNA fragment (+84 to +1096) that detects both full-length IGF-II mRNA (3.0 kb) and the 3’ cleavage
product of 1.8 kb (indicated on the left). For each mutant, the cleavage efficiency relative to DWT as
determined in at least 3 independent experiments (see Materials and Methods) is shown under the
lanes.
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Figure 4. (legend shown on next page)
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Figure 4. (A) Predicted minimal free energy structures of DWT and the various mutants harboring
increasing deletions. Numbering of the nucleotides is according to their original positions relative to
the cleavage site (straight arrow) in the wild type. The deletions are indicated by bent arrows. (B)
Northern blot analysis of total RNA from 293 cells transfected with the various constructs shown in (A).
The lanes are numbered according to the numbers of the constructs. Full-length IGF-II mRNA as well
as the 3’ cleavage product of 1.8 kb was detected using a 3’ specific probe hybridizing to nucleotides
+84/+1096. Sizes of the RNA species are indicated on the left in kb. The cleavage efficiency of each
mutant (relative to DWT) as determined in at least three independent experiments is shown under the
lanes.
Primer extension analysis.
In order to determine whether the cleavage site specificity is affected by the
various deletions in the stem-loop region, primer extension analysis was performed of
poly(A)+ RNA isolated from 293 cells transiently transfected with the different
constructs. Oligonucleotide DM6, complementary to nucleotides +99 to +120, was
used for the extension reactions. With all mutants, a single extension product of the
expected size was observed, indicating that if cleavage occurs, it is at the correct site
(Fig. 5). Even with the Bal31-generated deletion mutants [D-116/-31] and [D-145/-22],
which have a very low cleavage efficiency of 3 and 7% of the wild type (Fig. 3B),
respectively, an extension product of the expected size could be detected. Thus, neither
the absence of the stem-loop region nor the distortion of a native conformation around
the cleavage site appears to affect cleavage site specificity. This indicates that the
residues adjacent to the cleavage site suffice for specific recognition, although it is
clear that structural requirements must be met to allow efficient cleavage.
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Figure 5. Primer extension analysis of IGF-II RNAs. A 5’ end-labeled primer (DM6) complementary to
nucleotides +99 to +120 was hybridized to 1 or 3 mg (see Materials and Methods) of poly(A)+ RNA
from 293 cells transiently transfected with the various IGF-II minigene constructs. A sequencing
reaction carried out with the same primer was run along with the extension reactions as a size marker.
The position of the cleavage site is shown on the left by an arrow. Contents of the lanes is as follows:
lane 1: DWT, lane 2: [D-116/-31], lane 3: [D-145/-22], lane 4: [D-104/-78], lane 5: [D-135/-72], lane 6:
[D-135/-72, D-60/-18], lane 7: [D-135/-18].
Structure probing of the RNA region comprising the stem-loop domain and the
cleavage site domain.
In order to evaluate the computer predictions of the secondary structures around
the cleavage site, RNA structure probing experiments were performed using the primer
extension approach (see Materials and Methods). In vitro synthesized RNA was
subjected to limited RNase hydrolysis or chemical modification using structure-
specific reagents. After stopping the reactions, the RNAs were purified and hybridized
with oligonucleotides and primer extension reactions were carried out. Modified
nucleotides or cleaved bonds were detected as reverse transcriptase stops in the primer
extension reactions.
First, to detect nucleotides not involved in Watson-Crick base-pairing, the
following reagents were used: RNase T2, which cleaves 3’ to any unpaired nucleotide;
RNase T1, which cleaves 3’ to unpaired G residues, dimethylsulphate (DMS), which
methylates unpaired A’s at N-1 and unpaired C’s at N-3, and 1-cyclohexyl-3-
(2-morpholinoethyl) carbodiimide metho-p-toluenesulphonate (CMCT), which
modifies the N-3 group of unpaired U’s and weakly, the N-1 group of unpaired G’s.
Second, to detect double-stranded RNA regions, RNase V1 was used, which cleaves
RNA that is in helical conformations, whether base-paired or single-stranded but
stacked. For the primer extension reactions, two different primers were used: WS9502,
hybridizing to nucleotides -1/+21 and ED9954, hybridizing to nucleotides +30/+60.
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Typical experiments are shown in Fig. 6A and B; a summary of the probing data,
based on at least 5 independent experiments is shown in Fig. 6C.
 The chemical modification analysis combined with the enzymatic probing
allowed a characterization of a substantial part of the RNA region around the cleavage
site. In general, the reactivity pattern confirms the predicted secondary structure
obtained with the computer algorithm, although also some discrepancies were
observed.
The tops of both stem-loops upstream of the cleavage site were especially
reactive, indicating that these regions are very well accessible to the reagents (Fig.
6C). At the top of the 5’ stem-loop, nucleotides that were predicted to be located in
short helices, reacted with single-strand specific reagents, indicating that under our
assay conditions these base-pairs were rather unstable, if present at all. Also at the top
of the 3’ stem, some residues predicted to be base-paired, were reactive to single-
strand specific probes, indicating that also here the conformation is more open than
predicted.
At the base of the 3’ stem, a U-rich region from positions -69 to -63 showed
reactivity to RNase T2, suggesting that these nucleotides are not stably base-paired
(Fig. 6A and C). This may be due to the formation of an internal loop and two
mismatches in this region causing breathing of the helix.
Thus, the stem-loop domain contains regions of flexibility at the tops of both
stems and at the base of the 3’ stem. However, RNase V1 reactivity was seen in
predicted base-paired regions in the stem-loop domain at positions -122 to -119, -82 to
-79 and -49 to -45. This indicates that stable helices were formed in these regions.
Strong RNase V1 reactivity was also observed in the cleavage site domain at positions
-139, -138, confirming the formation of a stable helix above the cleavage site loop.
Under the assay conditions used, RNase V1 showed a preference for C-residues,
whereas it has been described to attack any nucleotide in helical conformation.
The residues at positions -144 to -140 and -2 to +1, forming the internal loop
around the cleavage site, showed no clear reactivity to single-strand specific probes,
except weakly for the G residue at position -143. This indicates that these bases are not
free in solution under the native conditions used. The U-residue at position +2, which
is predicted to be base-paired with the G at position -145 reacted with CMCT, but in
contrast, the nucleotides 5’-GA9G-3’ at the cleavage site were not reactive under
native conditions. These data show that the reactive sites of the nucleotides in the
cleavage site loop are protected from the reagents, suggesting that they are not
exposed, as would be expected for an open loop conformation.
In contrast to the residues of the cleavage site loop, nucleotides in the second
internal loop in the cleavage site domain (positions -155 to -151 and +8, +9) clearly
showed reactivity under native conditions (Figure 6A, B, and C). The A at position +8
and to a lesser extent the A at +9 were reactive to DMS and RNase T2; the G at
position -153 was strongly reactive to RNase T1. These results indicate that this loop
has a more open conformation than the loop of the cleavage site.
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(A)                                                       (B)
               
Figure 6. (legend shown on next page)
Structure probing of deletion mutants [D-135/-18] and [ D-135/-72, D-60/-18]
under native and semi-denaturing conditions.
In order to obtain a better insight into functionally important structural aspects
of the cleavage site domain, structure probing of deletion mutants [D-135/-18] and
[D-135/-72, D-60/-18] was carried out. Mutant  [D-135/-72, D-60/-18] has a much
lower cleavage efficiency than [D-135/-18] (Fig. 4A and B), suggesting that important
recognition determinants may be lost.
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Figure 6. Chemical modification analysis with DMS and CMCT, and enzymatic digestion with RNases
T1, T2, and V1. Modifications or digestions were performed in native buffer at 30 oC or room
temperature, respectively. Reverse transcription was carried out with (A) primer WS9502,
complementary to nucleotides -1 to +21 and (B) primer ED9954, complementary to nucleotides +30 to
+60. Control reactions without reagents, or sequencing reactions performed with the same primer
were run in parallel. The position of the cleavage site is indicated in (B). Numbering of the nucleotides
is as in (C). (C) Summary of the probing results. Residues that were reactive to DMS are indicated by
an arrow ('), residues reactive to CMCT are indicated by a triangle (), and residues showing
reactivity to RNases T1, -T2, or -V1 are indicated by a diamond (), a square (), or a dot (),
respectively. Weak or strong reactivity is represented by smaller or larger symbols.
Structure probing was performed in the presence (native conditions) and in the
absence (semi-denaturing conditions) of Mg2+ ions. Under the latter conditions, non-
Watson-Crick interactions are expected to be weakened. DMS was used to detect
single-stranded A’s and C’s, and CMCT for single-stranded U’s and G’s. Kethoxal
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was also used to detect single-stranded G-residues, instead of RNase T1, because this
compound might have a higher resolution due to its smaller size. Primer extensions
were done using primer DM6 that is complementary to nucleotides +99 to +120.
With mutant [D-135/-18], DMS modification was observed of the A residues at
positions +8 and +9 under native conditions, similar to DWT (Figs. 6B, 7A and 7B).
The reactivity of these nucleotides was not significantly enhanced under semi-
denaturing conditions. Similarly, the C at -12 and the A at -9, predicted to be located
in the terminal loop were reactive under both native and semi-denaturing conditions,
confirming their single-strandedness. Strong reactivity was observed with the
A-residues at positions -13 and -147, although these nucleotides are predicted to be
located in Watson-Crick helices. Also with CMCT and kethoxal, reactivity of
nucleotides in the predicted helices was seen. Thus, these helices may be rather
unstable. However, strong RNase V1 reactivity was observed with the C residues at
-139 and -138, similar to DWT (Fig. 6A, C, and data not shown). This indicates that a
short but stable helix is formed right above the cleavage site. The two bulged G
residues at positions -136 and -17, bordering the deletion site, are reactive to kethoxal
only under semi-denaturing conditions, suggesting that these nucleotides exist in a
stacking conformation.
Most significantly, nucleotides -144 to -140 and -2 to +1 show little or no
reactivity under native conditions. Under semi-denaturing conditions, however, the
A’s at -144, -140, and -1 become reactive to DMS, the U at -142 becomes reactive to
CMCT, and the G at -140 becomes reactive to kethoxal. The G’s at -143, -2 and +1
remain nonreactive. These results indicate that the nucleotides constituting the
cleavage site loop are not free in solution, but may be involved in non-Watson-Crick
base-pairings.
In mutant  [D-135/-72, D-60/-18], the situation is significantly different. In
general, a lower reactivity in the cleavage site domain was observed for this mutant,
but the nucleotides in the cleavage site loop were much more reactive (Fig. 8A and B).
Their reactivity was similar to the reactivity of the residues predicted to be located in
the terminal loop, which were also readily accessible by the reagents.
The reactivity of the A at position -1 towards DMS was also tested in deletion
mutant [D-135/-72] (Fig. 4A) and a number of previously constructed mutants
containing point mutations in or near the cleavage site loop (van Dijk et al., 1998). In
mutant [D-135/-72] and in the point mutants that are still cleaved, the same reactivity
pattern was observed as in [D-135/-18], whereas in the inactive mutants the A residue
was already reactive under native conditions (data not shown).
Thus, although an exact characterization of the structures formed in the
cleavage site domain will require additional experiments, there is correlative evidence
that an involvement of the cleavage site loop residues in non-Watson-Crick base
pairings may be important for cleavage.
What may cause the altered structure of the cleavage site loop in mutant
[D-135/-72, D-60/-18]? The computer algorithm predicts a wild type conformation in
the minimal free energy folding, and also the predicted suboptimal structures of this
mutant are rather similar to those of mutant [D-135/-18] (data not shown). Thus, it is
conceivable that the explanation could lie in the RNA folding pathway and/or higher
order interactions that are not considered by the algorithm. In summary, the structure
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probing data suggest that a specific structure maintained by a set of non-Watson-Crick
interactions in the cleavage site loop may be important for efficient recognition by an
endoribonuclease.
DISCUSSION.
In previous studies, it was established that for site-specific cleavage of full-
length IGF-II mRNAs, a 323 nucleotides long sequence element encompassing the
cleavage site (element II, positions -173 to +150) as well as a 2 kb upstream located
element of 103 nucleotides long (element I, running from positions -2116 to -2013) are
necessary. These two elements form a stable duplex, and the resulting RNA structure
can be subdivided into three separate folding domains: (1) a domain upstream of the
cleavage site that folds into two stable stem-loops, (2) an 83 nt duplex domain formed
by element I and the region downstream of the cleavage site, and (3) the RNA domain
in the direct proximity of the cleavage site, where the cleavage site itself is located in
an internal loop flanked by two helical regions and a second internal loop. In this
study, we set out to gain an understanding of the function of the different RNA
domains in cleavage by deletion analyses and the consequences of the deletions on
RNA folding were predicted by the MFOLD computer algorithm (Zuker, 1989). RNA
structure probing studies were employed to verify these computer predictions.
Assessing the importance of the stem-loop domain.
In order to gain insight into the importance of the conserved stem-loop region
upstream of the cleavage site, we initially introduced major deletions in this RNA
region using the Bal31 exonuclease system, resulting in four deletion mutants that
were predicted to have an altered configuration around the cleavage site (Fig. 3A).
Cleavage efficiency was severely reduced in all mutants, indicating that the deleted
sequences are important for cleavage. In other deletion mutants that bear increasing
deletions in the stem-loop domain but still have a predicted wild type configuration in
the cleavage site domain (Fig. 4A), the effects on cleavage efficiency were much less
severe. Even in mutant [D-135/-18], where the complete stem-loop domain was
deleted, cleavage efficiency was still 47% of the wild type. This indicates that the
stem-loop domain is not necessary for cleavage per se, but rather that the cleavage site
domain must be kept in a proper fold to allow cleavage. The observed reductions in
cleavage efficiency to about half of the wild type may be due to a destabilization of the
RNA structure or to the loss of the binding site for a specific protein which we have
identified previously and was found to have a moderately stimulating effect on
cleavage (van Dijk et al., 1998). Alternatively, determinants in the stem-loops may
interact directly with the endoribonuclease to stabilize nuclease binding and enhance
cleavage efficiency.
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Figure 7. Secondary structure analysis of deletion
mutant [D-135/-18] under native and semi-denaturing
conditions. (A) Autoradiograms resulting from the
chemical probing using DMS, CMCT, and kethoxal.
Modifications were performed under native (N) or
semi-denaturing (SD) conditions at 30 oC. Reverse
transcription reactions were done using primer DM6,
hybridizing to nucleotides +99 to +120. Control
reactions without reagents and a sequencing reaction
carried out with the same primer were run in parallel.
The positions of the cleavage site (straight arrow)
and the deletion site (bent arrow) are indicated. The
nucleotides in the cleavage site loop reactive under
semi-denaturing conditions to DMS, CMCT, and
kethoxal are marked by open arrows, triangles and
crosses, respecitvely. (B) Summary of the probing
data. Reactivity to DMS is indicated by an arrow ('),
reactivity to CMCT is indicated by a triangle (), and
reactivity to kethoxal is indicated by a cross ([).
Reactivity under native conditions is indicated by
filled symbols, and reactivity under semi-denaturing
conditions is indicated by open symbols. Stronger or
weaker reactivity is accompanied by larger or smaller
symbols, respectively.
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In mutant [D-135/-72, D-60/-18], cleavage was almost absent. This was
surprising, because it has a predicted wild type configuration around the cleavage site.
RNA structure probing data however, indicate the presence of conformational changes
in the cleavage site loop of this particular construct that may be responsible for this
effect (see below).
(A)
               
Figure 8.  (legend opposite)
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In order to determine whether the deletions that influence cleavage efficiency to
varying extents would also affect cleavage specificity, primer extension mapping of
the cleavage site was done in the different mutants. The results show that in all
mutants, if cleavage occurs, it is always at the correct cleavage site, since an extension
product at the expected position is observed for all mutants (Fig. 5). Thus, none of the
deletions affect cleavage site selection, not even in the case of the Bal31-generated
deletion mutants and mutant [D-135/-72, D-60/-18], where the efficiency of cleavage is
very low.
Our results thus indicate that deletions in the stem-loop domain that affect the
structure around the cleavage site severely reduce cleavage efficiency, but nevertheless
Figure 8.  Secondary structure analysis of deletion
mutant [D-135/-72, D-60/-18] under native (N) and
semi-denaturing (SD) conditions. (A) Autoradiograms
of chemical probing using DMS, CMCT, and kethoxal.
Reverse transcription reactions were done using primer
DM6. Control reactions without reagents and a
sequencing reaction performed with the same primer
were run in parallel. The positions of the cleavage site
(straight arrow) and the deletion sites (bent arrows) are
indicated. The nucleotides in the cleavage site loop
reactive to DMS, CMCT and kethoxal under native
conditions are shown by filled arrows, triangles and
crosses, respectively. Open marks indicate reactive
nucleotides under semi-denaturing conditions.
(B) Summary of the probing data. Reactivity to DMS is
indicated by an arrow ('), reactivity to CMCT is
indicated by a triangle (), and reactivity to kethoxal is
indicated by a cross ([). Reactivity under native
conditions is indicated by filled symbols, and reactivity
under semi-denaturing conditions is indicated by open
symbols. Stronger or weaker reactivity is accompanied
by larger or smaller symbols, respectively.
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specificity is not lost. This suggests that the most important recognition determinants
lie in the direct proximity of the cleavage site, and the major role of the flanking stem-
loop domain may be to stabilize the structure of this RNA region. Similarly, in an
archaeal precursor rRNA, main recognition of three cleavage sites appears to occur at
the sequences encompassing each site but adjacent structural elements enhance the
efficiency of cleavage (Russell et al., 1999).
Possible function of the duplex domain.
What might be the role of the duplex domain? We have previously shown that
the duplex domain is necessary for cleavage as its disruption, either by deletion or
inversion of element I abolishes cleavage completely (Scheper et al., 1995). Computer
folding predicts that in the absence of the duplex interaction between elements I and II,
the region of element II around the cleavage site from positions -20 to +20 can fold
back on itself to form a hairpin loop, thus disrupting the structure of the cleavage site
domain. In addition, a G-rich region of element II from positions +24 to +56 can adopt
a compact G-quadruplex structure in the absence of the duplex (Christiansen et al.,
1994), which might also interfere with structure formation around the cleavage site.
Preliminary structure probing data confirm that in the absence of the duplex interaction
structural rearrangements occur around the cleavage site (data not shown). Although
additional experiments will be required to get a clearer picture of the function(s) of the
duplex domain, we have strong indications that it may serve to stabilize the cleavage
site domain. This would be a similar function to that of the stem-loop domain.
Supporting this interpretation, (Christiansen et al., 1994) proposed a secondary
structure model for the RNA region around the cleavage site where the cleavage site is
also located in a hairpin loop formed by the flanking sequences. These authors based
their model on structural analyses of RNAs lacking element I, suggesting that in the
absence of the duplex, the structure around the cleavage site may indeed be different.
Therefore, element I may act in a manner similar as U3 snoRNA, which is proposed to
function as a chaperone to mold pre-rRNA into the correct higher order structure
resulting in the exposure of specific cleavage sites (Borovjagin and Gerbi, 1999).
Structure probing of the RNA region comprising the cleavage site domain and
the stem-loop domain.
In order to obtain biochemical information on the RNA structures formed in the
cleavage site domain and the stem-loop domain, chemical and enzymatic structure
probing experiments were performed. In general, the probing data fit well with the
predicted structure, although reactivity to single-strand specific probes was observed
in predicted base-paired regions at the tops of both stem-loops in the stem-loop
domain (Fig. 6A, B, and C). This indicates that in these regions the structure is less
compact than predicted, presumably due to the presence of numerous loops and
mismatches. In addition, computer predictions suggest the possibility of alternative
structure formation in these regions since an older version of MFOLD predicts a
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slightly different folding at the tops of the stems (van Dijk et al., 1998). Reactivity to
RNase V1, which is specific for helical regions, was observed in predicted double-
stranded regions in the stem-loop domain and the cleavage site domain, supporting the
computer model.
Strikingly, the nucleotides in the internal loop of the cleavage site (positions
-144 to -140 and -2 to +1) show little or no reactivity under native conditions. In
contrast, residues in the second loop (positions -155 to -151 and +8, +9) are readily
detected (Fig. 6A, B and C). Under semi-denaturing conditions however, the
nucleotides of the cleavage site loop also become reactive, except the G residues at
positions -2 and +1 (Fig. 7A and B). This suggests that the nucleotides constituting the
cleavage site loop are not free in solution, but are involved in non-Watson-Crick
interactions, causing the loop to adopt a structured geometry. In this respect, it is
relevant to note that the cleavage site loop is very rich in purines, which are known to
have a strong tendency to undergo stacking interactions (Saenger, 1984). An
alternative possibility is that the cleavage site loop is involved in a long-range tertiary
interaction. However, this possibility seems less likely since deletion of the complete
stem-loop domain in mutant [D-135/-18] did not alter the reactivity pattern of the
nucleotides in the loop (see below). In addition, no sequences were found in the duplex
domain that are expected on the basis of complementarity to be involved in tertiary
contacts with the cleavage site loop.
Comparison of the wild type structure with mutants.
Additional evidence that a specific conformation stabilized by non-Watson-
Crick pairings in the cleavage site loop may be functionally important was provided by
structure probing assays of deletion mutants [D-135/-72, D-60/-18], and [D-135/-18].
In our deletion experiments, we did the surprising observation that the intermediate
deletion mutant [D-135/-72, D-60/-18] was cleaved with a much lower efficiency (5%
of the wild type) than mutants [D-104/-78], [D-135/-72], and [D-135/-18] which are
cleaved with a two-fold reduced efficiency compared to the wild type level (Fig. 4B).
In the structure probing experiments, the residues in the cleavage site loop of mutant
[D-135/-18] showed a reactivity pattern that resembles DWT; the nucleotides become
reactive only under semi-denaturing conditions (Fig. 7A and B). In mutant [D-135/-72,
D-60/-18], however, these nucleotides are already highly reactive under native
conditions, indicating that the structure of the loop is different (Fig. 8A and B). Such a
conformational change in the loop may explain the reduced cleavage efficiency
observed in mutant [D-135/-72, D-60/-18]. A similar relation between changes in the
structure of the cleavage site loop and effects on cleavage efficiency was observed in
previously constructed mutants (van Dijk et al., 1998) that contain point mutations in
or near the cleavage site loop. Mutations that reduce cleavage efficiency caused the A
residue at position -1 to become reactive under native conditions, whereas mutants that
are efficiently cleaved, showed a wild type reactivity pattern (data not shown). These
results support the idea that a specific geometry is important for cleavage. Stacking
interactions and/or non-Watson-Crick base-pairs in the cleavage site loop may allow
functional groups to be presented for specific interaction with an endoribonuclease.
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Similarly, in a number of other, comparable, purine-rich internal loops, non-Watson-
Crick base-pairs were found to facilitate specific interactions with proteins. For
instance, in the HIV-1 Rev-responsive element (RRE), a G-G pair in the loop causes a
widening of the major groove, allowing base-specific contacts of the Rev protein to an
adjacent G-A pair (Battiste et al., 1996). Likewise, in the loop E and a-sarcin loop
from rRNA, non-Watson-Crick G-A and A-U pairs provide specific recognition
surfaces for proteins (Wimberly et al., 1993; Szewczak and Moore, 1995).
A model of the functions of the various RNA regions in cleavage.
On the basis of the above mentioned data, we suggest that the main function of
the stem-loop domain and also of the duplex domain is to stabilize the cleavage site
domain, since deletions in both regions interfere with local structure formation around
the cleavage site, accompanied by a loss of, or severe decrease in cleavage efficiency.
Thus, these two RNA folding domains may act in a cooperative manner to maintain a
correct structure in the cleavage site domain. Alternatively, determinants in the stem-
loops may directly interact with the nuclease to stabilize its binding and to enhance the
cleavage efficiency. The cleavage site loop adopts a compact structure through the
formation of unusual base-pairs and stacking interactions. Such a specific geometry in
the loop may be important for cleavage, since all mutants with an altered loop
configuration as judged by an increased sensitivity to single-strand specific reagents
showed a marked reduction in cleavage efficiency. A general implication of our results
is that a specific RNA recognition site can be heavily dependent on rather large
surrounding RNA regions for the maintenance of an appropriate structural context.
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MATERIALS AND METHODS
Materials. Plasmid pBluescript II (KS+) was obtained from Stratagene (La Jolla, CA, USA).
Restriction enzymes, T4 DNA ligase, and T7 RNA polymerase were purchased from
Boehringer, Mannheim, Germany. Pfu DNA polymerase was purchased from Stratagene,
RNase-free DNase was from Kabi-Pharmacia (Uppsala, Sweden). AMV reverse transcriptase
was from Pharmacia, RNase A and RNase T1 were purchased from Calbiochem (La Jolla CA,
USA). RNase T2 and RNase V1 were purchased from Gibco BRL Life Technologies and
Pharmacia Biotech, respectively. Bal31 exonuclease was purchased from BioLabs. Enzymes
were used as specified by the manufacturers. Nucleoside triphosphates (NTPs) and dNTPs
were obtained from Kabi-Pharmacia; BES [N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic
acid] was purchased from Sigma (St. Louis, MO, USA). A random primer labeling kit was
purchased from Amersham (UK), and a DNA sequencing kit was purchased from Kabi-
Pharmacia. An in vitro transcription kit and a poly(A)+ RNA isolation kit were purchased
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from Promega, RNAzol reagent was purchased from Biotecx Laboratories, Inc. (Houston,
Texas, USA), and Genescreen membranes were purchased from Du Pont de Nemours
(Dreieich, Germany). [a-32P]dCTP (3,000 Ci/mmol) and [a-32P]CTP (760 Ci/mmol) were
purchased from Amersham. Dimethylsulphate (DMS) was purchased from Sigma (St. Louis,
MO, USA); 1-cyclohexyl-3-(2-morpholinoethyl)-carbodiimide (CMCT) and kethoxal were
purchased from ICN Biomedicals Inc. E. coli  tRNA was purchased from Boehringer
Mannheim (Germany).
Construction of plasmids. Molecular cloning was performed according to established
protocols (Sambrook et al., 1989). Where necessary, 3' recessed ends were filled in with
Klenow polymerase and 3' protruding ends were removed with T4 DNA polymerase. All
positions within exon 9 of the IGF-II gene are indicated relative to the cleavage site; the
nucleotide upstream of the cleavage site is -1; the nucleotide downstream is +1 (Fig. 2B).
When exon 9 sequences were deleted or additional restriction sites were introduced, the
numbers indicated still refer to their original position in exon 9 relative to the cleavage site.
IGF-II minigene constructs were based on the construct EP7-9 and its derivatives EP7-9/Not
and EP7-9D-1955/-174 (DWT), all three described previously in (Meinsma et al., 1992).
EP7-9 contains a human genomic IGF-II fragment that starts 373 bp upstream of exon 7 and
extends to 4.7 kb downstream of the gene. In EP7-9/Not, a NotI site was constructed at
position +80. DWT lacks the sequence between elements I and II. All three constructs are
cleaved with a similar efficiency, indicating that neither the NotI site at position +80 nor
deletion of the sequence from -1955 to -174 interferes with cleavage (Meinsma et al ., 1992).
Expression of the constructs in transfected cells was driven by the immediate-early
cytomegalovirus enhancer/promoter (Boshart et al., 1985).
Major deletions were introduced in the upstream stem-loop domain (nt -7/-133) using
the Bal31 exonuclease as follows. Plasmid BS-Ifw/IIfw, which contains both sequence
elements I and II in the forward orientation (van Dijk et al., 1998) was digested with AvrII
(position -80). The digested DNA was then incubated with 0.5 U Bal31 and samples were
taken from the reaction mixture at various time points. Subsequently, the trimmed DNAs
were blunted and ligated. After transformation to E. coli, the resulting new clones were
checked by digestion analysis and sequencing, and four mutants, harboring deletions from
positions
[-116/-31]; [-145/-22]; [-116/-24]; and [-170/-6] were selected for PCR amplification of the
region encompassing the deletions. PCR was done using oligonucleotides ED9843
(5’ ClaI -204/-185 3’) and ED9722 (5’ NotI +60/+93). The resulting PCR products were
digested with ClaI and NotI, and cloned in the corresponding sites of plasmid EP7-9/Not. The
derived plasmids were checked by digestion analysis and sequencing.
In addition to the Bal31 mutants, another set of deletion mutants was generated using
oligonucleotides. Mutant [D-104/-78] was described previously in van Dijk et al. (1998).
Mutant [D-135/-72] was constructed by ligation of oligonucleotides ED9848 and ED9849
(containing a ClaI and a DraII site at the ends) with a DraII- NotI (positions –52 and +80,
respectively) fragment of EP7-9/Not. The resulting fragment was cloned into the ClaI/NotI
sites of EP7-9/Not. Mutant [D-135/-72, D-60/-18] was generated by ligation of
oligonucleotides ED9844 and ED9845 (ending in a ClaI and an Alw44I site) with an Alw44I-
NotI (positions –17/+80) fragment of EP7-9/Not. The product was cloned into the ClaI/NotI
sites of EP7-9/Not. For the construction of mutant [D-135/-18], the same procedure was
followed as for mutant [D-135/-72, D-60/-18], but now oligonucleotides ED9846 and ED9847
were used. Mutants [D-104/-78], [D-135/-72], [D-135/-72, D-60/-18], and [D-135/-18] were
recloned into pBluescript II (KS+) for in vitro transcription purposes. The region
encompassing elements I and II was PCR-amplified using oligonucleotides ED9601
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(5’ XbaI -2119/-2100 3’) and ED9604 (5’ BamHI +181/+202 3’). The PCR products were
digested with XbaI and BamHI and cloned into the corresponding sites in pBluescript II
(KS+). Sequences of the oligonucleotides used for the introduction of deletions, PCR
amplification, or primer extension are listed below. Altered nucleotides that were introduced
in order to construct restriction sites are underlined.
Oligonucleotide          Sequence
DM6             5'-CTGTCAATCCTCCTGACTTTTC-3'
WS9502       5’-CACACTCCCATCATCAGTGCAC-3’
ED9601        5'-GGCTGGTCTAGA GTTTCCATCAGGTTCCATCC-3'
ED9604        5'-GTCCGC GGATCCAAGAAACAAAGAGGGGGAAT-3'
ED9721        5’-AACCCCTGGGGGGGTGGCCTCGTCAGGATC-3’
ED9722        5'-AAAATCTCCCGCGGCCGCTTCCTACCCCAGAAC-3'
ED9843        5'-TGCCGCATCGATTGAGGAAGGAGTTTGGCCAC-3'
ED9844        5’-CGATGCCGGTAGCTGAGCAGACATGCCCCCACGAGTAGCCTGCATCTTTGCCCG-3’
ED9845        5’-TGCACGGGCAAAGATGCAGGCTACTCGTGGGGGCATGTCTGCTCAGCTACCGGCAT-3’
ED9846        5’-CGATGCCGGTAGCTGAGCAGACATGCCCCCACGAGTAGCCTGG-3’
ED9847        5’-TGCACCAGGCTACTCGTGGGGGCATGTCTGCTCAGCTACCGGCAT-3’
ED9848        5’-CGATGCCGGTAGCTGAGCAGACATGCCCCCACGAGTAGCCTGCATC-
                           TTTGCCCGTCTCCTGGG-3’
ED9849        5’-GTCCCCAGGAGACGGGCAAAGATGCAGGCTACTCGTGGGGGCATG-
                           TCTGCTCAGCTACCGGCAT-3’
ED9954        5’-CTCCCCCCGCCCAGCCCCCACTGCCCCCCACCCACCCC-3’
Cell culture and transfection. Human 293 cells were grown in Dulbecco’s modified Eagle’s
medium. The medium was supplemented with 10% fetal calf serum, 100 IU of penicillin per
ml, 100 mg of streptomycin per ml, and 300 mg of glutamine per ml. The 293 cells were
transfected in 75 cm2 flasks at a confluence of about 50% by the calcium phosphate
coprecipitation method (Sambrook et al ., 1989; Graham and van der Eb, 1973). Precipitates
were prepared with BES-buffered saline (BBS) (Sambrook et al., 1989) and contained 10 mg
of CMV/IGF-II constructs and 1.0 mg of RSV-Luciferase (de Wet et al., 1987), and were
added to the cells. After 4 hours, the medium was aspirated and the cells were supplied with
fresh serum-containing medium. After 30 to 48 hours the cells were washed with PBS and
harvested in PBS with 0.025 % trypsin-0.02 % EDTA. To compare transfection efficiencies
of the various IGF-II expression constructs, 10% of the cells were used for a luciferase assay
(de Wet et al ., 1987). RNA was isolated from the remaining 90% of the cells.
RNA isolation and analysis. Total RNA was isolated using the RNAzol reagent according to
the manufacturer’s instructions. Cells isolated from a 75 cm2 flask were lysed in 1.5 ml of
RNAzol reagent and RNA was isolated from the water phase by isopropanol precipitation and
resuspended in water. RNA was glyoxalated, size-separated on a 1% agarose-10 mM sodium
phosphate gel, and transferred to a GeneScreen membrane. The RNA was fixed on the
membrane by irradiation with long-wavelength UV light for 2.5 minutes. Northern blots were
hybridized in the presence of 50% formamide in glass cylinders with continuous rotation at 42
oC according to the GeneScreen protocols. As a probe, a 1.0 kb SmaI fragment from the
human IGF-II exon 9 (positions +84 to +1096), hybridizing to both the full-length IGF-II
RNAs and the 3' cleavage product, was used. The DNA fragments were labeled by random
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priming with [a-32P]dCTP following the Amersham protocols. After 2 hours of
prehybridization, the probe was added at a final concentration of 106 cpm/ml. Blots were
washed after overnight hybridization, to a final stringency of 0.5 x SSC- 1% SDS at 65 oC
(1 x SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and exposed to Fuji RX X-ray film.
The amounts of cleavage products were determined by densitometric scanning of the
autoradiographs of at least 3 independent experiments. Cleavage efficiencies were determined
by calculating the amount of 3' cleavage product divided by the total amount of IGF-II RNA.
Variation between the calculated cleavage efficiencies in separate experiments was less than
10%.
In vitro transcription. In vitro RNAs were synthesized using T7 RNA polymerase on
linearized DNA templates according to the instructions of the manufacturer in the presence of
1 mM of each NTP. pBluescript II (KS+) plasmids containing IGF-II inserts (described above)
were linearized with EcoRV to generate full-length RNA. After RNA synthesis (30 minutes),
the template was degraded by DNaseI treatment (1 U in 25 ml reaction mixture for 10 minutes
at 37 oC) and the RNA was phenol/chloroform extracted, ethanol precipitated, washed in 70%
ethanol and dissolved in DEPC-treated water.
Primer extension mapping of the cleavage site. Primer extensions were carried out as
described by (McKnight and Kingsbury, 1982). Poly(A)+ RNA was isolated using the
Promega Poly(A) + RNA isolation kit according to the manufacturer’s instructions. A 5'
[a-32P]ATP end-labeled oligonucleotide (DM6), complementary to nucleotides +99/+120
downstream of the cleavage site, was annealed to 1-3 mg of poly(A)+ RNA (from cells
expressing the Bal31-generated constructs and constructs [D-135/-72, D-60/-18] and
[D-135/-18], 3 mg of poly(A)+ RNA was used instead of 1 mg) in 1 M NaCl, 0.17 M Hepes-
KOH pH 7.5, and 0.33 mM EDTA pH 8.0. Subsequently, the primer was extended towards
the cleavage site in 0.55 mM dATP/dCTP/dGTP/dTTP, 50 mM \Tris-HCl pH 8.2, 5 mM
MgCl2, 50 mM KCl, 0.05 mg/ml BSA, and 5 mM DTT. The extension products were
electrophoresed on sequencing gels along with a sequencing reaction carried out with the
same primer as a marker. The gels were exposed to Fuji RX X-ray films or to
Phosphorimager screens (Molecular Dynamics, USA).
Chemical and enzymatic probing. The method for structure probing was adapted from
Christiansen et al . (1994). Prior to modification of in vitro transcribed RNAs with DMS, 4 mg
(10 pmol) RNA was denatured/renatured in 20 ml modification buffer (70 mM Hepes-KOH
pH 7.8, 10 mM MgCl2, 270 mM KCl for native conditions; 70 mM Hepes-KOH pH 7.8, 1
mM EDTA for semi-denaturing conditions). The RNAs were heated to 95 0C for 1 minute,
followed by a 10 minutes incubation at 56 0C. Then, the samples were allowed to cool slowly
to room temperature. An additional 180 ml of modification buffer was added, and reactions
were initiated by the addition of 2 ml of DMS. Untreated control reactions were treated
similarly, except for the fact that DMS was omitted. Reactions were incubated for 5 minutes
at 30 0C, and terminated by the addition of DMS termination buffer (1.0 M Tris-acetate pH
7.5, 1.0 M mercaptoethanol, 1.5 M sodium-acetate, 0.1 mM EDTA).
For modification with CMCT, the same denaturation/renaturation procedure was
followed as for DMS modification, but now the modification buffer contained 16.7 mM
sodium-borate, 10 mM MgCl2, and 270 mM KCl for native conditions, and 16.7 mM sodium-
borate, 1 mM EDTA for semi-denaturing conditions. Subsequently, 20 ml of a 42 mg/ml
solution of CMCT in modification buffer was added, and the samples were incubated for 20
minutes at 30 0C. The reactions were stopped by placing the samples on ice.
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For modification with kethoxal, the same denaturaton/ renaturation procedure as for
DMS modification was followed. Then samples were incubated with 200 mg kethoxal for 10
minutes at 30 0C. The reactions were terminated by adding 20 ml kethoxal precipitation buffer
(0.3 M NaAc, pH 6.0; 0.25 M boric acid).
The DMS- or CMCT modified RNAs were precipitated with 3 volumes ethanol in the
presence of 10 mg E. coli tRNA as a carrier. Then, the RNAs were reprecipitated together
with a [g-32P] end-labeled oligonucleotide (DM6 or ED9722) followed by annealing and
primer extension analysis as described above. For the kethoxal-modified RNAs, the procedure
was the same, except that precipitation was done in the presence of kethoxal precipitation
buffer.
For enzymatic probing, 2 mg (10 pmol) of in vitro synthesized RNA and 10 mg E. coli
tRNA was denatured/renatured in 80 ml reaction buffer (10 mM Tris-HCl pH 7.5, 10 mM
MgCl2, 50 mM KCl for native conditions, and 10 mM Tris-HCl, 1 mM EDTA for semi-
denaturing conditions) for 1 minute at 95 0C, 10 minutes at 56 0C, and slow cooling to room
temperature. Then, 0.1 U RNase T1, 0.1 U RNase T2, or 0.2 U RNase V1 was added,
followed by 10 minutes incubation at room temperature. The reactions were terminated by
phenol-chloroform extraction of the RNAs. Subsequently, the RNAs were precipitated by 3
volumes ethanol in the presence of an extra 10 mg of E.coli tRNA, and reprecipitated with a
[32P] end-labeled oligonucleotide (DM6, ED9954, or WS9502). Then, the RNAs were
subjected to primer extension analysis, as described above.   
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CHAPTER 5
Kinetics and regulation of site-specific endonucleolytic
cleavage of human IGF-II mRNAs
Erwin L. van Dijk, John S. Sussenbach, Annemie M.C.B. Koonen-Reemst and
P. Elly Holthuizen. University Medical Center Utrecht, Department
Physiological Chemistry, Utrecht, The Netherlands.
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SUMMARY
Human insulin-like growth factor II (IGF-II) mRNA can be cleaved at a
specific site in the 4 kb long 3’-UTR. This yields a stable 3’ cleavage product of 1.8 kb
consisting of 3’-UTR sequences and a poly(A) tail, and an unstable 5’ cleavage
product containing the coding region. Obviously, after cleavage the coding region of a
particular IGF-II mRNA is targeted to rapid degradation and it is not involved in
protein synthesis anymore. Cleavage is therefore thought to provide an additional way
to control IGF-II gene expression. In this study, we have investigated the cleavage
efficiency of the various IGF-II mRNA species, which are generated by transcription
from four promoters in the IGF-II gene, and differ among each other in their 5’-UTR
(leader) sequences. In addition, we have examined the kinetics of cleavage and its role
in destabilization and translation of the IGF-II mRNAs using IGF-II constructs that are
under the control of a tetracycline-responsive promoter. The data indicate that under
standard cell culture conditions, cleavage is a slow process and has little effect on the
mRNA decay rate and protein production. In studies with human Hep3B cells that
endogenously express IGF-II, no effect on the cleavage efficiency is observed when
the cells are grown in the presence of trichostatin A (an inhibitor of IGF-II gene
expression), dexamethasone (a stimulator of IGF-II gene expression), or in the
presence or absence of serum. However, when the cells reach confluence, cleavage is
upregulated leading to 2-3 fold higher levels of the 3’ cleavage product, indicating that
cleavage is regulated in a cell density-dependent manner. Our results indicate that site-
specific endonucleolytic cleavage of the IGF-II mRNAs may have a limited role in the
degradation of the IGF-II mRNAs and the production of IGF-II protein. Possibly, the
3’ cleavage product itself may have an intrinsic cellular function.
INTRODUCTION
Human insulin-like growth factor II (IGF-II) is a mitogenic polypeptide of 67
amino acids with important functions in cell growth and development (Jones and
Clemmons, 1995). Depending on the cell type in which it is expressed, IGF-II can
exhibit remarkably different activities. IGF-II can promote either cell proliferation or
differentiation; it strongly affects cellular survival and counteracts apoptosis in some
cell systems, whereas in other cell lines an apoptosis-inducing effect by IGF-II is
observed (Engstrom et al., 1998, and references therein). Thus, as IGF-II is involved in
many physiological processes, a proper regulation of its expression is of crucial
importance. Indeed, IGF-II gene expression is regulated at virtually all levels, ranging
from developmental stage-dependent and tissue-specific activity of four different
promoters to post-translational processing of the IGF-II precursor protein (for a
review, see Holthuizen et al. (1999)).
Previously, we have observed that, in addition to the different mRNAs that are
transcribed from the four promoters P1 to P4 of the human IGF-II gene and range in
size from 6.0 to 2.2 kb, also a smaller RNA species of 1.8 kb is formed (De Pagter-
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Holthuizen et al., 1988). This RNA is the product of endonucleolytic cleavage at a
specific site in the 3’-UTR of the full-length IGF-II mRNAs (Meinsma et al., 1991). In
addition to this 1.8 kb RNA, which represents the 3’ cleavage product, also a 5’
cleavage product is formed that contains the coding region of the mRNA. Similar
observations were made for the rat IGF-II gene (Nielsen and Christiansen, 1992), and
the mouse IGF-II gene (Holthuizen et al., 1993). Because the 5’ cleavage product
lacks a poly(A) tail, it is very unstable and not translated (Nielsen and Christiansen,
1992). Thus, as cleavage abolishes the protein-coding potential of a particular mRNA,
it provides the cell with a putative additional mechanism to control IGF-II protein
production, acting at the level of mRNA stability.
In recent years, it has become clear that gene regulation at the level of mRNA
stability is rather common (Beelman and Parker, 1995; Ross, 1995; Jacobson and
Peltz, 1996; Wickens et al., 1997). Initiation of mRNA degradation can occur through
poly(A) shortening, arrest of translation at a premature stopcodon (nonsense-mediated
decay, NMD), or through endonucleolytic cleavage. To date, specific endonucleolytic
cleavage has been observed for a number of mRNAs.  Examples are the mRNAs
encoding albumin (Dompenciel et al., 1995; Chernokalskaya et al., 1997), the cytokine
groa  (Stoeckle, 1992), avian apo-very-low density lipoprotein II (Binder et al., 1989),
the transferrin receptor (Binder et al., 1994), and the Xenopus homeodomain protein
Xlhbox2 (Brown and Harland, 1990; Brown et al., 1993). The c-myc mRNA can be
cleaved in the coding region, but can also be destabilized through AU-rich elements in
the 3’-UTR (Swartwout and Kinniburgh, 1989; Ioannidis et al., 1996). Recently, it has
been reported that the human a-globin mRNA can also be cleaved at a specific site in
the 3’-UTR (Wang and Kiledjian, 2000a).
Our previous studies aimed at elucidating the determinants for recognition of
the cleavage site by an endoribonuclease. We have found that extensive RNA
secondary structures formed by two widely separated sequence elements are required
for cleavage (Scheper et al., 1995). These RNA structures may act cooperatively to
maintain a sequence- and structure-specific cleavage site located in an RNA internal
loop (van Dijk et al., 1998; van Dijk et al., 2000).
The aim of the present study is to obtain a better insight into the kinetics of
specific endonucleolytic cleavage of the IGF-II mRNAs and the impact on the overall
mRNA decay rate and protein production using a tetracycline-inducible system. In
addition, we have studied the effects of various exogenous factors on cleavage in
human Hep3B cells that endogenously express IGF-II.
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RESULTS
Influence of the 5´ leader sequences on the efficiency of specific endonucleolytic
cleavage.
The human IGF-II gene contains four promoters (P1-P4), which are
differentially active during development and in different tissues. Transcription from
these four promoters results in transcripts that differ in their 5’-UTRs (leaders), but
have the IGF-II coding region and 3´-UTR in common (Fig. 1A). The leaders vary
significantly in their length and composition. Leader L1 consists of exons 1-3 and is
586 nt long and very GC rich. Leader L2 (408 nt) consists of exon 4 sequence and is
moderately rich in G and C residues; leader L3 (1171 nt) consists of exon 5 sequence,
is rich in C-residues and is the longest 5’-UTR; leader L4 consists of exon 6 sequence
and is the shortest 5’-UTR with only 109 nt. Computer-assisted RNA secondary
structure prediction suggests that leaders L1 and L3 contain stable secondary
structures; leader L2 is less structured, and leader L4 does not contain any stable
secondary structure at all (not shown). It was established that transcripts with leaders
1, 2, and 4 are efficiently translated, whereas leader 3 has a strongly repressive effect
on translation (de Moor et al., 1994). Thus, it appears that the leaders have significant
effects on translation of the messengers.
In order to test the possibility that the nature of the individual leaders also
affects cleavage, we set out to determine the cleavage efficiency of IGF-II mRNAs
carrying the different leaders. For this purpose, we generated constructs in which the
four different leaders (L1 to L4) are connected to the IGF-II open reading frame and
the 4 kb long 3’-UTR (Fig. 1A). These constructs were transiently transfected to
human 293 cells, which do not express IGF-II endogenously, but are able to perform
the cleavage reaction. After transfection, total RNA was isolated from the cells and
subjected to Northern blot analysis. Unfortunately, especially for the 5.0 and the 5.3 kb
mRNA species, considerable interference of the full-length IGF-II RNA signals with
the 28S ribosomal RNA was observed, due to comigration of this rRNA species with
the IGF-II mRNAs (data not shown). Therefore, poly(A)+ RNA was isolated and
analyzed by Northern blotting using the 3’-UTR specific probe (Fig. 1B). The result
shows that all four IGF-II transcripts are cleaved, since the 1.8 kb 3’ cleavage product
is observed with all mRNAs. The IGF-II RNA signals on a number of Northern blots
were quantified by Phosphorimager scanning, and the efficiency of cleavage was
calculated by dividing the amount of 3´cleavage product by the total amount of IGF-II
RNA, i.e. the sum of the full-length RNA and the cleavage product. Small, but distinct
differences in cleavage efficiency were observed; the cleavage efficiency of the
transcript with the shortest and least structured 5’-UTR, L4, was set at 100%. The L1
and L3 RNAs are cleaved rather efficiently, with 140 and 141%, respectively, relative
to L4 RNA; L2 is cleaved less efficiently than L1 and L3, but still more efficiently
than L4, with 111%. Thus, although the 5’-UTR sequences do not have all-or-none
effects on cleavage, they do affect the efficiency of cleavage to a certain extent. The
results suggest a positive correlation between complex structure formation in the
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5’-UTR and cleavage, since the highly structured leaders L1 and L3 are cleaved with
a higher efficiency than the unstructured leader L4.
(A)
              
5’ 3’
P1 P2 P3 P4
1 2 3 4 5 6 7 8 9
 
Leader 1
Leader 2
Leader 3
Leader 4
5.3 kb
5.0 kb
6.0 kb
4.8 kb
(B)
          
Figure 1. Effect of the 5’ leaders on
cleavage efficiency. (A) Structure of the
human IGF-II gene and the mRNAs
generated by transcription from
promoters P1 to P4; the transcripts differ
among each other in their 5’ leader
sequences, but have their coding region
and 3´-UTR in common. Promoters P1 to
P4 are indicated by bent arrows. Exons 1
to 9 are indicated by boxes; open boxes
represent untranslated sequences, filled
boxes represent the IGF-II coding region.
The sizes of the transcripts with leaders
L1 to L4 are indicated in kb on the right.
(B) Northern blot analysis of poly(A)+
RNAs isolated from 293 cells transfected
with plasmids L1 to L4; these plasmids
express the IGF-II transcripts with
leaders L1 to L4 shown in (A). The blot
was hybridized with the IGF-II 3’-UTR
specific probe; the detected RNA
species are indicated in kb on the left.
The calculated cleavage efficiencies of
the different transcripts are indicated
below the lanes.
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Effect of cleavage on the rate of mRNA decay and protein production.
Subsequently, we have investigated the consequence of cleavage on overall
mRNA degradation. Initial studies were performed in human Hep3B cells that
endogenously express IGF-II and murine Ltk-  cells stably transfected with IGF-II
minigene expression plasmids. Actinomycin D was used to inhibit transcription and
the IGF-II RNA levels were measured at various time points after administration of
this drug. No significant changes in the IGF-II RNA levels were observed within the
first 24 hours after transcription arrest, whereas the unstable c-myc transcript quickly
vanished under the same conditions, indicating that transcription inhibition was
complete (data not shown). These results suggested that the IGF-II transcripts are very
stable, although it is generally known that actinomycin D can cause artificial
stabilization of some RNAs. Since actinomycin D non-specifically inhibits
transcription of all genes, especially after longer time-points, non-physiological
conditions may result from extended actinomycin D incubations. Therefore, we
favored to use a tetracycline-inducible system, in which the expression of a specific
gene of interest can be induced or repressed with minimal interference with the
cellular physiology.
(A)
             
L4- WTD
L4- WTmutD
*
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Figure 2. (A) Schematic representation of the transcripts from plasmids pTet-L4-DWT and pTet-L4-
DWTmut. The nucleotide positions bordering the 5’-UTR (leader L4), the IGF-II open reading frame
(ORF), and the 3’-UTR are indicated. The deleted region of the 3’-UTR as in DWT (van Dijk et al.,
1998) is indicated by a triangle. The cleavage site (CS) is marked by an arrow. The asterisk indicates
the positions of the point mutations in pTet-L4-DWTmut. (B) Northern blot analysis of total RNA
isolated from human 293 cells transiently transfected with pTet-L4-DWT in the presence of 100 ng/ml
tetracycline. After 24 hours, the tetracycline was removed and the cells were harvested for RNA
isolation at the indicated time points. The blot was probed with an IGF-II 3’-UTR specific probe
hybridizing to nucleotides 84 to 1096 downstream of the cleavage site and a GAPDH coding region
probe. (C) Kinetics of the appearance of the full-length L4-)WT RNA (¨ ) and the 3’ cleavage product
(Ä) after transcription induction. The IGF-II RNA signals were quantified by Phosphorimager scanning
and were normalized against the GAPDH RNA signals.
We have constructed two IGF-II expression plasmids that contain a promoter
that can be repressed by tetracycline (Fig. 2A). In plasmid pTet-L4-DWT, the 5’-UTR
of the 4.8 kb IGF-II mRNA (leader 4), which is the shortest leader and has no
significant secondary structure, is fused to the IGF-II open reading frame and the
0
0.5
1
1.5
2
2.5
3
3.5
4
0 10 20 30
hours after transcription induction
IG
F
-II
/G
A
P
D
H
Chapter 5
100
3’-UTR of IGF-II mRNA. The 3´-UTR lacks the region from positions 876 to 2657 in
the transcript which was designated DWT in van Dijk et al. (1998) because it was
previously shown to be dispensable for cleavage (Meinsma et al., 1992). To generate
plasmid pTet-L4-DWTmut, point mutations that completely abolish cleavage were
introduced (Fig. 2A) (three nucleotide substitutions at positions -142, -141, and -140
and two nucleotide deletions at positions -144 and -143; see Materials and Methods)
(van Dijk et al., 1998). The plasmids were used for transient transfection assays in
human 293 cells, which are a suitable model system to study in vivo cleavage, since
these cells do not express IGF-II endogenously, but are able to perform the cleavage
reaction.
First, to examine the rate of cleavage, the 293 cells were transfected with
plasmid pTet-L4-DWT in the presence of 100 ng/ml tetracycline to repress the
expression of the construct. After 24 hours, tetracycline was removed and
subsequently, RNA was isolated at various time points and analyzed by Northern
blotting using an IGF-II 3’-UTR-specific probe that detects both the full-length IGF-II
mRNAs as well as the 3’ cleavage product (Fig. 2B). The blot was also probed for
endogenous GAPDH mRNA levels as a control for loading differences. The full-
length IGF-II RNA levels increased rapidly up to 6 hours after tetracycline removal,
followed by a slower increase up to 24 hours (Fig. 2B, C). Accumulation of the 1.8 kb
3’ cleavage product, however, was very slow up to 9 hours after transcription
induction. The relative amount of the 3´cleavage product was only 7.7% of the total
IGF-II RNA at 6 hours after transcription induction as determined by Phosphorimager
scanning and quantification; at 9 hours after transcription induction, the relative
amount of the 3’ cleavage product was slightly increased to 12% of the total IGF-II
RNA. From 9 to 24 hours after transcription induction, a more rapid increase was seen
up to 30% at 24 hours. Thus, there appears to be a significant time delay between
formation of the full-length RNA and the cleavage product. These results indicate that
the accumulation of the 3’ cleavage product proceeds rather slowly.
In order to directly test the effect of cleavage on the rate of mRNA degradation,
the reverse approach was taken in a subsequent experiment. The 293 cells were
transiently transfected with plasmids pTet-L4-DWT and pTet-L4-DWTmut in the
absence of tetracycline to allow expression of the constructs. At 24 hours after
transfection, tetracycline was added to a concentration of 500 ng/ml to ensure
complete inhibition of transcription. Subsequently, RNA was isolated at various time
points, and subjected to Northern blot analysis using the IGF-II 3’-UTR-specific probe
and the GAPDH probe (Fig. 3A). Control transfections carried out in the presence of
500 ng/ml tetracycline did not yield any expression of the constructs, showing that the
inhibition of transcription was complete. For both constructs, no significant decrease
in the full-length RNA levels was observed up to 6 hours after transcription inhibition,
indicating that the RNAs are rather stable. After 8 and 10 hours, however, the RNA
levels were decreased to about 85% of the initial levels at time-point 0, and after 28
hours, a reduction to ~33% was found. Similar decay kinetics were observed for both
the L4-DWT and the L4-DWTmut RNAs, irrespective of the presence or absence of
cleavage, indicating that cleavage did not accelerate the decay rate of the L4-DWT
RNA (Fig. 3B, C).
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(A)                                                                                   
(B)                                                   (C)
                  
Figure 3. (A) Northern blot analysis of total RNA isolated from human 293 cells transiently transfected
with pTet-L4-DWT or pTet-L4-DWTmut in the absence of tetracycline or, as a control, in the presence
of 500 ng/ml tetracycline. At 24 hours after transfection, tetracycline was added to a concentration of
500 ng/ml to repress expression of the constructs and cells were harvested at the indicated time
points. The blot was hybridized with the IGF-II 3’-UTR specific probe and a GAPDH coding region
probe. (B) Kinetics of the full-length L4-DWT RNA levels (¨ ) and the levels of the 3’ cleavage product
(Ä) after transcription arrest. (C) Kinetics of the L4-DWTmut RNA levels (¨ ) after transcription arrest.
While the L4-DWT full-length RNA levels declined, the abundance of the 3’
cleavage product did not decrease throughout the course of the experiment (Fig. 3B).
Although the formation of the 3’ cleavage product continues during the experiment
due to ongoing cleavage, this will be with a diminished rate since the substrate full-
length RNA levels decline. This result confirms previous observations that the 3’
cleavage product is a very stable RNA species. Notably, the level of the 3’ cleavage
product at time-point 0 was about fourfold lower than that at 6 hours after transcription
inhibition. This suggests that at time-point 0 (24 hours after transfection), the levels of
the 3’ cleavage product had not yet reached a steady-state level, reflecting the slow
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rate of cleavage. Thus, both the formation and the degradation of the 1.8 kb 3’
cleavage product appear to be very slow.
In order to examine whether protein synthesis is affected by cleavage of the
IGF-II mRNAs, reporter plasmids pTet-L4-luc-DWT and pTet-L4-luc-DWTmut were
constructed. In these plasmids, the IGF-II open reading frame was replaced by the
luciferase open reading frame. This was necessary, since it is impossible to measure
IGF-II production by the cells due to the large amounts of IGF-II present in the
medium. The 293 cells were transiently transfected with these plasmids; suboptimal
amounts of DNA were used for transfection to ensure that the expression levels of the
constructs are in the linear range. After transfection, RNA was isolated from the cells
and analyzed on Northern blots. The transcript derived from pTet-L4-luc-DWT is
efficiently cleaved, indicating that cleavage can still occur when the IGF-II open
reading frame is replaced by the luciferase open reading frame (Fig. 4A). This is in
agreement with our previous results showing that a region from the IGF-II 3´-UTR
containing sequence elements I and II can confer cleavage of a heterologous mRNA
(Meinsma et al., 1992). In contrast to L4-luc-DWT, the transcript from pTet-L4-luc-
DWTmut is not cleaved at all, confirming our previous observation that the introduced
mutations completely abolish cleavage (Fig. 4A) (van Dijk et al., 1998). At 30 hours
after transfection, the cells were tested for their luciferase activity. No difference was
observed in luciferase activity of the cells transfected with either pTet-L4-DWT or
pTet-L4-DWTmut, indicating that cleavage has no effect on luciferase expression (Fig.
4B).
In conclusion, the results indicate that under the standard cell culture conditions
used in our transient transfection assays, cleavage is a slow process and has little effect
on the mRNA decay rate and protein production.
Influence of TSA, dexamethasone, and serum on IGF-II gene expression and
mRNA cleavage in Hep3B cells.
To study the effects on regulation of cleavage by exogenous factors, we have
used the human hepatoma cell line Hep3B as a model system. These cells
endogenously express IGF-II and have the ability to grow continuously in the absence
of serum, suggesting that the endogenously synthesized IGF-II stimulates the sustained
growth of these cells. Hep3B cells express high amounts of the 6.0 kb mRNA, derived
from promoter P3 and lower quantities of the smaller 4.8 kb mRNA species, derived
from promoter P4. Several exogenous factors have been described to influence IGF-II
expression, such as glucose levels, hormones, glucocorticoids and growth conditions
(Asfari et al., 1995; Ramasharma and Li, 1987; Backlin et al., 1998; Dell et al., 1997;
Corkins et al., 1999). To investigate whether any of these factors would affect
cleavage, Hep3B cells were grown in the absence of serum (with serum replacement
medium (TCH) lacking IGF-II, see Materials and Methods) to allow measurements of
secreted IGF-II, or in the presence of 10% fetal calf serum. The cells were exposed to
a variety of conditions and subsequently, media were collected and RNA was isolated
from the cells and analyzed on Northern blots.
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Figure 4. Effect of cleavage on luciferase expression. (A) Northern blot analysis of RNA isolated from
293 cells transiently transfected with pTet-L4-luc-DWT or pTet-L4-luc-DWTmut. The blot was
hybridized with the IGF-II 3’-UTR specific probe. The sizes of the full-length RNAs and the 3’ cleavage
product are indicated in kb on the left. As a control for loading differences, the blot was also probed
with a GAPDH DNA fragment. (B) The luciferase activity of cells transiently transfected with pTet-L4-
luc-DWTmut relative to the activity of cells transfected with pTet-L4-luc-DWT, which was set at 100%.
The result shown represents the mean value of 5 independent experiments, and the error bar shows
the calculated standard deviation.
First, the histone deacetylase inhibitor trichostatin A (TSA), which has been
described to inhibit IGF-II gene expression (Gray et al., 1999), was examined for its
effect on the cleavage efficiency in Hep3B cells growing in serum replacement
medium. The cells were grown to a density of 50% confluence, and TSA was added to
concentrations of 100 and 240 ng/ml, respectively. After 18 hours of incubation, cells
were harvested for RNA isolation, and the isolated RNAs were analyzed by Northern
blotting (Fig. 5A). The results show that upon TSA treatment, the 6.0 kb full-length
IGF-II mRNA levels decline, but the levels of the 3´ cleavage product remain constant.
Phosphorimager quantification of the signals after normalization with the 28S rRNA
and the GAPDH mRNA levels in a number of independent experiments indicates that
the decline of the 6.0 kb full-length mRNA is about twofold. However, this decline of
the full-length RNA is probably not due to increased cleavage efficiency, since no
increase in the level of the 1.8 kb 3’ cleavage product is observed. These data suggest
that the TSA treatment leads to an inhibition at the level of transcription and does not
affect cleavage. In fact, the kinetics after TSA administration resembles that observed
after transcription inhibition using tetracycline in the tetracycline-inducible system
(Fig. 3A).
Chapter 5
104
(A)          (B)                                    
(C)  
       
Figure 5. Effects of various exogenous factors on IGF-II mRNA levels and cleavage in Hep3B cells.
(A-C) Northern blot analyses of RNAs isolated from Hep3B cells, using the IGF-II 3’-UTR specific
probe. As a control for loading differences, the blots were also hybridized with a GAPDH probe. (A)
Cells were treated with either DMSO alone (-) or with the indicated amounts of TSA dissolved in
DMSO. Cells were harvested for total RNA isolation after 18 hours. (B) Cells were treated with the
indicated concentrations of dexamethasone and grown for a further 18 hours before harvesting for
RNA isolation. (C) Cells growing in the serum replacement medium TCH without fetal calf serum were
supplied with 10% fetal calf serum and harvested after 24 hours. Cells growing on 10% fetal calf
serum were deprived from serum for 24 hours and harvested for RNA isolation.
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In contrast to the decline of the 6.0 kb mRNA levels, the levels of the 4.8 kb mRNA
species are not decreased, which is in agreement with observations by Gray et al.
(1999), and suggests that the decrease in the 6.0 kb mRNA abundance is due to
specific effects of TSA on human promoter P3, which drives the formation of the 6.0
kb mRNA species. We also observed that the TSA treatment inhibits the growth of the
Hep3B cells (not shown), which might at least partly be due to the decrease in IGF-II
expression.
Second, the effect of dexamethasone addition on cleavage efficiency was tested.
Dexamethasone is a synthetic glucocorticoid, which has been reported to stimulate
IGF-II expression in a number of systems (Price et al., 1992; Dell et al., 1997; Cheng
et al., 1998; Yoshiko et al., 1998), although also downregulation of IGF-II expression
has been observed (Senior et al., 1996; Backlin et al., 1998). In order to test whether
cleavage of the IGF-II mRNAs is influenced by dexamethasone, Hep3B cells growing
in the presence of 10% fetal calf serum were treated with increasing amounts of this
drug up to 1 mM. After 18 hours of incubation, the cells were harvested for RNA
isolation, and the isolated RNAs were subjected to Northern blot analysis (Fig. 5B).
Dexamethasone treatment leads to an increase of about twofold in both the 6.0 kb and
the 4.8 kb full-length IGF-II mRNA levels at all concentrations used, indicating that
IGF-II gene expression in Hep3B cells is upregulated by dexamethasone. Similar
results were obtained with cells growing in the serum replacement medium (not
shown). The abundance of the 3’ cleavage product also slightly increased, although
less than the full-length mRNAs. These results suggest that the increased levels of the
full-length IGF-II mRNAs are not due to a significant reduction in cleavage efficiency,
since no absolute decrease in the levels of the 3´cleavage product was seen. However,
the lower relative abundance of the 3´cleavage product compared to the full-length
IGF-II mRNAs may be due to a slight decrease in cleavage efficiency, although it is
also possible that the levels of the 3´cleavage product had not yet reached a steady-
state level. Thus, the increase in the full-length IGF-II mRNA levels upon
dexamethasone treatment may be mainly due to an increased transcriptional activity.
This indicates that dexamethasone, like TSA, acts at the level of transcription.
Third, we have tested to what extent serum addition or deprivation affects
cleavage. Hep3B cells growing in the serum replacement medium were supplied with
10% fetal calf serum, and at 24 hours after addition of the serum, the cells were
harvested for RNA isolation. The reverse experiment was also performed: cells
growing in the presence of 10% fetal calf serum were transferred to serum-free
medium and harvested after 24 hours for RNA isolation. The isolated RNAs were
analyzed by Northern blotting. Fig. 5C shows that no significant changes in the full-
length IGF-II mRNA levels or the levels of the 3’ cleavage product were observed
after 24 hours of addition or deprival of serum. Similar results were obtained after 4, 8,
and 32 hours of incubation (data not shown). These data indicate that in Hep3B cells,
neither IGF-II gene transcription nor cleavage are significantly affected by the
presence or absence of serum.
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Cleavage is upregulated at high cell density.
Another factor that has been described to affect IGF-II expression in several
systems is cell density. For this reason, we examined the effect of the growth status of
the Hep3B cells on cleavage efficiency. Cells were seeded at a density of 0.8 x 104
cells /cm2 (day 0), and were grown in serum replacement medium, which was
refreshed every day. Starting day 1, cells were counted each day and were harvested
for RNA isolation; media were collected for IGF-II protein measurements. From day 1
to day 4, the cells proliferated rapidly till 100% confluence was reached at a density of
~4.5 x 104 cells /cm2 (day 4) (Fig. 6A and B). Instead of arresting growth at this point,
however, the cells continued to proliferate at a high rate, followed by growth arrest at
day 8 at a density of ~15 x 104 cells /cm2 (Fig. 6A). At this point, multiple layers of
cells had formed (Fig. 6B). On the subsequent day after growth arrest, a slight
decrease in cell number was seen due to cell death. RNA was isolated from cells in the
subsequent phases of the growth curve and subjected to Northern blot analysis (Fig.
6C) using the IGF-II 3’-UTR specific probe. When the cells reached confluence, a
significant 2-fold elevation of the amount of the 3’ cleavage product was observed and
this elevation further continued to about 3-fold. At day 5, a peak level of the 3’
cleavage product was observed, after which the levels declined again. No significant
changes in the full-length IGF-II mRNA levels were seen, however.
The IGF-II protein levels in the medium during the growth of the Hep3B cells
were also examined; medium samples taken from cells at 2, 4, 5, 8, and 9 days after
seeding were analyzed by Western blotting (Fig. 6D). At 2 days after seeding, no
IGF-II protein could be detected in the medium. From 4 to 9 days after seeding, a
marked increase in the IGF-II levels was observed, up to high amounts of IGF-II at
day 9. These observations indicate that high cell density conditions do not lead to a
decrease in IGF-II production in Hep3B cells. Rather, the strong increase in the IGF-II
levels up to day 9 suggests that the production of IGF-II is even stimulated at high
density, although the number of cells also increases.
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Figure 6. IGF-II gene expression and mRNA cleavage efficiency as a function of Hep3B cell density.
(A) Growth curve of Hep3B cells growing on the TCH serum replacement medium. Cells were seeded
at 0.8 x 104 cells /cm2 (day 0). Medium was refreshed daily. (B) Photomicrographs of Hep3B cells at
day 2, 3, 4, 5, and 8. (C) Northern blot analysis of RNAs isolated from the cells harvested at days 1 to
9 after seeding, and grown to the densities indicated in (A). The blot was first hybridized with the IGF-II
3´-UTR specific probe, and subsequently re-probed with the GAPDH probe to control for loading
differences. (D) Western blot analysis of medium samples taken from the cells at days 2, 4, 5, 8, and
9, simultaneously while harvesting them for RNA isolation. A protein size marker, recombinant IGF-II
(20 ng), and a control medium sample (-) in which no cells had grown, were run in parallel.
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Notably, the Hep3B IGF-II proteins migrate with two distinct rates through the gel,
both slower than the 7.5 kDa recombinant IGF-II used as a control; one migrates as a
protein of ~10 kDa, and the other as a protein of ~25 kDa. Presumably, these signals
represent improperly processed precursor IGF-II; it is rather common that tumor cell
lines express so-called “big IGF-II” (Zapf, 1994).
The observations described above suggest that IGF-II gene transcription and
protein production per cell do not change drastically at high cell densities. The levels
of the 3’ cleavage product, however, are significantly upregulated.
In SHSY-5Y cells, it was originally observed that cleavage of IGF-II mRNA
results in the formation of an abundant 3´cleavage product of 1.8 kb and much lower
levels of the 4.2 kb 5´cleavage product, indicating that this RNA is less stable than the
3´cleavage product (Holthuizen et al., 1993). In order to confirm that this is also the
case in Hep3B cells, RNA isolated from Hep3B cells grown in the serum replacement
medium to 50% confluence was subjected to Northern blot analysis using an IGF-II
coding-region specific probe and the 3´-UTR-specific probe (Fig 7A). Hybridization
with the 3’-UTR specific probe readily detects the 3´ cleavage product in addition to
the full-length IGF-II mRNA species of 6.0 and 4.8 kb. Using the coding region-
specific probe, the full-length IGF-II mRNAs are also detected, but the 5´cleavage
product is hardly visible. The same experiment was performed with RNA isolated
from cell grown to 100% confluence (Fig 7B). Again, a significant increase in the
level of the 3´cleavage product was seen. Under these conditions, the 5´ cleavage
product of 4.2 kb also becomes visible, but the levels are much lower than for the 3’
cleavage product. This result confirms that also in Hep3B cells, cleavage of the IGF-II
mRNAs results in the formation of a stable 3’ cleavage product and an unstable 5’
cleavage product. In addition, the observation that the levels of both cleavage products
increase, indicates that the elevated levels of the 3’ cleavage product observed at high
cell density in Hep3B are due to an increased cleavage efficiency cells, rather than a
stabilization of the 3’ cleavage product.
(A)                               (B)
  
Figure 7. Northern blot
analyses of RNA isolated
from Hep3B cells at (A) 50%
and (B) 100% confluence.
The blots were probed with
an IGF-II coding region (CR)
specific probe and the IGF-II
3’-UTR specific probe as
indicated above the lanes.
The sizes of the detected
RNA species are indicated in
kb on the left.
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Having established that Hep3B cells show increased cleavage efficiency at
high cell densities, we determined whether this phenomenon was specific for Hep3B
cells or could occur in other cell types as well. Murine Ltk-  cells, which do not produce
endogenous IGF-II, have been stably transfected with the human IGF-II minigene
construct DWT, and it was shown that these cells express and cleave the transcript
from this IGF-II minigene (Meinsma et al., 1992; van Dijk et al., 1998). These stably
transfected Ltk- cells were grown to 50 and 100% confluence. Subsequent Northern
blot analysis of total RNA isolated from the cells using the IGF-II 3’-UTR specific
probe shows that no elevation of the levels of the 3´cleavage product occurs in these
cells at high densities (Fig. 8). This indicates that the increase in cleavage efficiency
under high cell density conditions is not a general phenomenon that occurs in any cell
type but may be specific for a restricted set of cell types including Hep3B cells.
In conclusion, our data indicate that cleavage is upregulated at high cell density
in Hep3B cells. This phenomenon may be specific for cells that endogenously express
IGF-II.
DISCUSSION.
In the present study, we have investigated the effects on cleavage efficiency of
the different 5´ leader sequences present in the various IGF-II transcripts in transient
transfection assays. Subsequently, the kinetics of IGF-II mRNA cleavage and its effect
on mRNA decay and protein production was studied, again in transient transfection
assays. In addition, we have examined regulation of IGF-II mRNA cleavage in human
Hep3B cells, which endogenously express IGF-II.
The human IGF-II gene contains four promoters, which are differentially active
during development and in different tissues. The 5´ leaders (L1- L4) of the different
transcripts derived from these promoters differ significantly in their length and
composition; while L2 and L4 do not show significant secondary structure, L1 and L3
are rather long and highly structured. It was established previously that the leaders
have significant effects on translation efficiency (de Moor et al., 1994); while IGF-II
Figure 8. Northern blot analysis of RNA isolated from
murine Ltk- cells expressing the human IGF-II minigene
DWT, carrying a deletion in the 3´-UTR from position
-1955 to -174 relative to the cleavage site (van Dijk et
al., 1998). The blot was probed with the IGF-II 3´-UTR
specific probe. The cells were grown to the %
confluence indicated above the lanes; the sizes of the
detected RNA species are indicated in kb on the left.
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mRNAs carrying leaders 1, 2, and 4 are efficiently translated, leader 3 strongly
represses translation. In this report, we show that the leaders also differentially
influence cleavage efficiency. The efficiency of cleavage of the L4-containing
transcript was set at 100%; the mRNAs with L1, L2, and L3 were found to be cleaved
with efficiencies of 140, 111, and 141% relative to L4, respectively. These results
suggest a positive correlation between secondary structure formation in the leader and
cleavage efficiency, with the extensively structured leaders L1 and L3 being cleaved
with the highest efficiencies. Thus, the leaders appear to affect both translation and
cleavage, but in a different manner. Whereas the L3-transcript deviates strongly from
the other transcripts in its translation efficiency, it is cleaved with an intermediate
efficiency. This suggests that there is no direct link between translation and cleavage,
in contrast to several other systems; cleavage of the 9E3, the c-myc, and the groa
transcripts have been described to be dependent on translation (Stoeckle and Hanafusa,
1989; Wisdom and Lee, 1990; Stoeckle, 1992). Similar to IGF-II mRNA cleavage,
however, endonucleolytic cleavage of the Xenopus homeobox mRNA Xlhbox2 was
also found to be independent of translation (Brown and Harland, 1990). The lack of a
connection with translation allows cleavage to be regulated in response to exogenous
stimuli independently of translation regulation.
Another important issue to be addressed is the rate of cleavage and its role in
IGF-II mRNA degradation. For this reason, we have performed kinetic studies using a
tetracycline-inducible system. This provides a way to manipulate the expression of a
specific gene of interest without interfering with the expression of the other genes. We
have made the following observations. (1) There is a significant time delay between
the appearance of the full-length IGF-II mRNA and the formation of the 3’ cleavage
product after transcription induction. After the lag phase, the accumulation of the
cleavage product accelerates. The delay in formation of the cleavage product may
indicate that cleavage only occurs when there is a sufficient amount of IGF-II mRNA.
Alternatively, cleavage may require the formation of suitable higher order structures in
the IGF-II mRNAs, which occurs slowly. Previously, we have already shown that
complex secondary structures are required for cleavage (Scheper et al., 1995). A third
possibility is that specific RNA-protein complexes must be formed before cleavage
can occur. (2) Point mutations that inactivate cleavage do not lead to a slower
degradation rate of the RNAs after transcription inhibition; both RNAs that are cleaved
and RNAs that are not cleaved were reduced to 33% of the initial levels after 28 hours.
This indicates that specific endonucleolytic cleavage does not contribute significantly
to the general decay of the IGF-II mRNAs. In contrast to the full-length RNAs, no
decline in the levels of the 3’ cleavage product was seen throughout the experiment
indicating that this RNA species is very stable. (3) No difference in luciferase
expression was observed between cleaved and non-cleaved RNA, in agreement with
the lack of effects of specific endonucleolytic cleavage on IGF-II mRNA turnover.
From these data, we conclude that under the standard cell culture conditions
used in our transient transfection assays, cleavage is slow and does not play a
significant role in overall IGF-II mRNA degradation or protein production. Cleavage
leads to the production of a very stable 1.8 kb 3’ cleavage product, which remains
present in the cells for a long time after its formation.
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Hep3B cells, which endogenously express high amounts of the 6.0 kb IGF-II
transcript and lower quantities of the 4.8 kb mRNA species, were used to examine
whether under certain circumstances the efficiency of specific endonucleolytic
cleavage might be altered. Hep3B cells were grown in the presence of different
exogenous factors: (1) the histone deacetylase inhibitor trichostatin A (TSA), which
was previously described to have a negative effect on IGF-II expression in Hep3B
cells (Gray et al., 1999), (2) the synthetic glucocorticoid dexamethasone, which
appears to have a stimulating effect on IGF-II expression (Price et al., 1992; Dell et
al., 1997; Cheng et al., 1998; Yoshiko et al., 1998), although downregulation of IGF-
II as a result of dexamethasone treatment has also been observed (Senior et al., 1996;
Backlin et al., 1998); (3) also the effect of addition or deprivation of serum on IGF-II
expression and cleavage was tested.
TSA and dexamethasone oppositely affect the full-length IGF-II mRNA levels
(Fig. 5A and B); TSA causes a decline in the 6.0 kb full-length IGF-II mRNA levels
(but not the 4.8 kb mRNA levels), whereas dexamethasone leads to a 2-fold increased
abundance of both full-length mRNA species. Neither of the two compounds,
however, influences the levels of the 3’ cleavage product. This suggests that the
observed effects on the full-length mRNA levels are not caused by changes in
cleavage efficiency, but by changes in transcriptional activity. No significant effects
were seen on the full-length IGF-II mRNA levels or on the levels of the 3’ cleavage
product upon addition or deprivation of serum (Fig. 5C), suggesting that neither IGF-II
gene transcription nor endonucleolytic cleavage of the mRNAs is responsive to serum
factors.
Several studies have shown that cell density affects IGF-II expression in
different cell types. Both in the rat IEC-6 and the rat BRL-3A cell lines an
upregulation of IGF-II has been observed at increasing cell densities, leading to the
hypothesis that IGF-II may act as a survival factor at high cell densities in these cells
(Kutoh et al., 1995; Corkins et al., 1999). These reports prompted us to investigate
whether IGF-II gene expression and IGF-II mRNA cleavage in Hep3B cells are also
regulated in a cell density-dependent manner. The cells were grown to different
densities and isolated RNAs were analyzed on Northern blots using an IGF-II 3´-UTR-
specific probe. Interestingly, a consistent increase of 2-3 fold in the abundance of the
3’ cleavage product was observed when the cells reached confluence, indicating that
cleavage is upregulated with increasing cell densities (Fig. 6C). It can be excluded that
the increase in the levels of the 3’ cleavage product is an indirect consequence of
changes in the rate of IGF-II mRNA synthesis, because no changes in the levels of the
cleavage product were seen upon treatment of the cells with TSA or dexamethasone.
No cell density-dependent increase in cleavage efficiency was observed in stably
transfected murine Ltk- cells expressing the human IGF-II minigene DWT. This
suggests that the phenomenon is cell-type specific, rather than a general effect of
growth inhibition.
What might be the physiological relevance of this increased cleavage
efficiency? It is unlikely that in Hep3B cells, even at high cell densities, the specific
endonucleolytic cleavage significantly affects the expression of IGF-II; under standard
conditions, the amount of cleavage product is about 15% of the total IGF-II mRNA,
i.e. the sum of the 6.0 and the 4.8 kb full-length mRNAs and the 3’ cleavage product.
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This is raised to about 45% at high cell densities. This level of cleavage efficiency is
similar to that observed with the transcript L4-luc-DWT (Fig. 4A). This RNA is also
cleaved relatively efficiently, but still shows no decrease in luciferase expression in
comparison with the mutant RNA that is not cleaved. This suggests that with the
endogenous IGF-II mRNAs in Hep3B cells even under high cell density conditions
and with the L4-luc-DWT transcripts under standard conditions in the 293 cells, the
rate of cleavage is still rather low. In that case, the 1.8 kb 3’ cleavage product must be
exceptionally stable to explain the high relative abundance of this RNA species.
Indeed, the 1.8 kb 3’ cleavage product appears to be very stable, since the level of the
3’ cleavage product did not decline after transcription arrest in the transient
transfection experiment shown in Fig. 3A and B, in contrast to the full-length mRNAs,
which were reduced to ~33% of the initial levels after 28 hours. The unusual stability
of the 3’ cleavage product is probably conferred by a highly conserved G-quadruplex
structure at its 5’ end that may protect the RNA from exonucleolytic degradation
(Christiansen et al., 1994). These observations also imply that cleavage with an
efficiency that is sufficiently high to accelerate IGF-II mRNA decay should lead to
very high cellular levels of the 1.8 kb 3’ cleavage product.
Although it is possible that in other cell types and/or under the influence of
other exogenous stimuli, cleavage efficiency is sufficient to accelerate the decay of the
IGF-II mRNAs, our data do not support a significant role for cleavage in regulation of
IGF-II mRNA stability. Rather, the 3’ cleavage product may have an intrinsic cellular
function. The unusual stability of this RNA is in favor of this hypothesis since stable
non-coding RNAs have been shown to carry out diverse functions in both prokaryotes
and eukaryotes (reviewed by Wagner and Simons (1994); Delihas (1995); Kelley and
Kuroda (2000)). Computer-assisted secondary structure prediction suggests that the
1.8 kb 3’ cleavage product is highly base-paired. Interestingly, several regions in this
RNA appear to be rich in structural motifs that are common to functional non-coding
RNAs as determined with a specialized computer algorithm available on the World
Wide Web at http://rnagene.lbl.gov/.
How does cleavage of the IGF-II mRNAs relate to other systems? For a number
of mRNAs, endonucleolytic cleavage has been described. Cleavage of the IGF-II
mRNAs is distinct from these systems in a number of respects. For example, the
determinants for recognition of the cleavage site are very complex in the case of IGF-
II mRNA cleavage; while for cleavage of the apoII, the albumin, and the Xenopus
Xlhbox2B mRNAs short sequences in a single-stranded environment appear to be
sufficient (Binder et al., 1989; Chernokalskaya et al., 1997; Brown et al., 1993),
cleavage of the IGF-II mRNAs requires extensive RNA structures that may act in a
cooperative manner to stabilize a highly specific cleavage site (van Dijk et al., 1998;
van Dijk et al., 2000). To our knowledge, the transferrin receptor mRNA is the only
other system that has been described to require large regions of RNA structure for
specific cleavage in its 3’-UTR. Interestingly, an upstream sequence element was
found to be required for cleavage of this mRNA as well (Binder et al., 1994), similar
to the requirement for the upstream element I in the IGF-II mRNAs. Cleavage of the
IGF-II mRNAs occurs independently of deadenylation, similar to most, but not all
systems; it was shown that cleavage of groa mRNA is associated with poly(A) tail
shortening (Stoeckle, 1992), and also cleavage of the yeast PGK1 mRNA and the
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human a-globin mRNA have been described to be coupled with poly(A) tail
shortening, (Vreken and Raue, 1992; Wang and Kiledjian, 2000a). In addition to its
complex structural requirements and its independence of deadenylation, also its
independence of translation distinguishes IGF-II mRNA cleavage from a number of
other systems, as mentioned above.
In summary, experiments have been performed to gain insight into the kinetics
and physiological role of the site-specific endonucleolytic cleavage of the IGF-II
mRNAs, which appears to be rather unique. Unfortunately, we have not been able to
define its exact physiological function, but we have established that it is regulated in a
cell density-dependent manner. The unusually stable 1.8 kb 3´cleavage product shows
interesting structural features, such as the G-quadruplex structure and the motifs
common to functional RNAs. This makes it tempting to speculate that this RNA might
have an intrinsic physiological function.
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MATERIALS AND METHODS
Materials. Expression plasmids pTet-Splice and pTet-tTak were purchased from Gibco BRL
Life Technologies. Plasmid pGL3 was from Promega. Tetracycline was purchased from
Sigma (St. Louis, MO, USA). Restriction enzymes and T4 DNA ligase were purchased from
Roche Molecular Biochemicals, Mannheim, Germany. Enzymes were used as specified by the
manufacturers. dNTPs were obtained from Kabi-Pharmacia, BES [N,N-bis(2-hydroxyethyl)-
2-aminoethanesulfonic acid] was from Sigma (St. Louis, MO, USA). A random primer
labeling kit was purchased from Amersham (UK), and a DNA sequencing kit was purchased
from Kabi-Pharmacia. A poly(A)+ RNA isolation kit were purchased from Promega, RNAzol
reagent was purchased from Biotecx Laboratories, Inc. (Houston, Texas, USA), and
Genescreen membranes were purchased from Du Pont de Nemours (Dreieich, Germany).
["-32P]dCTP (3,000 Ci/mmol) was purchased from Amersham. Trichostatin A and
dexamethasone were purchased from ICN Biomedicals Inc. (Costa Mesa, CA, USA) and
Sigma (St. Louis, MO, USA), respectively. TCH defined serum replacement was purchased
from ICN Biomedicals Inc.
Construction of plasmids. Molecular cloning was performed according to established
protocols (Sambrook et al., 1989). Where necessary, 3' recessed ends were filled in with
Klenow polymerase and 3' protruding ends were removed with T4 DNA polymerase. All
positions within exon 9 of the IGF-II gene are indicated relative to the cleavage site; the
nucleotide upstream of the cleavage site is -1; the nucleotide downstream is +1. When exon 9
sequences were deleted or additional restriction sites were introduced, the numbers indicated
still refer to their original position in exon 9 relative to the cleavage site.
The leader plasmids were constructed as follows. The IGF-II expression plasmid EP7-9/Not
(Meinsma et al., 1992) was digested with Alw44I to generate a fragment that contains the
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IGF-II 3’-UTR sequence from position -17 to 210 nucleotides downstream of the
polyadenylation site; this fragment was inserted in the Xba site of expression plasmid
CMV-0. The resulting plasmid, designated CMV-1.8, was digested with BamHI and NotI
(position +80). DNAs containing PCR-generated leader sequences L1, -L2, -L3, and -L4 and
the IGF-II open reading frame (de Moor, 1994) were digested with BamHI and XhoI to
generate fragments that contain the 5’-UTR and the IGF-II coding region. Plasmid EP7-9/Not
was digested with XhoI and NotI (positions -2291 and +80). The resulting fragment was
ligated with the leader-fragments and subsequently, the BamHI/NotI digested plasmid CMV-
1.8 was added to the ligation reactions, resulting in plasmids CMV-L1, CMV-L2, CMV-L3,
and CMV-L4.
Plasmid pTet-L4-DWT was constructed as follows. Plasmid pTet-Splice was digested
with XhoI and BamHI to generate a fragment that contains the tetracycline-responsive
minimal CMV promoter. This fragment was inserted in the AatII and BamHI sites of plasmid
CMV-L4 that encompass the CMV promoter, resulting in plasmid pTet-L4. Plasmids DWT
and DWTmut were digested with ClaI and XbaI (positions -1961 and +1051 in the 3’-UTR)
and the resulting fragments were inserted in the ClaI and XbaI sites of plasmid pTet-L4.
Construct DWTmut contains the following mutations: A(-144) and G(-143) have been
deleted, and U(-142), A(-141), G(-140) have been changed to C, U, and C, respectively (van
Dijk et al., 1998).
To generate plasmids pTet-L4-luc-DWT and pTet-L4-luc-DWTmut, the following
procedure was followed. First, an XhoI-XbaI fragment of the IGF-II 3’-UTR (from positions
-2292 to +1047) was inserted in the XbaI site of the luciferase expression plasmid pGL3
(directly downstream of the luciferase coding region). The resulting plasmid was digested
with HindIII and ClaI, yielding a fragment that contains the luciferase open reading frame and
the IGF-II sequence from positions -2292 to -1961. This fragment was inserted in the HindIII/
ClaI sites of plasmids pTet-L4-DWT and pTet-L4-DWTmut.
Culture and transient transfection of 239 cells. Human 293 cells were grown in Dulbecco’s
modified Eagle’s medium. The medium was supplemented with 10% fetal calf serum, 100 IU
of penicillin per ml, 100 mg of streptomycin per ml, and 300 mg of glutamine per ml. The cells
were transfected in 25 cm2 flasks at a confluence of  50% by the calcium phosphate
coprecipitation method (Graham and van der Eb, 1973). Two hours before transfection,
tetracycline was added to the medium to a concentration of 100 ng/ml to repress the
expression of the constructs. Precipitates were prepared with BES-buffered saline (BBS)
(Sambrook et al., 1989) and contained 3.3 mg of pTet-IGF-II constructs and 3.3 mg of
pTet-tTak (de Wet et al., 1987), and were added to the cells. After 4 hours, the medium was
aspirated and the cells were supplied with fresh serum-containing medium, again with 100
ng/ml tetracycline. After 24 hours, the tetracycline was removed to induce expression of the
constructs. At various time-point after transcription induction, the cells were washed with
PBS and harvested in PBS with 0.025 % trypsin-0.02 % EDTA. For the reverse experiment,
to follow the degradation of the transcripts, the cells were transfected in the absence of
tetracycline. After 24 hours, tetracycline was added to a concentration of 0.5 mg/ml to repress
transcription of the constructs. At various time-point thereafter, the cells were washed with
PBS and harvested in PBS with 0.025 % trypsin-0.02 % EDTA. For the experiments to
determine the effect of cleavage on protein production, 3.3 mg of pTet-L4-luc-DWT or
pTet-L4-DWTmut were cotransfected with pTet-tTak in the absence of tetracycline. After 4
hours, medium was refreshed and 30 hours later, cell extracts were prepared for luciferase
assays (Sambrook et al., 1989; de Wet et al., 1987).
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Culture of Hep3B cells. Human Hep3B cells were grown in a-Minimal Essential Medium
(a-MEM) supplemented with 100 IU of penicillin per ml, 100 :g of streptomycin per ml, 300
mg of glutamine per ml and 2% of the defined serum replacement TCH (ICN Biomedicals
Inc.) or 10% fetal calf serum.
To study the effect of trichostatin A (TSA) on cleavage efficiency, Hep3B cells
growing on serum replacement medium or on 10% fetal calf serum were seeded at a density
of 3 x 103 cells/ cm2 in 25 cm2  flasks, grown to a density of 1.6 x 104 cells/ cm2  (~50%
confluence) and supplied with fresh medium containing 0-240 ng/ml TSA. After 18 hours, the
cells were harvested in PBS with 0.025% trypsin-0.02% EDTA. Media were collected for
IGF-II measurements and RNA was isolated and subjected to Northern blot analysis.
To study the effect of dexamethasone on cleavage efficiency, the same procedure was
followed except that the cells were given fresh medium containing 0-1000 ng/ml
dexamethasone.
To study the effect of serum/ growth factors, cells growing on 10% fetal calf serum at
a density of 50% confluence were deprived from serum by replacing the serum-containing
medium with serum-free medium. At various time points ranging from 4 to 32 hours, the cells
were harvested for RNA isolation. The reverse experiment was also performed; cells growing
on TCH were supplied with 10% fetal calf serum and harvested at various time points ranging
from 4 to 32 hours thereafter.
The effect of the growth conditions was examined as follows. Cells were seeded at a
density of 0.8 x 104  in 25 cm2 flasks and grown to a variety of different densities ranging
from 0.8 x 104  to 15 x 104 cells/ cm2 (~25% to >>100% confluence). Medium was refreshed
daily. Cells were counted each day using a counting chamber after suspending them in PBS
with 0.025% trypsin-0.02% EDTA. After harvesting the cells, RNA was isolated and
subjected to Northern blot analysis.
RNA isolation and analysis. Total RNA was isolated using the RNAzol reagent according to
the manufacturer’s instructions. Cells isolated from a 25 cm2 flask were lysed in 0.75 ml of
RNAzol reagent and RNA was isolated from the water phase by isopropanol precipitation and
resuspended in water. RNA was glyoxalated, size-separated on a 1% agarose-10 mM sodium
phosphate gel, and transferred to a GeneScreen membrane. The RNA was fixed on the
membrane by irradiation with long-wavelength UV light for 2.5 minutes. Northern blots were
hybridized in the presence of 50% formamide in glass cylinders with continuous rotation at
42 oC according to the GeneScreen protocols. As a probe, a 1.0 kb SmaI fragment from the
human IGF-II exon 9 (positions +84 to +1096), hybridizing to both the full-length IGF-II
RNAs and the 3' cleavage product, was used. The DNA fragments were labeled by random
priming with [a-32P]dCTP following the Amersham protocols. After 2 hours of pre-
hybridization, the probe was added at a final concentration of 106 cpm/ml. Blots were washed
after overnight hybridization, to a final stringency of 0.5 x SSC- 1% SDS at 65 oC (1 x SSC is
0.15 M NaCl plus 0.015 M sodium citrate) and exposed to Fuji RX X-ray film. The amounts
of cleavage products were determined by Phosphorimager scanning of the blots of at least 3
independent experiments. Cleavage efficiencies were determined by calculating the amount of
3' cleavage product divided by the total amount of IGF-II RNA. Variation between the
calculated cleavage efficiencies in separate experiments was less than 10%.
Poly(A)+ RNA was isolated from total RNA preparations using the Poly(A)+ RNA
isolation kit from Promega according to the manufacturer’s instructions.
Western blot analysis. IGF-II protein levels in media taken from Hep3B cells growing on
serum replacement medium TCH were measured as follows: All protein present in 400ml
medium was precipitated by adding 1000 ml of ice-cold acetone and pelleted by centrifugation
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in a microfuge at 14,000 rpm. Pellets were dissolved in 25 ml of SDS sample buffer, and
loaded onto a 10-20% gradient SDS polyacrylamide gel. After electrophoresis, protein was
transferred to a nitrocellulose membrane by electroblotting. Subsequently, the membrane was
stained with Ponceau S (Sigma) to check for equal loading and blocked in 2% milk powder
(Protivar) for 1 h. Incubation with rabbit-anti-human anti IGF-II polyclonal antiserum
(GroPep Ltd. Adelaide, Australia) was performed overnight at 4 oC (1:1000 in 0.1% milk
powder in TBS-Tween (150 mM NaCl, 10 mM Tris-HCl pH 8.0, 0.2% Tween-20)). The
membrane was washed in TBS-Tween, and exposed to biotinylated donkey-anti-rabbit Ig
(Amersham)(1:400 in TBS-Tween) for 1 h. The membrane was again washed in TBS-Tween,
followed by incubation with horseradish-coupled streptavidin (Amersham) (1:1500 in TBS-
Tween). For detection, the Enhanced Chemiluminescence (ECL) system (NEN Life Science
Products Inc., Boston, MA) was used.
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6.1. Introduction.
The human IGF-II gene is a complex transcription unit containing four
promoters that are active in a developmental stage-dependent and tissue-specific
fashion. Transcription from these different promoters yields a population of transcripts
ranging in size from 2.2. kb to 6.0 kb. The various transcripts differ in their 5’-UTR
sequences and are translated with different efficiencies. All transcripts share the 552 nt
long IGF-II coding region, and, apart from the minor 2.2 kb transcript which is
polyadenylated at an alternative upstream site, the 4 kb long 3’-UTR is also common
to all transcripts. In addition to these different transcripts, a smaller, polyadenylated
RNA species of 1.8 kb was detected on Northern blots when an IGF-II 3’-UTR
specific probe was used. Subsequent experiments indicated that this RNA is not
transcribed from another promoter, but is formed by endonucleolytic cleavage of the
full-length IGF-II mRNAs. The cleavage site was mapped to the single nucleotide
resolution to a specific site located 2183 nt downstream of the translation stopcodon in
the 3875 nt long 3’-UTR.
6.2. Mechanistic aspects of cleavage.
Having mapped the specific endonucleolytic cleavage site, experiments were
initiated to identify the RNA regions necessary for cleavage. Various deletions were
introduced in an IGF-II minigene construct and subsequently tested for their effects on
cleavage efficiency in an in vivo system (Meinsma et al., 1992). This revealed that for
in vivo cleavage, a region from positions -173 to +150 relative to the cleavage site is
necessary (element II). Unexpectedly, deletion of a region 2 kb upstream of the
cleavage site abolished cleavage, demonstrating that an additional sequence is required
for cleavage. Further analysis mapped this sequence to be located between positions
-2116 and -2013 (element I). Thus, two regions, the 104 nucleotides long element I
and the 323 nucleotides long element II, are required for endonucleolytic cleavage of
the IGF-II mRNAs. Subsequent RNA folding studies indicated that a major part of
element I, which is rich in C-residues can form a 83 nt long duplex with the G-rich
downstream region of element II from positions +18 to +101. The upstream part of
element II is predicted to fold into two stem-loops and the cleavage site itself is
predicted to be located in an internal loop. Thus, three separate RNA folding domains
can be distinguished in the cleavage unit: (1) the stem-loop domain from positions
-133 to -7, (2) the duplex domain from -2108 to -2029 and +18 to +101, and (3) the
cleavage site domain from -161 to -136 and -6 to +16.
Several experiments have been performed to gain a better understanding of the
role of these different RNA folding domains in cleavage. First, to gain insight into the
recognition determinants in the direct proximity of the cleavage site within the
cleavage site domain, a number of point mutations were introduced in the loop of the
cleavage site and in its flanking sequences that were predicted to be base-paired
(Chapter 3). Apart from a few exceptions, all of the introduced mutations reduced the
efficiency of cleavage to 0-30% of the wild type cleavage efficiency, indicating that
the presence of specific nucleotides around the cleavage site is of critical importance.
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Only a few mutations in the region from -161 to -136, opposite to the cleavage site,
allow wild type cleavage efficiency, suggesting that the requirement for specific
nucleotide identity in this region is less stringent than in the region adjacent to the
cleavage site. In agreement with this view, the -161 to -136 region is also less
conserved among related species than the region around the cleavage site. In fact, the
region from positions -14 to +52 is 100% conserved between human, rat and mouse.
Interestingly, the nucleotides in the region from -161 to -136 that could not be mutated
without interfering with cleavage, are also invariantly conserved between human, rat
and mouse, suggesting an important physiological function of cleavage. The dramatic
reduction in cleavage efficiency upon two G-C base pair substitutions into two A-U
base pairs in a predicted 6 bp helix near the cleavage site (mutant [-149,-148,+5,+6]) is
somewhat surprising. For it is known that in a continuous A-form Watson-Crick RNA
double helix, the bases are not well accessible for specific interactions with proteins
and one would not expect the requirement for specific residues in such an
environment. This result thus suggests that the region around the cleavage site may
adopt another structure than the one predicted by the computer algorithm.
In order to gain more insight into the RNA structures formed around the
cleavage site in solution and to verify the computer predictions, biochemical structure
probing assays were performed using in vitro synthesized RNAs that contain both
elements I and II (Chapter 4). Generally, the probing results confirm the computer
predictions; we obtained strong evidence that the upstream stem-loops are indeed
formed. Importantly however, the reactivities of the nucleotides around the cleavage
site are not in agreement with the computer prediction. These nucleotides do not react
with single-strand-specific reagents, suggesting that they are not easily accessible in
solution. In the absence of magnesium, however, they do react with the reagents,
indicating that the residues around the cleavage site are involved in non-Watson-Crick
base pairings. A functional significance of these non-Watson-Crick pairings is
suggested by the observation that point mutations that interfere with cleavage also
affect the reactivity of the nucleotides around the cleavage site (unpublished data),
whereas mutations that allow efficient cleavage do not. Thus, the data suggest that
specific nucleotides around the cleavage site are necessary, and these nucleotides must
be present in a specific configuration maintained by non-Watson-Crick interactions.
However, more detailed structural analyses using chemical reagents or NMR structure
determination will be required to gain further detailed information on the RNA
structures formed around the cleavage site.
What are the roles of the flanking stem-loop domain and of the duplex domain?
It was previously shown that formation of the duplex is absolutely required for
cleavage, since deletion or inversion of element I completely abolishes cleavage
(Scheper et al., 1995). Computer folding suggests that the absence of the duplex
interaction leads to dramatic structural changes around the cleavage site. One main
role of the duplex domain may be the maintenance of a correct folding around the
cleavage site. A similar role may be played by the stem-loop domain, since deletions
in this region are predicted to cause different foldings around the cleavage site and
indeed such deletions completely disrupt cleavage. Specific deletions in the stem-loop
domain, designed to maintain the proper folding around the cleavage site, however, do
not result in a strong decrease in cleavage efficiency. Even in the absence of the
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complete stem-loop domain, cleavage occurs relatively efficiently provided that the
structure around the cleavage site remains intact. Combining these results leads to a
model where the cleavage site is located between two large highly structured RNA
domains that mainly serve to keep the local structure intact. Furthermore, it can be
implied that the loop of the cleavage site consists of irregular RNA structures that must
be formed by non-Watson-Crick interactions.
Cleavage of the IGF-II mRNAs requires much more complex RNA structures
than cleavage of a number of other mRNAs known to date, such as the transcript of the
Xenopus maternal homeobox gene Xlhbox2, which only requires a short sequence in a
single-stranded environment (Brown and Harland, 1990; Brown et al., 1993). This
does not necessarily indicate that the recognition of the cleavage site in IGF-II mRNAs
per se is more complex than that of the cleavage site in the Xlhbox2 message. Rather,
the complex requirements for cleavage of the IGF-II mRNAs may reflect the fact that
the nucleotides constituting the internal loop of the cleavage site are distant in the
primary sequence; nucleotides -144 to -140 must be placed opposite to nucleotides -2
to +1 by RNA folding. In contrast, the sequence recognized by the Xlhbox2
endonuclease is a continuous stretch of 16 nucleotides that may be located in a hairpin
loop. This requires only one stable helix below it to prevent it from being captured in
alternative foldings. It will be interesting to determine whether nucleotides -144 to
-140 and -1 to +2 on top of a hairpin loop can be sufficient to provide a specific
cleavage site. Thus, while cleavage is possible in the absence of the flanking stem-loop
domain and possibly also of the duplex domain, these regions may have a regulatory
function in cleavage, possibly through binding specific proteins that influence
cleavage efficiency.
In a search for such proteins, EMSA studies were carried out using in vitro
synthesized IGF-II RNAs and protein extracts from human Hep3B cells that
endogenously express and cleave IGF-II mRNA. These studies yielded the
identification of a protein that specifically binds to the 5’ stem-loop in the proximity of
the cleavage site (Chapter 3). Point mutations in the protein binding site that disrupt
binding of the protein lead to a moderate reduction in cleavage efficiency of 15 to
35%, suggesting that this protein is not an essential factor, but that it has a modulating
effect on cleavage. Thus, the stem-loop domain harbors a binding site for a specific
protein that may have a regulatory role in cleavage.
Another potential target for cleavage regulation and an interesting structural
feature of the cleavage unit is the G-rich sequence in element II downstream of the
cleavage site from positions +24 to +56. This region was found to adopt a stable G-
quadruplex structure by (Christiansen et al., 1994) based on studies with RNAs that
lack element I. In the presence of element I, however, this region can form a duplex
structure with element II. Thus, a competition may exist between formation of the
duplex between elements I and II or formation of the G-quadruplex structure in
element II. In the ‘duplex state’ cleavage can occur because the cleavage site is in the
correct structure, whereas in the ‘G-quadruplex state’, cleavage cannot occur. An
interesting analogy comes from the telomerase system. Telomerase is a specialized
reverse transcriptase that contains its own RNA template for synthesis of telomeric
DNA, and plays an important role in tumor growth (Greider and Blackburn, 1989;
Kim et al., 1994). The sequence of the telomerase RNA template is
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5’-CUAACCCUAAC-3’ and reverse transcription results in the DNA sequence
5’-GGTTAGGGTTAG-3’ (Feng et al., 1995). This DNA sequence can adopt a
G-quadruplex structure, and it has been hypothesized that formation of this
G-quadruplex may facilitate unwinding of the telomeric RNA:DNA duplex (Zahler et
al., 1991). Subsequently, a new duplex must be formed to allow a next extension. On
this basis, compounds have been designed that interfere with this process to inhibit
telomerase activity. Several compounds that inhibit the G-quadruplex to duplex
transition by stabilizing the quadruplex have been described (Hurley et al., 2000). Also
specific proteins that stabilize quadruplex structures have been identified (Fang and
Cech, 1993a; Fang and Cech, 1993b). In a similar manner, factors that stabilize or
destabilize the G-quadruplex in the IGF-II mRNA could inhibit or stimulate cleavage,
respectively. After cleavage of the IGF-II mRNAs, the G-quadruplex is thought to
protect the 3’ cleavage product from exonucleolytic degradation.
6.3. Functional aspects of cleavage.
Several observations argue in favor of an important biological function of
endonucleolytic cleavage of the IGF-II mRNAs. (1) The 100% conservation between
human, rat and mouse of the sequence around the cleavage site between positions -14
to +52. In fact, this region is the most conserved part of the entire IGF-II gene (Nielsen
and Christiansen, 1992). (2) Also the nucleotides in the opposite strand that by
mutagenesis studies were found to be important for cleavage are invariantly conserved,
whereas those that are not important for cleavage are not conserved. (3) The specificity
of cleavage; single point mutations around the cleavage site completely disrupt
cleavage. (4) The regulated manner of cleavage in Hep3B cells; a 2-3 fold
upregulation of cleavage is consistently observed when the cells reach confluence
(Chapter 5).
What may be the function of cleavage? Cleavage results in the destabilization
of the coding part of an mRNA, since an unstable 5’ cleavage product is formed. Thus,
it is obvious that cleavage could serve to accelerate the degradation of the IGF-II
mRNAs, provided that it occurs efficiently enough. The experiments described in
Chapter 5, however, indicate that at least under standard cell culture conditions in 293
cells, this is not the case. Cleavage has no significant effect on protein production,
despite the fact that about 43% of the RNA exists as a cleavage product in the case of
the reporter L4-luc-DWT RNA that contains the luciferase open reading frame and the
IGF-II 3’-UTR. In Hep3B cells, which endogenously express IGF-II, a lower level of
cleavage efficiency is observed (only 15% of the mRNAs are cleaved). Under high cell
density conditions, an upregulation of IGF-II mRNA cleavage of 2-3 fold was seen.
But even this level of cleavage efficiency is unlikely to affect the overall decay rate of
the full-length mRNAs since a similar level was also observed for the L4-luc-DWT
RNA but did not affect the steady-state levels of this RNA. Similar steady-state levels
were observed for the L4-luc-DWT RNA and the L4-luc-DWTmut RNA, which is not
cleaved. In addition, no decrease in the full-length IGF-II mRNA levels was seen at
high cell density, provided that the cells were frequently given fresh medium
containing growth components. Thus, although it is possible that under different
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conditions and/or in a different cell type, cleavage efficiency is sufficient to accelerate
mRNA decay, our data do not support a significant role for cleavage in mRNA
degradation.
An interesting possibility is that the 3’ cleavage product itself performs an
intrinsic cellular function. Two major observations point into this direction. (1) The
unusual stability of the 1.8 kb IGF-II RNA species. Numerous stable non-coding
RNAs have been shown to carry out diverse functions in both prokaryotes and
eukaryotes (reviewed by Wagner and Simons (1994); Delihas (1995); Kelley and
Kuroda (2000)). Computer-assisted secondary structure prediction suggests that the
1.8 kb 3’ cleavage product is highly base-paired. Interestingly, several regions in this
RNA appear to be rich in structural motifs that are common to functional non-coding
RNAs as determined with a specialized computer algorithm available on the World
Wide Web at http://rnagene.lbl.gov/. (2) The G-quadruplex formed by the sequence
from positions +24 to +56, which is likely to play an important role in the stability of
the 3’ cleavage product. The sequence that forms this G-quadruplex is, except from
one nucleotide at position +53, 100% conserved between human rat and mouse. It will
be interesting to determine the possible intrinsic biological function of the IGF-II 3’
cleavage product.
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SAMENVATTING
Het humane insuline-achtige groeifactor II (IGF-II) speelt een belangrijke rol
bij de embryonale ontwikkeling en is geassocieerd met tumorgroei. In gekweekte
cellen kan IGF-II diverse effecten veroorzaken, afhankelijk van het celtype waarin het
tot expressie komt, zoals groeistimulatie, of juist remming van groei en stimulatie van
celdifferentiatie. Terwijl IGF-II een overlevingsfactor is in sommige systemen,
induceert het in andere celtypes juist geprogrammeerde celdood (apoptose). IGF-II is
dus betrokken bij diverse fysiologische processen, en het is derhalve waarschijnlijk dat
IGF-II genexpressie nauwkeurig gereguleerd wordt. Inderdaad vindt er op
verscheidene niveaus regulatie plaats; op het niveau van transcriptie (i.e. synthese van
het ´boodschapper´ mRNA) door middel van ontwikkelings- en weefselspecifieke
activiteit van vier verschillende promoters (i.e. de startplaats van transcriptie)(P1-P4)
in het IGF-II gen. Transcriptie vanaf deze promoters leidt tot de vorming van mRNA
moleculen die onderling verschillen in de lengte en samenstelling van hun 5´
onvertaalde deel (5’-UTR). Dit leidt vervolgens tot verschillen in de translatie
(eiwitproductie)-efficiëntie van deze mRNAs en genereert de mogelijkheid om IGF-II
expressie te reguleren op het niveau van translatie. Verder is nog bekend dat IGF-II
expressie gereguleerd wordt op het niveau van post-translationele bewerking van het
IGF-II eiwit.
Tijdens de karakterisering van het humane IGF-II gen en de IGF-II mRNAs
werd een RNA met een grootte van 1.8 kb gedetecteerd dat co-lineair is met het 3’
uiteinde van het IGF-II gen. Dit RNA bleek gevormd te worden door plaats-specifieke
endonucleolytische klieving in het 3’ onvertaalde deel (3’-UTR) van de IGF-II
mRNAs en niet door transcriptie vanaf een extra promoter. Het 1.8 kb RNA
vertegenwoordigt dus het 3’ klievingsproduct; het bestaat uit 3’-UTR sequentie en een
poly(A) staart, en is zeer stabiel. Klieving van de IGF-II mRNAs genereert ook een 5’
klievingsproduct, hetgeen de IGF-II coderende sequentie bevat. Dit 5’
klievingsproduct is in tegenstelling tot het 1.8 kb 3’ klievingsproduct onstabiel, en
wordt niet meer getransleerd. Deze observaties hebben geleid tot de hypothese dat
klieving van de IGF-II mRNAs kan fungeren als een additioneel mechanisme om IGF-
II genexpressie te reguleren.
Begonnen werd met het in kaart brengen van de RNA gebieden die nodig zijn
voor in vivo klieving. Hiertoe werden deleties aangebracht in een IGF-II minigen in
een expressieplasmide voor transfectie-studies. Deze experimenten toonden aan dat er
twee gebieden in de IGF-II 3’-UTR nodig zijn voor klieving: een sequentie van 323
nucleotiden rondom de klievingsplaats (element II), en een sequentie van 104
nucleotiden lang dat 2013 nucleotiden stroomopwaards gelegen is (element I). RNA-
vouwings-studies lieten vervolgens zien dat element I, dat zeer rijk is aan C-
nucleotiden, een stabiele duplex kan vormen met een G-rijk stroomafwaards gelegen
gebied in element II. Direct stroomopwaards van de klievingsplaats in element II
kunnen twee ‘haarspeldlussen’ gevormd worden, en de klievingsplaats zelf wordt
vooorspeld in een interne lus gelegen te zijn. De RNA gebieden die nodig zijn voor
klieving kunnen dus onderverdeeld worden in drie verschillende vouwingsdomeinen:
(1) het duplex domein, gevormd door de interactie tussen nucleotiden -2108/-2029
(posities ten opzichte van de klievingsplaats) van element I en +18/+101 van element
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II, (2) het haarspeldlussen domein in het stroomopwaards gelegen deel (posities -133
tot -7) van element II, en (3) het klievingsplaatsdomein, gevormd door nucleotiden -
161/-136 en -6/+16, met de klievingsplaats gelegen in een interne lus.
De studies beschreven in dit proefschrift begonnen met pogingen om eiwitten te
identificeren die specifiek aan de hierboven beschreven RNA gebieden binden, en zo
een rol zouden kunnen spelen bij klieving (Hoofdstuk 3). Hiertoe werden in vitro
gesynthetiseerde RNA moleculen die deze gebieden bevatten geïncubeerd met
extracten van humane Hep3B cellen, die endogeen IGF-II tot expressie brengen. Dit
leverde een specifiek RNA-eiwit complex op dat alleen gevormd wordt in de
aanwezigheid van het haarspeldlussen domein. Met behulp van puntmutaties werd de
bindingsplaats van het eiwit nauwkeurig in kaart gebracht. Het complex bleek
gevormd te worden halverwege de eerste van de twee haarspeldlussen. Wanneer
puntmutaties die de eiwitbinding verstoren in het IGF-II minigen werden
geïntroduceerd, leverde dit een gematigde reductie in klievingsefficientie op, hetgeen
suggereert dat het RNA-eiwitcomplex niet essentieel is voor klieving, maar een
modulerende rol in klieving zou kunnen hebben.
Hoofdstuk 3 beschrijft ook experimenten waarin het belang van de nucleotiden
rondom de klievingsplaats voor klieving werd onderzocht. Verscheidene puntmutaties
werden geïntroduceerd rondom de klievingsplaats in het IGF-II minigen, en het effect
hiervan op de in vivo klievingsefficientie werd onderzocht. De resultaten tonen
duidelijk aan dat de identiteit van specifieke nucleotiden rondom de klievingsplaats
zeer belangrijk is, omdat vrijwel alle puntmutaties de klieving ernstig verstoren. De
nucleotiden in het gebied direct naast de klievingsplaats van posities –6 tot +16 lijken
belangrijker te zijn dan de nucleotiden in het hier tegenover liggende deel van posities
-161 tot –136. Interessant genoeg is dit gebied ook duidelijk meer geconserveerd in de
evolutie, hetgeen het belang van deze nucleotiden voor klieving onderstreept.
Hoofdstuk 4 beschrijft verdere experimenten om meer inzicht te krijgen in de
rol van de verschillende RNA vouwingsdomeinen in klieving. Verscheidene deleties
werden geïntroduceerd in het haarspeldlussen domein en de effecten op de voorspelde
RNA vouwing en in vivo klievingsefficiëntie werden bestudeerd. Hieruit bleek dat alle
deleties die de voorspelde RNA vouwing veranderen ook de klieving vrijwel volledig
verstoren. Deleties die de wild type RNA vouwing intact laten hebben echter een veel
minder drastisch effect op klieving, hetgeen aangeeft dat een specifieke vouwing
rondom de klievingsplaats belangrijk is. Het haarspeldlussen domein is op zichzelf niet
nodig voor klieving, omdat het geheel verwijderd kan worden zonder de klieving
drastisch te verstoren, zolang de vouwing rondom de klievingsplaats maar intact blijft.
Dit blijkt uit de resultaten met een mutant (D-135/-18) waarbij het gehele
haarspeldlussen domein verwijderd is; deze mutant laat een redelijke
klievingsefficientie zien van 47% van de wild type. Een opvallend resultaat echter
werd verkregen met een mutant waarbij op een deel van de tweede haarspeldlus na het
gehele haarspeldlussendomein verwijderd was (D-135/-72,D-60/-18). Hoewel de
klievingsplaats zich bij deze mutant in de voorspelde wild type configuratie bevindt, is
de klievingsefficiëntie ernstig verstoord. Dit resultaat gaf aanleiding de
computervoorspelling van de RNA-vouwing te verifiëren door middel van
biochemische structuuranalyse van het RNA (Hoofdstuk 4). De resultaten van deze
studies suggereren dat zowel in het wild type RNA als in mutant D-135/-18 de
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nucleotiden in de lus rondom de klievingsplaats niet ongepaard zijn, maar betrokken
bij niet-Watson-Crick interacties, hetgeen een specifieke conformatie genereert. In
mutant D-135/-72,D-60/-18 echter, gedragen deze nucleotiden zich als vrij in
oplossing. Deze resultaten suggereren dat een specifieke conformatie, gevormd door
niet-Watson-Crick interacties, belangrijk is voor klieving. In overeenstemming met
deze hypothese werd gevonden dat puntmutaties rondom de klievingsplaats die de
klieving verstoren ook de conformatie rondom de klievingsplaats veranderen in
tegenstelling tot mutaties die geen effect hebben op klieving.
Hoofdstuk 5 laat experimenten zien die uitgevoerd zijn om meer inzicht te
verkrijgen in de fysiologische functie van klieving van IGF-II mRNA. De kinetiek van
klieving en de rol van klieving in de afbraak van IGF-II mRNA en eiwitproductie werd
getest met behulp van IGF-II constructen onder controle van een tetracycline-
induceerbare promoter. De niveaus van het IGF-II mRNA en het 3´ klievingsproduct
werden bepaald door Northern blot analyse. Na inductie van transcriptie werd een
snelle toename gezien van de niveaus van het IGF-II mRNA; de niveaus van het 3´
klievingsproduct begonnen pas geruime tijd later toe te nemen, hetgeen aangeeft dat
klieving een traag proces is. In het omgekeerde experiment waarbij de transcriptie
werd geremd, werd de afbraaksnelheid van wild type IGF-II mRNA vergeleken met de
afbraaksnelheid van mutant IGF-II mRNA dat niet meer gekliefd wordt. Beide
mRNAs werden met dezelfde snelheid afgebroken. Ook op het niveau van
eiwitsynthese werd geen verschil gezien tussen het wild type IGF-II mRNA en de
gemuteerde versie. Deze resultaten laten zien dat in het gebruikte testsysteem klieving
een gering effect heeft op mRNA afbraak en eiwitsynthese.
Regulatie van klieving onder invloed van externe factoren werd onderzocht in
humane Hep3B cellen, die endogeen IGF-II tot expressie brengen en het mRNA
klieven. Het effect van verscheiden externe factoren op de efficientie van klieving
werd getest. De invloed van trichostatine A (TSA), een histon deacetylase remmer,
dexamethason, een synthetisch glucocorticoïde, aan- of afwezigheid van serum in het
medium, en celdichtheid werden onderzocht. De verkregen resultaten suggereren dat
TSA, dexamethason, en serum geen invloed hebben op klieving. Celdichtheid echter,
heeft wel effect op klieving; bij een toename van de cellen werd een toename van de
niveaus van het 3´ klievingsproduct waargenomen, terwijl de niveaus van het volle
lengte IGF-II mRNA gelijkbleven of afnamen, afhankelijk van de frequentie van
medium verversing. We hebben dus waargenomen dat klieving in Hep3B cellen
gereguleerd wordt afhankelijk van de dichtheid van de cellen. De betekenis van de
toename van klieving bij hoge celdichtheid is echter niet duidelijk. De ongebruikelijke
stabiliteit van het 3´ klievingsproduct, waarschijnlijk veroorzaakt door de
geconserveerde G-rijke sequentie aan het 5´uiteinde maakt het aantrekkelijk te
speculeren dat dit RNA wellicht een intrinsieke functie vervult in de cel.
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SAMENVATTING
Het humane insuline-achtige groeifactor II (IGF-II) speelt een belangrijke rol
bij de embryonale ontwikkeling en is geassocieerd met tumorgroei. In gekweekte
cellen kan IGF-II diverse effecten veroorzaken, afhankelijk van het celtype waarin
het tot expressie komt, zoals groeistimulatie, of juist remming van groei en
stimulatie van celdifferentiatie. Terwijl IGF-II een overlevingsfactor is in sommige
systemen, induceert het in andere celtypes juist geprogrammeerde celdood
(apoptose). IGF-II is dus betrokken bij diverse fysiologische processen, en het is
derhalve waarschijnlijk dat IGF-II genexpressie nauwkeurig gereguleerd wordt.
Inderdaad vindt er op verscheidene niveaus regulatie plaats; op het niveau van
transcriptie (i.e. synthese van het ´boodschapper´ mRNA) door middel van
ontwikkelings- en weefselspecifieke activiteit van vier verschillende promoters (i.e.
de startplaats van transcriptie)(P1-P4) in het IGF-II gen. Transcriptie vanaf deze
promoters leidt tot de vorming van mRNA moleculen die onderling verschillen in de
lengte en samenstelling van hun 5´ onvertaalde deel (5’-UTR). Dit leidt vervolgens
tot verschillen in de translatie (eiwitproductie)-efficiëntie van deze mRNAs en
genereert de mogelijkheid om IGF-II expressie te reguleren op het niveau van
translatie. Verder is nog bekend dat IGF-II expressie gereguleerd wordt op het
niveau van post-translationele bewerking van het IGF-II eiwit.
Tijdens de karakterisering van het humane IGF-II gen en de IGF-II mRNAs
werd een RNA met een grootte van 1.8 kb gedetecteerd dat co-lineair is met het 3’
uiteinde van het IGF-II gen. Dit RNA bleek gevormd te worden door plaats-
specifieke endonucleolytische klieving in het 3’ onvertaalde deel (3’-UTR) van de
IGF-II mRNAs en niet door transcriptie vanaf een extra promoter. Het 1.8 kb RNA
vertegenwoordigt dus het 3’ klievingsproduct; het bestaat uit 3’-UTR sequentie en
een poly(A) staart, en is zeer stabiel. Klieving van de IGF-II mRNAs genereert ook
een 5’ klievingsproduct, hetgeen de IGF-II coderende sequentie bevat. Dit 5’
klievingsproduct is in tegenstelling tot het 1.8 kb 3’ klievingsproduct onstabiel, en
wordt niet meer getransleerd. Deze observaties hebben geleid tot de hypothese dat
klieving van de IGF-II mRNAs kan fungeren als een additioneel mechanisme om
IGF-II genexpressie te reguleren.
Begonnen werd met het in kaart brengen van de RNA gebieden die nodig zijn
voor in vivo klieving. Hiertoe werden deleties aangebracht in een IGF-II minigen in
een expressieplasmide voor transfectie-studies. Deze experimenten toonden aan dat
er twee gebieden in de IGF-II 3’-UTR nodig zijn voor klieving: een sequentie van
323 nucleotiden rondom de klievingsplaats (element II), en een sequentie van 104
nucleotiden lang dat 2013 nucleotiden stroomopwaards gelegen is (element I).
RNA-vouwings-studies lieten vervolgens zien dat element I, dat zeer rijk is aan
C-nucleotiden, een stabiele duplex kan vormen met een G-rijk stroomafwaards
gelegen gebied in element II. Direct stroomopwaards van de klievingsplaats in
element II kunnen twee ‘haarspeldlussen’ gevormd worden, en de klievingsplaats
zelf wordt vooorspeld in een interne lus gelegen te zijn. De RNA gebieden die nodig
zijn voor klieving kunnen dus onderverdeeld worden in drie verschillende
vouwingsdomeinen: (1) het duplex domein, gevormd door de interactie tussen
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nucleotiden -2108/-2029 (posities ten opzichte van de klievingsplaats) van element I
en +18/+101 van element II, (2) het haarspeldlussen domein in het stroomopwaards
gelegen deel (posities -133 tot -7) van element II, en (3) het klievingsplaatsdomein,
gevormd door nucleotiden -161/-136 en -6/+16, met de klievingsplaats gelegen in
een interne lus.
De studies beschreven in dit proefschrift begonnen met pogingen om eiwitten
te identificeren die specifiek aan de hierboven beschreven RNA gebieden binden, en
zo een rol zouden kunnen spelen bij klieving (Hoofdstuk 3). Hiertoe werden in vitro
gesynthetiseerde RNA moleculen die deze gebieden bevatten geïncubeerd met
extracten van humane Hep3B cellen, die endogeen IGF-II tot expressie brengen. Dit
leverde een specifiek RNA-eiwit complex op dat alleen gevormd wordt in de
aanwezigheid van het haarspeldlussen domein. Met behulp van puntmutaties werd
de bindingsplaats van het eiwit nauwkeurig in kaart gebracht. Het complex bleek
gevormd te worden halverwege de eerste van de twee haarspeldlussen. Wanneer
puntmutaties die de eiwitbinding verstoren in het IGF-II minigen werden
geïntroduceerd, leverde dit een gematigde reductie in klievingsefficientie op,
hetgeen suggereert dat het RNA-eiwitcomplex niet essentieel is voor klieving, maar
een modulerende rol in klieving zou kunnen hebben.
Hoofdstuk 3 beschrijft ook experimenten waarin het belang van de
nucleotiden rondom de klievingsplaats voor klieving werd onderzocht. Verscheidene
puntmutaties werden geïntroduceerd rondom de klievingsplaats in het IGF-II
minigen, en het effect hiervan op de in vivo klievingsefficientie werd onderzocht. De
resultaten tonen duidelijk aan dat de identiteit van specifieke nucleotiden rondom de
klievingsplaats zeer belangrijk is, omdat vrijwel alle puntmutaties de klieving
ernstig verstoren. De nucleotiden in het gebied direct naast de klievingsplaats van
posities –6 tot +16 lijken belangrijker te zijn dan de nucleotiden in het hier
tegenover liggende deel van posities -161 tot –136. Interessant genoeg is dit gebied
ook duidelijk meer geconserveerd in de evolutie, hetgeen het belang van deze
nucleotiden voor klieving onderstreept.
Hoofdstuk 4 beschrijft verdere experimenten om meer inzicht te krijgen in de
rol van de verschillende RNA vouwingsdomeinen in klieving. Verscheidene deleties
werden geïntroduceerd in het haarspeldlussen domein en de effecten op de
voorspelde RNA vouwing en in vivo klievingsefficiëntie werden bestudeerd. Hieruit
bleek dat alle deleties die de voorspelde RNA vouwing veranderen ook de klieving
vrijwel volledig verstoren. Deleties die de wild type RNA vouwing intact laten
hebben echter een veel minder drastisch effect op klieving, hetgeen aangeeft dat een
specifieke vouwing rondom de klievingsplaats belangrijk is. Het haarspeldlussen
domein is op zichzelf niet nodig voor klieving, omdat het geheel verwijderd kan
worden zonder de klieving drastisch te verstoren, zolang de vouwing rondom de
klievingsplaats maar intact blijft. Dit blijkt uit de resultaten met een mutant (D-135/-
18) waarbij het gehele haarspeldlussen domein verwijderd is; deze mutant laat een
redelijke klievingsefficientie zien van 47% van de wild type. Een opvallend resultaat
echter werd verkregen met een mutant waarbij op een deel van de tweede
haarspeldlus na het gehele haarspeldlussendomein verwijderd was (D-135/-72,D-60/-
18). Hoewel de klievingsplaats zich bij deze mutant in de voorspelde wild type
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configuratie bevindt, is de klievingsefficiëntie ernstig verstoord. Dit resultaat gaf
aanleiding de computervoorspelling van de RNA-vouwing te verifiëren door middel
van biochemische structuuranalyse van het RNA (Hoofdstuk 4). De resultaten van
deze studies suggereren dat zowel in het wild type RNA als in mutant D-135/-18 de
nucleotiden in de lus rondom de klievingsplaats niet ongepaard zijn, maar betrokken
bij niet-Watson-Crick interacties, hetgeen een specifieke conformatie genereert. In
mutant D-135/-72,D-60/-18 echter, gedragen deze nucleotiden zich als vrij in
oplossing. Deze resultaten suggereren dat een specifieke conformatie, gevormd door
niet-Watson-Crick interacties, belangrijk is voor klieving. In overeenstemming met
deze hypothese werd gevonden dat puntmutaties rondom de klievingsplaats die de
klieving verstoren ook de conformatie rondom de klievingsplaats veranderen in
tegenstelling tot mutaties die geen effect hebben op klieving.
Hoofdstuk 5 laat experimenten zien die uitgevoerd zijn om meer inzicht te
verkrijgen in de fysiologische functie van klieving van IGF-II mRNA. De kinetiek
van klieving en de rol van klieving in de afbraak van IGF-II mRNA en
eiwitproductie werd getest met behulp van IGF-II constructen onder controle van
een tetracycline-induceerbare promoter. De niveaus van het IGF-II mRNA en het 3´
klievingsproduct werden bepaald door Northern blot analyse. Na inductie van
transcriptie werd een snelle toename gezien van de niveaus van het IGF-II mRNA;
de niveaus van het 3´ klievingsproduct begonnen pas geruime tijd later toe te nemen,
hetgeen aangeeft dat klieving een traag proces is. In het omgekeerde experiment
waarbij de transcriptie werd geremd, werd de afbraaksnelheid van wild type IGF-II
mRNA vergeleken met de afbraaksnelheid van mutant IGF-II mRNA dat niet meer
gekliefd wordt. Beide mRNAs werden met dezelfde snelheid afgebroken. Ook op
het niveau van eiwitsynthese werd geen significant verschil gezien tussen het wild
type IGF-II mRNA en de gemuteerde versie. Deze resultaten laten zien dat in het
gebruikte testsysteem klieving een gering effect heeft op mRNA afbraak en ook op
eiwitsynthese.
Regulatie van klieving onder invloed van externe factoren werd onderzocht in
humane Hep3B cellen, die endogeen IGF-II tot expressie brengen en het mRNA
klieven. Het effect van verscheiden externe factoren op de efficientie van klieving
werd getest. De invloed van trichostatine A (TSA), een histon deacetylase remmer,
dexamethason, een synthetisch glucocorticoïde, aan- of afwezigheid van serum
(groeifactoren) in het medium, en celdichtheid werden onderzocht. De verkregen
resultaten suggereren dat TSA, dexamethason, en serum geen invloed hebben op
klieving. Celdichtheid echter, heeft wel effect op klieving; bij een toename van de
celdichtheid werd een toename van de niveaus van het 3´ klievingsproduct
waargenomen, terwijl de niveaus van het volle lengte IGF-II mRNA gelijkbleven of
afnamen, afhankelijk van de frequentie van medium verversing. We hebben dus
waargenomen dat klieving in Hep3B cellen gereguleerd wordt afhankelijk van de
dichtheid van de cellen. De betekenis van de toename van klieving bij hoge
celdichtheid is echter niet duidelijk. De ongebruikelijke stabiliteit van het 3´
klievingsproduct, die waarschijnlijk veroorzaakt wordt door de geconserveerde G-
rijke sequentie aan het 5´uiteinde, maakt het aantrekkelijk te speculeren dat dit RNA
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wellicht een intrinsieke functie vervult in de cel. Het zal interessant zijn deze
mogelijkheid experimenteel te testen.
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